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Introduction 
Diastolic Left Ventricular Dysfunction: 
The Epicenter of the Heart Failure Syndrome
A pathophysiological perspective
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1.1 General Introduction
Heart failure may be caused by either diastolic or systolic dysfunction, known as diastolic heart
failure or systolic heart failure(9). Diastolic heart failure is a clinical syndrome characterized by
symptoms and signs of heart failure, a preserved left ventricular ejection fraction, and abnormal
diastolic function(8,409,410). Systolic heart failure is a clinical syndrome characterized by
symptoms and signs of heart failure, and a reduced left ventricular  ejection fraction, as a
manifestation of abnormal systolic function. Approximately one third of patients with congestive
heart failure have predominantly diastolic heart failure. Another third have impairment of both
systolic and diastolic function, and the remainder primarily have disordered systolic function(67).
Recently the existence of pure diastolic dysfunction as a cause of chronic heart failure is called
in question, because of subtle derangements of systolic performance in the presence of a normal
left ventricular ejection fraction(153,276,403-405). Thus, so called diastolic heart failure is
possibly caused by a combination of both diastolic and systolic dysfunction. To discriminate
diastolic from systolic heart failure, the use of resting left ventricular ejection fraction is however
widely accepted. Because most heart failure patients are symptomatic on exertion, a correlation
between resting left ventricular ejection fraction and symptoms is absent(282). The widespread
use of left ventricular ejection fraction to describe left ventricular performance results more from
its easy measurability than from conceptual soundness as it is a pre- and afterload, and
contractility dependent parameter.
The purpose of this thesis is to provide a pathophysiological perspective, based on new
clinical findings on the mechanisms by which left ventricular dysfunction may lead to heart
failure.
1.2 Heart failure and left ventricular ejection fraction
Left ventricular contractility, pre- and afterload
In order to generate an adequate cardiac output at rest and during exercise, while operating at
normal left ventricular filling pressures, the left ventricle must generate enough pressure to
overcome the resistance offered by the systemic circulation. This vital pump function is best
described by Ohm’s law as it applies to the circulation: Blood Pressure (BP) = Cardiac Output
(CO) s Total Peripheral Resistance (TPR). Cardiac output is maintained by the cyclic
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LV Wall Stress =
LV Pressure x LV Radius
2 x LV Wall Thickness
contraction and relaxation of the left ventricle, which generates arterial pressure and propels
blood forward depending on pre- and afterload and myocardial contractility(54). Contractility or
inotropic state is the inherent capacity of the myocardium to contract independently of changes
in pre- or afterload. At a molecular level, an increased inotropic state can be explained by
enhanced interaction between calcium ions and the contractile proteins and an increase in the
calcium transient. Factors that increase contractility include exercise and adrenergic stimulation.
An increase in contractility may be  associated with enhanced rates of relaxation, called a positive
lusitropic effect. Preload is defined as the wall stress at the end of diastole which determines the
maximal resting length of the sarcomere. Measurement of wall stress in vivo is difficult because
the radius of the left ventricle neglects the confounding influence of the complex anatomy of the
left ventricle. Surrogate measurements of the indices of preload include left ventricular
end-diastolic pressure or dimensions(258). Left ventricular systolic load or afterload is a function
of both internal (cardiac) properties and external (vascular) factors that impede the forward flow
of blood(38). Wall stress develops when tension is applied to a cross-sectional area, and the units
are force per unit area(258). According to LaPlace's law:
 
The afterload during ejection varies with decreasing left ventricular volume according
LaPlace's law, i.e., the left ventricular pressures generated during ejection interact with systolic
left ventricular geometry and wall thickness to determine left ventricular afterload(38). 
Aortic impedance (= arterial input impedance) gives another accurate measure of the afterload.
Systemic vascular resistance is the most widely used vascular impedance parameter. However,
systemic vascular resistance alone is an inadequate measurement of afterload. The vascular
contribution to left ventricular afterload is the product of a complex interaction between a variety
of vascular parameters, which, in addition to systemic vascular resistance, include arterial
compliance, viscoelasticity, and blood inertia. These factors, acting directly and through reflected
waves, produce the arterial pressure wave form. During left ventricular systole, when the aortic
valve is open, the left ventricular cavity and the systemic arterial system are in continuity. Blood
flow and blood pressure are the physiological mediators that connect the heart and the systemic
circulation(38). End-systolic wall stress reflects the three major components of the afterload,
namely, the peripheral resistance, the arterial compliance, and the peak intraventricular
pressure(258). 
Myocardial damage and its sequellae
An index event either may cause damage of the myocardium, with loss of functioning
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cardiomyocytes, or failure of the cardiomyocytes to contract or relax properly. Irrespective the
nature of the index event, left ventricular dysfunction ensues with a reduction in pumping
capacity of the heart. Often a subclinical course follows with the patient remaining asymptomatic
for even long periods of time(43,151,233). The adrenergic system, the renin angiotensin
system(83,259) and the cytokine system(218,268) initially may reduce the sequellae of an
impaired left ventricular pumping capacity following left ventricular dysfunction. Thus, in the
absence of abnormal loading conditions (e.g. acute mitral- or aortic regurgitation), left ventricular
dysfunction is a prerequisite for the development of the syndrome of heart failure, but is in itself
not sufficient to render the patient symptomatic(217,291). The neurohormonal system, together
with a process which is called 'ventricular remodeling', following an index event, are thought to
be responsible for the development and progression of the syndrome of heart failure. The process
of left ventricular remodeling affects both left ventricular size and geometry as well as the
functioning of the individual cardiomyocytes.
Due to this remodeling process, functional reserve in heart failure is hampered, i.e.  the force
frequency response is blunted(243,244). The failing heart is therefore not able to sufficiently
increase stroke volume by a decrease in end-systolic volume secondary to an exercise-induced
increase in heart rate. Also in case of symptomatic non-dilated left ventricular hypertrophy with
normal resting left ventricular ejection fraction and decreased left ventricular distensibility, a
blunted force-frequency response may contribute to signs and symptoms of heart
failure(142,209,343,354). Thus the dysfunctional left ventricle, irrespective of its dimensions or
ejection fraction, shows a blunted force-frequency response and depends on its ability to utilize
preload reserve to increase stroke volume at increased demand. The concomitant increase in
filling pressure totally depends on left ventricular distensibility as will be discussed below.
In symptomatic dilated cardiomyopathy patients the same pathophysiological mechanisms
ensue as a cause of increased filling pressures during exercise(7,280,337). A fall in left
ventricular diastolic distensibility causes heart failure symptoms due to reduced preload reserve
and a rise in left ventricular filling pressure(203). Factors that influence left ventricular diastolic
distensibility can be categorized as extrinsic or intrinsic to the left ventricular chamber, the latter
affecting the dynamic process of myocardial contraction and diastolic relaxation, and structural
components of the left ventricular chamber wall.
Myocardial contraction and diastolic relaxation
Dynamic changes in left ventricular distensibility depend on the amount of persisting diastolic
cross bridge interactions determining diastolic myocardial tone. As early as in 1927 Meek(232)
defined tone as “a sustained partial contraction, independent of the systolic contractions, by
virtue of which the muscle fibers resist distension during diastole more than they would because
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of their mere physical properties”. If the extent of myocardial relaxation decreases, a larger
amount of diastolic cross bridges remain present with a concomitant decrease in left ventricular
wall distensibility. Only recently clinical evidence emerged that  nitric oxide (NO), derived from
NO-donors or from coronary and endocardial endothelium and myocardium, following receptor-
mediated stimulation, increases diastolic left ventricular distensibility by means of a relaxation
hastening effect(267).
During the diastolic phase of the cardiac cycle a compliant myocardium enables the ventricles
to collect blood at low filling pressures and determines the ability of the myocardium to stretch.
Adequate myocardial relaxation is the result of a  low cytosolic calcium concentration ([Ca2+]i),
10.000 fold lower than outside the cell, attained by the energy consuming process of cytosolic
Ca2+ removal. Myocardial contraction follows  electrically activated Ca2+ transients. Electrical
depolarization of the sarcolemma enables Ca2+ entry from the extracellular space into the
cardiomyocytes via L-type Ca2+  channels(152). A relatively small amount of extracellular
calcium releases a larger amount of calcium from the sarcoplasmatic reticulum through the
ryanodine receptor.The ryanodine receptor, a sarcoplasmatic reticulum Ca2+ release channel, is
required for excitation-contraction coupling(75,123,220,223,402). Cytosolic calcium
concentration rises and increases the binding of calcium to troponin C. Troponin is the key
component of the calcium-dependent switch of the contractile apparatus in striated muscle like
myocardium. There are three subunits of troponin: troponin C, a Ca2+-binding calmodulin-like
protein; troponin T, which attaches the complex to tropomyosin, anchoring it to the thin filament
as well as having a regulatory role; and troponin I, named for its ability to inhibit actin-myosin
interactions at diastolic levels of Ca2+. As cytosolic Ca2+ increases in systole, it binds to a
regulatory Ca2+-binding site on troponin C, leading to increasing affinity of troponin C for
troponin I and weakening the interactions of troponin I and actin. This permits movement of
tropomyosin-troponin on the thin filament such that the inhibition of actin-myosin interaction is
diminished, increasing the probability of crossbridge cycling and muscle shortening and tension
development. The aortic valve opens and blood is ejected from the left ventricle(29,246).
The contraction cycle ends when calcium is actively removed from the cytosol against a steep
concentration gradient back into the sarcoplasmatic reticulum and extracellular space. Calcium
removal is followed by myocardial relaxation and ventricular diastolic filling.  The transition
from contraction to relaxation occurs simultaneously with the plateau phase of the cellular action
potential and simultaneously with the descending limb of the cytoplasmic calcium transient. This
transition from contraction to relaxation occurs during early ejection in healthy hearts, and even
prior to aortic valve opening in diseased hearts. In normal hearts and with normal load,
myocardial relaxation is completed at minimal left ventricular pressure during the rapid filling
period(106). The further course of diastolic filling with the later part of rapid  filling, with slow
filling and with atrial contraction is not a passive phase of the cardiac cycle, but is a phase during
which ventricular stiffness is further modulated by several factors, including ongoing myocardial
relaxation. In addition to passive myocardial and ventricular properties, these ongoing active
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processes determine diastolic left ventricular pressure and the development of pulmonary
congestion at rest and during exercise(106).
Depolarization of the cell membrane and subsequent contraction of the myocardium may be
seen as a gross distortion of a delicate equilibrium of relatively low cytosolic calcium content
accomplished during diastole. A low diastolic cytosolic calcium concentration in combination
with a sufficiently high ATP concentration is mandatory to detach enough systolic actin-myosin
cross-bridges. Compared with contraction (a 'downhill' process) relaxation (an 'uphill' process)
is more prone to disturbances in energy supply. It is therefore of no surprise that this process of
diastolic relaxation is the first to be affected in various disease states(29).
Relaxation abnormalities decrease the ability of the myocardium to stretch. Diastolic
relaxation is prolonged in heart failure, together with an increase in diastolic cytosolic Ca2+
content(30,80,122,321). The dynamic process of myocardial relaxation depends on how the
cardiomyocyte handles Ca2+ fluxes. The cardiomyocyte functions optimally when a high peak of
the Ca2+ transient is combined with a low diastolic cytosolic Ca2+ concentration ([Ca2+]i)(86). An
increase in diastolic [Ca2+]i results in an increase in residual cross-bridge interactions causing
increased diastolic myocardial stiffness and decreased diastolic stretch. In case of an increased
diastolic [Ca2+]i, compensatory mechanisms are not optimally available to the myocardium when
the contraction load increases. In failing myocardium the Ca2+ transient is wider, its upstroke and
decay shallower and diastolic [Ca2+]i higher(138,158,222,278). Beta-adrenergic blockade,
however may restore calcium dynamics and normalizes expression of calcium-handling proteins,
eventually leading to improved hemodynamic function in mammalian cardiomyopathic
hearts(42,285).
 Some controversy exists about the role of this altered Ca2+ handling by failing
cardiomyocytes(137,275,338). Is this altered Ca2+ handling causing impaired cardiomyocytal
diastolic and systolic function? Or is the way the failing cardiomyocyte handles its Ca2+ an
answer to the different phenotype of contractile protein composition(275)? Structural myocardial
changes may also impair its ability to stretch, as will be discussed below.
Recently it was shown, that in the end-stage failing human heart, basal contractility is well
preserved but "contractility reserve" (the ability to increase contractility with heart rate or
sympathetic stimulation) is severely depressed. These fundamental changes in myocardial
performance may play a role in the deterioration of pump function which causes reduced exercise
capacity of the heart failure patient(see below)(138).
Also recently, the contractile response to the myosin light chain 2 dephosphorylation was
found to be enhanced in failing hearts, despite the reduced level of basal myosin light chain 2
phosphorylation. The enhanced response to myosin light chain 2 dephosphorylation in failing
cardiomyocytes might result from differences in basal phosphorylation of other thin and thick
filament proteins between donor and failing hearts. Regulation of calcium sensitivity via myosin
light chain 2 phosphorylation may be a potential compensatory mechanism to reverse the
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detrimental effects of increased calcium sensitivity and impaired calcium handling on diastolic
function in human heart failure(318,371,372).
Myocardial remodeling and hypertrophy
A fall in cardiac output after cardiac muscle damage from myocardial infarction (MI), viral
infection, or pressure overload due to hypertension or valvular heart disease results in activation
of signaling pathways including adrenergic, renin angiotensin (including angiotensin-(1-
7))(87,88,210,359), and cytokine, designed as stress responses(28,35,72,78,218,221). The
chronic activation of these pathways in heart failure results in defects in excitation-contraction
coupling including: (A) Protein kinase-A hyperphosphorylation of the cardiac ryanodine receptor
that results in depletion of FK506 (tacrolimus) binding protein (FKBP12.6) (which helps keep
the channel closed in diastole) from the channel macromolecular complex, causing a diastolic
Ca2+ leak that depletes sarcoplasmic reticulum (SR) Ca2+(123,290,294,402); and (B) reduced SR
Ca2+ reuptake via  sarcoplasmic reticulum Ca2+-ATPase(22,222,223,234,294). Other defects in
the response in heart failure include alterations in the cytoskeleton(101,377,398) and the
extracellular matrix (imbalance between matrix metalloproteinases and tissue inhibitors of
metalloproteinase) (167,168,221,231,251,345,379).
A decrease in cardiac output decreases pulse pressure, which is sensed by high pressure
baroreceptors as a decrease in the fullness of the arterial system. Arterial under filling sensed by
arterial baroreceptors determines the “integrity” of the circulation (i.e. cardiac output and total
peripheral resistance) and activates neurohormonal systems to maintain cardiac output(322). This
neurohormonal activation, together with mechanical myocardial overload following myocardial
damage, triggers myocardial molecular and cellular remodeling and hypertrophy. 
The remodeling process follows cardiomyocytic contractile and relaxation abnormalities,
hypertrophy, apoptosis(248,335) and necrosis, together with interstitial changes, including the
extracellular matrix. Two recent experimental studies(387,401) demonstrate that cardiomyocyte
apoptosis can be a major component of the failing heart. Although not analyzed directly, the
phenotype and even the reduced survival of these transgenic mice can only be explained by a
concomitant reduction of cardiomyocyte regeneration. Taken together with other available data,
the results presented in these two papers make a strong case for the need to develop a new
understanding of normal and pathological cardiac homeostasis in which both cardiomyocyte
death and cardiomyocyte renewal are essential for the maintenance of cardiac function and its
adaptation to different physiological and pathological demands (10,27,248,249,255,292).
The remodeling process may be   reversible provided the   cause of the remodeling has been
either suppressed or attenuated (11,19,45,82,120,125,149,194,202,231,253,362,363,406). Elegant
animal experiments showed reverse remodeling with reduced systolic wall stress and improved
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adrenergic signaling by passive external support that does not generate diastolic
constriction(309). Myocardial remodeling initially may restore cardiac output with a subsequent
deactivation of the neurohormonal systems(233). The left ventricular remodeling process,
however, is not a new steady state, but in itself progressive and leading to further deterioration
of left ventricular pump function and progression of heart failure(66,136,217).
Ventricular dilatation and a decrease in ejection fraction in heart failure may not be the result
of contractile failure per se, but primary the result of the structural cardiomyocytic and interstitial
changes. In other words, to generate the same stroke volume, an increase in end diastolic left
ventricular volume (not related  to a preload-mediated increase in sarcomere length) mandates
a decrease in left ventricular ejection fraction(5,6,66,138,370). Left ventricular stroke volume,
despite a reduced ejection fraction, is indeed often normal(66,147).
In dilated  cardiomyopathy  the left ventricle dilates (with a secondary fall in left ventricular
ejection fraction) due to impaired cardiomyocytic function and marked interstitial fibrosis. These
myocardial changes influence overall pump performance of the heart(173,225). Recently it was
shown in patients with dilated cardiomyopathy, that NO augments left ventricular stroke volume
and left ventricular stroke work because of a NO-mediated rightward shift of the diastolic left
ventricular pressure-volume relation and a concomitant increase in left ventricular preload
reserve(267). These new findings indicate the potential existence of a diastolic stroke volume
reserve, caused by an increase in myocardial distensibility which enables utilization of the Frank-
Starling mechanism at relatively low filling pressures. In the failing heart, a high left ventricular
wall stress in the presence of a high left ventricular diastolic volume, and, more importantly, a
high left ventricular filling pressure, initiates signaling cascades leading to hypertrophy and
remodeling(136). Left ventricular pressure changes do affect wall stress to a greater extent as
compared to changes in left ventricular diastolic volume. In other words, according to LaPlace’s
law, doubling filling pressure doubles wall stress, whereas doubling end-diastolic volume, causes
an increase in wall stress of only 1,3 times.
Myocardial hypertrophy has long been recognized as one of the heart's mechanisms for
compensating a pressure or volume overload(94). This compensation has often been viewed as
a feedback loop in which the concentric hypertrophy, which develops in pressure overload,
normalizes wall stress while the eccentric hypertrophy, which develops in volume overload,
allows for an increase in total stroke volume to compensate that which is lost from
regurgitation(55). While the concentric hypertrophy of pressure overload often is compensatory,
many examples are noted where either too little hypertrophy occurs to normalize stress or in other
cases, in which hypertrophy exceeds the amount needed for normalization. These observations
invoke nonmechanical mechanisms which modulate the degree to which the mechanical signal
of pressure overload is translated into an increase in myocardial mass. Hypertrophy develops
when the rate of myocardial protein synthesis exceeds that of protein degradation. It now appears
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that in pressure overload this imbalance is created as synthesis rate increases while in volume
overload hypertrophy appears to accrue because degradation rate decreases(55). 
The fact that the failing heart, during exercise, depends on the Frank-Starling mechanism as
its functional reserve mechanism per se, calls upon different potentially harmful signaling
pathways for hypertrophy and myocardial remodeling if filling pressures and wall stress remain
elevated(2,135,136,141,169,347). The prognosis of chronic cardiac hypertrophy patients can be
affected significantly by modulation of the signaling mechanisms rather than reduction of cardiac
hypertrophy itself. Therefore, what  should be treated in patients with chronic cardiac hypertrophy
may be the signaling mechanisms mediating cardiac hypertrophy, which have more pronounced
effects upon cell survival and death of individual cardiomyocytes(135,240).
Myocardial hypertrophic changes, secondary to increased myocardial stretch, are able to
compensate for decreased myocardial contractility or increased load of any cause or both.
Hypertrophy may be able to increase contractile myocardial function initially, however
hypertrophy by itself has eventually a plethora of effects on dynamic and structural properties of
the cardiomyocyte(121,212,256). The process of myocardial hypertrophy may be physiologic as
in athletes, or causes damage on the long run after an initial period of cardiac compensation.
Intrinsic myocardial compensatory mechanisms, elicited by myocardial stretch, are influenced
by autocrine, paracrine, and endocrine mediated effects of nitric oxide, angiotensin II, endothelin
1, insulin like growth factor, transforming growth factor-ȕ, fibroblast growth factor,
cardiotrophin-1, aldosterone, and B-type natriuretic peptide (46,308,311,323,373). Myocardial
stretch induces, apart from the length-dependant activation, myocardial gene expression of
different autocrine and paracrine working substances utilizing some sort of mechanotransduction
of the cardiomyocytal sarcolemma influencing the cell nucleus(20,41,143,247,284). These
substances have different effects on myocardial stiffness. Mechanotransduction of course, is
compromised in case the extracellular compartment prevents the cardiomyocyte to
stretch(15,320).
 Myocardial stretch is, apart from systemic and exogenous reflex mechanisms, able to increase
myocardial contractile force as will be discussed below. Important in this respect is that the
amount of stretch, which depends on the myocardial stiffness, determines the height of the force
increase. In other words, the easier myocardium stretches, the better it is able to cope with an
increase in contraction load. Implicitly this statement tells us that systolic function importantly
depends on diastolic myocardial stiffness. This holds true for intrinsic compensatory myocardial
mechanism as the ‘Frank-Starling mechanism’ and ‘Von Anrep effect’ and not for systemic and
other exogenous reflex mechanisms. In order to preserve pump function, it is therefore of utmost
importance that the myocardium is protected against every cause of a decrease in myocardial
stiffness. If an increased wall stress sustains, and is not lowered by the intrinsic myocardial
compensatory mechanisms, a process of myocardial hypertrophy is initiated(212).
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Heart failure symptoms and left ventricular ejection fraction
Despite intense investigation of thousands of heart failure patients in many clinical trials, we still
do not understand the exact pathophysiological mechanisms of heart failure
symptoms(16,84,92,131,206,208,260,261,288,344,349). Inclusion of heart failure patients in
most clinical trials was based on the presence of a reduced ejection fraction. In the ACC/AHA
guidelines on heart failure(140). the following statement has been made: "The mechanisms
responsible for exercise intolerance in patients with chronic heart failure have not  been clearly
defined. Patients with a very low ejection fraction may be asymptomatic, whereas patients with
preserved left ventricular systolic function may have severe disability. The apparent discordance
between the severity of systolic dysfunction and the degree of  functional  impairment is not well
understood despite intense investigation".
Several factors may contribute to the above mentioned lack of understanding. 
1. In case of a dilated left ventricle (high end-diastolic volume) with a normal stroke volume
(i.e. low EF) during rest and exercise, the human body will not notice the presence of left
ventricular dysfunction because of a near normal overall pumping capacity of the heart
despite a reduced EF. The human body is not aware of a low EF but perceives low minute
volume and high filling pressures(322). Unfortunately their is no relation between EF and
these two parameters. A reduced minute volume activates systemic neuro humoral reflex
mechanisms, an increase in left ventricular filling pressure reduces the compliance of  the
lungs causing dyspnea. 
2. The use of left ventricular ejection fraction as the clinical standard to evaluate left
ventricular systolic performance(56). Ejection fraction may be reduced exclusively by an
increase in end-diastolic volume and not necessarily by a decrease in stroke volume. In
heart failure a reduced left ventricular ejection fraction usually is the result of dilatation of
a remodeled left ventricle and has a poor correlation with symptoms in the presence of a
normal left ventricular stroke volume(66,178).
3. It is assumed that a normal resting left ventricular ejection fraction is synonymous with
preserved left ventricular  systolic function. This may not be the case, since in diastolic
heart failure patients, despite their normal resting left ventricular ejection fraction, left
ventricular systolic function is probably impaired as evident from other measures of left
ventricular performance(153,276,403-405). One aspect of systolic left ventricular
dysfunction is its incompetence to increase contractility with an increase in heart rate on
exertion. This so called blunted or negative force-frequency response of failing
myocardium causes a lack of exertional decrease in end-systolic left ventricular volume to
increase left ventricular stroke volume(2). To increase left ventricular stroke volume, the
failing myocardium therefore depends on its preload recruitable stroke work, i.e. the Frank-
Starling mechanism. In case of diastolic dysfunction, and blunted left ventricular preload
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reserve, subtle systolic dysfunction may therefore lead to heart failure irrespective of a
normal or low ejection fraction, i.e. a non-dilated or dilated left ventricle respectively. The
use of ejection fraction to distinguish systolic from diastolic heart failure thus may not be
acceptable anymore because heart failure patients with either a normal or low ejection
fraction probably have both diastolic and systolic dysfunction(170).
4. For practical purposes resting left ventricular ejection fraction is used in the large clinical
trials as a function of left ventricular performance. Because most patients with heart failure
only are symptomatic on exertion, resting left ventricular ejection fraction has a poor
correlation with symptoms during exercise(282).
5. Systolic heart failure (low left ventricular ejection fraction) is discriminated from diastolic
heart failure (normal left ventricular ejection fraction) because systolic heart failure is
thought to have a worse prognosis than diastolic heart failure.  Diastolic heart failure was
associated with a lower annual mortality rate of approximately 8% as compared to annual
mortality of 19% in heart failure with systolic dysfunction(109,216). More recently,
however, careful examination of the available studies raises the possibility that the natural
history of patients with diastolic heart failure may not be different from that observed in
pa t i en t s  w i th  conges t ive  hea r t  f a i lu re  and  r educed  sys to l i c
function(18,150,151,326,339,375). So, as far as prognosis is concerned, systolic heart
failure and diastolic heart failure with so called preserved systolic function, i.e.  normal left
ventricular ejection fraction, may be two of a kind(374).
6. Furthermore, the use of left ventricular ejection fraction does not give information on
diastolic left ventricular function in heart failure. Therefore the presence of diastolic
dysfunction can not be excluded on the basis of a reduced left ventricular ejection fraction
per se.
7. Symptoms of heart failure like dyspnea on exertion may also occur in a variety of unrelated
conditions, including  obesity, lung disease, and myocardial ischemia. This could lead to
a false diagnosis of heart failure with preserved left ventricular ejection fraction.
8. In the absence of significant mitral regurgitation, the increase in stroke volume during
dynamic exercise is largely the result of a combined increase in preload and contractility.
In the presence of mitral regurgitation, however, dynamic changes in the severity of
regurgitation during exercise may compromise the normal increase in forward stroke
volume and hence reduce maximal cardiac output and exercise capacity(187). In patients
with heart failure due to left ventricular systolic dysfunction, exercise-induced changes in
forward stroke volume during exercise are strongly influenced by exercise-induced changes
in the severity of functional mitral regurgitation. Exercise-induced changes in the severity
of functional mitral regurgitation may contribute to limit exercise capacity in heart failure
patients(187). 
9. EF is neither a measure of contractility nor a load-independent measurement of systolic
function(47,410).
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10. Increased aortic stiffness may limit exercise tolerance in patients with dilated
cardiomyopathy. A stiffer aorta may interfere with both systolic and diastolic left
ventricular function. The combination of a stiffer left ventricle with a stiffer central
vasculature can further reduce exercise performance in patients with an already depressed
left ventricular function. Changes in aortic stiffness may be a clinically important parameter
in predicting heart failure symptomatology(36,159,312).
From 1 to 10  it becomes clear why some patients with reduced left ventricular ejection fraction
do not have signs and symptoms of heart failure and why patients with normal left ventricular
ejection fraction are symptomatic. A more detailed analysis of systolic and diastolic left
ventricular function instead of a simple left ventricular ejection fraction measurement therefore
is necessary.
Defining left ventricular function.
Cardiovascular physiologists have been researching ways to characterize the two fundamental
properties of the left ventricle. First, its passive aspects,  that is how easily the left ventricle can
be filled, depending on left ventricular diastolic distensibility, and  second, left ventricular
contractility, or how strong it gets when activated. Left ventricular pressure-volume analysis has
proven to be the best way to assess both aspects(154,211).The analysis is performed by
simultaneously measuring the pressure and volume(13,346) of blood inside the left
ventricle(356). These two signals are measured as curves in time, but then plotted with left
ventricular volume on the x-axis and  left ventricular pressure on the y-axis, so that each time the
left ventricle contracts and relaxes, it creates a so called left ventricular pressure-volume loop.
Points along the pressure-volume loop indicate the changes in left ventricular volume and
pressure.
Pressure-volume relationships have provided extensive insight into left ventricular pumping
characteristics(154,301). As advances in noninvasive methods continue to evolve, reliance on
invasive methodologies to characterize diastolic left ventricular properties will continue to fade
into the background. At present, however, simultaneously acquired left ventricular pressure and
volume remains the gold standard for the two primary myocardial  properties which determine
stiffness (myocardial relaxation and myocardial material properties), and  have clearly played a
central role in the evolution of our understanding of cardiac diastolic disease and its
treatment(154,317).
Introduction
21
1.3 Left ventricular diastolic distensibility and heart failure
Structure of the left ventricular wall
The healthy left ventricle, with its remarkable mechanical efficiency, has a gothic architecture,
which results from the disposition of the myocardial fibers supported and maintained by a normal
collagen matrix scaffold. The myocardial fibers of the left ventricle have an oblique and spiral
orientation of 60b(12). Despite the sarcomere shortening of only 15%, the global left ventricular
ejection fraction is around 60% due to this myocardial fiber orientation. As evident from three-
dimensional MRI images and from measurements  of  the curvature and thickness of the
ventricular walls, the normal left ventricle was recently compared to a gothic building(65). In this
model, the remarkable structural strength of the gothic left ventricle, that allows it to withstand
the important stresses in its wall associated with the cardiac pumping function, is the result of its
geometry, i.e. left ventricular volume, left ventricular shape and left ventricular wall thickness,
and of the structure of the myocardium. A Romanesque transformation often characterizes the
diseased left ventricle of heart failure patients.
The myocardium is composed of muscle fibers, a functional syncytium of cardiomyocytes,
embedded in an extracellular matrix containing endothelial cells, fibrillar collagen, fibroblasts,
and macrophages. The total amount of non-cardiomyocytes in the myocardium outnumbers the
amount (not the volume) of cardiomyocytes.
Endothelial cells
Experimental work during the past 15 years has demonstrated that endothelial cells in the heart
play an obligatory role in regulating and maintaining cardiac function, in particular, at the
endocardium and in the myocardial capillaries where endothelial cells directly interact with
adjacent cardiomyocytes(48,388). Removing the endocardial layer experimentally showed the
same calcium desensitizing effect as muscle shortening does, but differs as compared to all other
inotropic interventions(348,381). Endothelium- mediated auto-/paracrine signaling by nitric oxide
interacts with other cardiopulmonary pathways, such as beta-adrenergic or cholinergic pathways
in the heart, atrial and B-type natriuretic peptide activity(77,215,228), and circulating thyroid and
aldosterone hormones(48,245). Nitric oxide is released from the coronary and endocardial
endothelium possibly as a result of flow-induced shear stress and the cyclic mechanical
deformation that occurs during the cardiac cycle(328). Both coronary flow and minute volume
usually increase during exercise with a secondary increase in nitric oxide release.
Nitric oxide induces an early onset of ventricular relaxation, thereby enhancing ventricular
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relaxation, early rapid filling, and diastolic left ventricular distensibility.  In many cases, this
effect may be accompanied by a slight decrease in peak systolic pressure despite the often
unaltered rate of pressure development and unaltered ejection properties(71).
Such apparently negative inotropic effects may be regarded by many as potentially detrimental;
rather, they should be considered as potentially beneficial to cardiac function (272), acting as a
compensatory feedback, when the physiological effects on contraction duration of enhanced
ventricular preload and/or afterload are superimposed on the pathological prolongation of
contraction duration in ventricular hypertrophy, especially if tachycardia intrudes on diastolic
filling time(48). Interestingly, Pinsky et al.(283)  have demonstrated that there is a cyclical release
of nitric oxide in the beating heart, most marked subendocardially, which peaks at the time of
ventricular relaxation and early rapid filling. These appropriately timed, brief bursts of nitric
oxide release would provide important beat-to-beat modulation of ventricular relaxation, early
filling, and diastolic coronary perfusion. The  subendocardial localization would suggest
endocardial endothelial cells as its major source(48).
An increase in left ventricular diastolic distensibility, (i.e., low left ventricular end-diastolic
pressures at high left ventricular end-diastolic volume), with its preload induced increase in
stroke volume, constitutes one of the most fundamental modulators of cardiac systolic function
(23,48,51,52,146,197,272,273,286,289,328).
In addition to endothelial nitric oxide production with its paracrine effect on the myocardium,
nitric oxide is also produced within the cardiomyocyte in the presence of three isoforms of nitric
oxide synthase(NOS): eNOS(NOS3), iNOS(NOS2), or nNOS(NOS1), exerting autocrine effects
(26,163,325,396,415). Recently, basal release of nitric oxide is reported in the isolated heart,
which significantly augments preload-induced increase of cardiac output, i.e. the Frank-Starling
mechanism(289).
To quantify the relationship between applied force and nitric oxide synthesis, intermittent
compressive or distending forces applied to ex vivo non beating hearts were shown to cause
bursts of nitric oxide synthesis, with peak nitric oxide levels linearly related to ventricular
transmural pressure(283). Experimentally removing coronary and endocardial endothelial cells
abolishes the nitric oxide signal, which may indicate that these cells transduce mechanical
stimulation into nitric oxide production in the heart(283). Taken together, these studies may help
explain load-dependent relaxation, cardiac memory for mechanical events of preceding beats,
diseases associated with myocardial distension, autoregulation of myocardial perfusion and
protection from thrombosis in the turbulent flow environment within the beating heart(283).
These results, together with previous findings that nitric oxide modulates the force-frequency
relation, beta-adrenergic inotropic response(23), myocardial relaxation(272,273), and possibly
heart rate, indicate the potential importance of nitric oxide in the regulation of myocardial
performance(289).
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The effects of nitric oxide on myocardial function are postulated to be mediated by the
intracellular messenger cGMP via a depression of myofilament sensitivity to intracellular Ca2+
(17,95,146,273,332,340,365). Recently data became available that effects of the nitric oxide
donor sodium nitroprusside on cell contraction are mediated by changes in intracellular pH
(pHi)(146).
Bioassay studies showed the tonic release of a stable substance with potent myocardial
activity: "myofilament desensitizing agent"(330). Like nitric oxide, this "myofilament
desensitizing agent" did show a reduction in the amplitude of cardiomyocyte shortening, an
earlier onset of cardiomyocyte relaxation and an increase in diastolic length. These effects are,
like nitric oxide, not accompanied by changes in the cytosolic Ca2+ transient, indicating that they
result from a reduced Ca2+ sensitivity of the contractile proteins. Thus both nitric oxide and this
"myofilament desensitizing agent" enhance myocardial relaxation and increase active diastolic
elasticity by reducing diastolic tone(328). 
Endothelial modulation of myocardial function can now be seen as an important regulatory
pathway influencing heterometric and homeometric autoregulatory mechanisms (see below).
Eventually, modulation of the myofilamentary affinity for Ca2+ is the major component of the
underlying basis of the Frank-Starling mechanism(182). Cardiac endothelial cells release different
factors that exert important paracrine effects on myocardial systolic and diastolic
function(49,50,130,329). It is estimated that no cardiomyocyte is more than 3 to 5µ from an
endothelial cell(328,329). Results of experimental studies (91,105,201,235,327,331) are
confirmed in human subjects(272,273). These studies have demonstrated that vascular as well
as endocardial endothelial cells exert a paracrine influence on cardiomyocytal function.
Cardioactive factors released by the cardiac endothelium include nitric oxide, endothelin,
adenylpurines and other substances as yet chemically unidentified(328). The cardiac endothelial
cells also possess enzymatic activities which contribute to changes in local levels of substances
as angiotensin II and bradykinin(328). These endothelial paracrine factors influence myocardial
systolic and diastolic function predominantly by modifying cardiac myofilament properties rather
than altering cytosolic Ca2+ transients(307).
Fibrillar collagen
Another important constituent of the ‘non-cardiomyocytal compartment’ is fibrillar collagen.
Fibrillar collagen (type I and type III, with a shift in collagen III to I in heart failure) is the main
structural protein of the extracellular matrix occupying 4% of the interstitial space. Type III
collagen is far less abundant and more distensible than type I collagen which has the tensile
strength of steel. A collagen network (endo-, peri-, and epimysium) scaffolds the cardiomyocytes
to maintain tissue architecture and cardiomyocyte alignment  during the cardiac cycle. The
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amount of collagen in the extracellular matrix(400), but to a greater extent, collagen cross-linking
and the ratio of type III and type I collagen are important determinants of myocardial
stiffness(15,179,392).
The cardiomyocyte: structural properties
The cytosol is the fluid region of the cell cytoplasm that lies outside of the cell organelles.
Initially, the cytosol was thought to be a fairly homogeneous “soup” in which all of the organelles
floated. It is now known that the cytosol of all cells contains a cytoskeleton. In general, the
cytoskeleton helps to maintain cell shape and mobility and provides anchoring points for other
cellular structures(3,128,129,200). The cardiomyocyte cytoskeleton is composed of myofibrillar
and extramyofibrillar or cytoplasmic compartments. In contrast to our knowledge of the
importance of alterations in proteins that actively participate in cardiomyocyte contraction,
relaxation and growth, there is less information regarding the role of cytoarchitectural
components of the cardiomyocyte in normal and pathological states.
A myofibril comprises a chain of sarcomeres. A sarcomere is the segment from one Z-disc to
the next and consists of two halves of an I-band and one A-band. A sarcomere is both the
structural and functional unit of cardiac muscle and contains two types of filaments: thick
filaments, composed of myosin, and thin filaments, containing actin. Myosin is an unique enzyme
because it can move along an actin myofilament by coupling the hydrolysis of ATP to
conformational changes. Such an enzyme, which converts chemical energy into mechanical
energy, is called a mechanochemical enzyme or motor protein. Myosin is the motor, actin
filaments are the tracks along which myosin moves, and ATP is the fuel that powers the motility.
Coordinated, synchronous contraction of the heart is facilitated by mechanical coupling between
sarcomeres at Z-discs, adjacent cardiomyocytes at intercalated discs, and cardiomyocytes and the
extracellular matrix at costameres and dystrophin-glycoprotein complexes(257).
The myofibrillar cytoskeleton includes titin(127,383,393,395) (the largest protein known and
the third most abundant cardiac protein), myosin binding protein C(226,298,389,390) (a protein
located within sarcomeric A-bands), and  desmin(124,139,351,382) (a longitudinally oriented
intermediate filament (IF) bridging between  the Z-discs(37) in the same myofibril). Its alignment
with the sarcomere is held in place by numerous intermediate filament-associated proteins (IFAP)
including skelemin at the M line and synemin at the Z-disc, and vinculin (an adapter protein which
attach actin filaments to integrins)(20,41,85,90,103,104,257,305). Nebulette is an actin binding
Z-disc protein, extending approximately 25% of the thin filament length(239,254,315).
Transduction of mechanical stress into biochemical signals is largely mediated by a group of
integral membrane proteins called integrins(306). They link the extracellular matrix to the
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cellular cytoskeleton to provide physical integration between the outside and the inside of the
cardiomyocyte.  Extracellular ligands, like collagen, fibronectin or laminin, activate  integrins
which initiate signaling in multiple intracellular pathways through the integrin bound protein
melusin. Melusin interacts with the cytosolic domain of integrin and acts as a biomechanical
sensor which regulates gene expression, growth and survival of  cardiomyocytes(20,41,60). It is
suggested(20), that progression to cardiac failure does not depend on the phenotype of
hypertrophy, but may be related to the balance between the activation of protective and
deleterious pathways. In other words, as discussed above, it is not the hypertrophy per se that
determines a detrimental outcome(172), but rather the different signaling pathways (integrin
mediated versus activation of Gq-coupled receptors(299) or cytokine receptors) that are activated
in response to the chronic overload state of the heart, with a potential protective role for the
integrin mediated hypertrophy signaling pathway(20,302,333). 
The extramyofibrillar cytoskeleton is composed of at least three classes of fibers: tubulin-
containing microtubules (24 nm) (microtubules are polymers of Į- and ȕ-tubulin that can
polymerize and depolymerize to participate in multiple cellular processes, including growth and
proliferation)(413), actin microfilaments (7 nm) and intermediate filaments (10 nm).
The ability to modulate the amount and degree of polymerization of tubulin may have
important therapeutic implications. On the levels of the sarcomere and the cardiomyocyte a
persistent increase in microtubule density accounts to a remarkable degree for the contractile
dysfunction seen in pressure-overload right ventricular hypertrophy(413). A persistent increase
both in microtubules and in their biosynthetic precursors exists in pressure-hypertrophied
myocardium. Increased microtubule density constitutes primarily a viscous load on the
cardiomyocyte contractile apparatus in pressure-overload cardiac hypertrophy(412). 
Biophysical interactions among sarcolemmal integrin receptors and the cytoplasmic
(extramyofibrillar) and myofibrillar cytoskeleton are still largely unknown(350). The
integrin-cytoskeleton complex may act as a mechanoreceptor  translating signals from the
extracellular  matrix and inducing biochemical signals within the cell that regulate gene
expression and cellular growth(20,41,90,305). The extracellular matrix together with cytoskeletal
proteins are the  major  determinant for passive myocardial properties. An active component of
myocardial stiffness depends on the intensity of diastolic cross-bridge interaction, which
determines diastolic myocardial tone as was discussed above.
The passive myocardial stiffness was initially thought to originate from the extracellular
collagen matrix of the endo-, peri-, and epimysium. Investigation on  isolated cardiomyocytes
made it however clear, that stiff structures are located within the cell as well. The stiff
extracellular or interstitial elements, which help prevent overstretch of muscle tissue, may be
relevant only at more extreme, pathological, stresses and strains(394). and the intracellular
elements, produce myocardial stiffness in the more physiological range of diastole(112). These
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elements, the cytoskeletal proteins, e.g., titin,  store elastic energy during cardiomyocyte
contraction below the equilibrium length (restoring force) and develop passive force when the
cardiomyocyte is stretched(110-112,205).
The cardiomyocyte: functional properties
Despite early reports of dynamic changes in diastolic distensibility of the left ventricular
chamber(232,316) it was not before the 1970's that clinicians became aware of this important
myocardial property. Myocardial distensibility was initially thought to be dependent on
myocardial material properties, left ventricular wall thickness and geometry. This implied that
the relation between left ventricular  diastolic pressure and volume could change only as a result
of chronic myocardial changes (i.e., myocardial scarring or hypertrophy). In line with this
assumption left ventricular pressure was used as a surrogate for left ventricular volume(336).
However, clinical observations, that angina pectoris caused a change in wedge pressure in
patients with indwelling, right sided catheters, changed this traditional view. Nowadays we
understand clearly that intrinsic dynamic factors, like myocardial relaxation, coronary vascular
perfusion, and residual diastolic left ventricular myocardial tone, can instantaneously influence
diastolic left ventricular distensibility (262).
Animal experiments showed that the myocardium does not relax to a totally passive “flaccid”
state, but instead rapidly relaxes to a lower level of residual cross bridge cycling associated with
a basal level of energy use and heat production, as was discussed above
(68,184,211,317,342,353,414). In both animal and human myocardium, diastolic volume at a
given diastolic pressure, is partly dependent on weakly bound cross bridges as a function of the
diastolic calcium concentration in the cardiomyocyte(160,317,342). This residual diastolic cross
bridge cycling, therefore actually may modify the Frank-Starling mechanism, a modification
which  simply would not exist if the diastolic or resting mechanical myocardial properties were
completely passive(160,342).
Influencing these  active diastolic myocardial properties, in a way that left ventricular diastolic
distensibility increases (i.e.  a downward and rightward shift of the left ventricular diastolic
pressure-volume curve) results in an increase in end-diastolic sarcomere length at a given end-
diastolic pressure and improved left ventricular systolic performance by increasing preload
reserve(272,273,289). The left ventricular wall stress (‘afterload’) in this case will only be
minimally increased because of a larger radius in the setting of unchanged pressure prior to
contraction. 
Preload effects on rate of left ventricular pressure fall, however, is still subject to debate
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(98,99,106,107,189,411). Afterload is an acute determinant of the end-diastolic pressure-volume
relation, which, therefore, does not provide a load-independent assessment of diastolic
function(189).
The active diastolic myocardial properties are determined by residual diastolic interaction of
contractile proteins related to changes in rate and extent of myocardial relaxation, among other
factors. Relaxation refers to the process by which the myocardium returns to its initial length and
tension following a contraction. The onset of left ventricular filling occurs before the end of
relaxation from the previous systole. The ventricular diastolic pressure-volume relation is
influenced by the rate and extent of myocardial relaxation from the previous
systole(106,189,191,265).
The rate of relaxation affects the atrioventricular pressure difference, which is the driving force
behind early ventricular filling. The efficient and complete reuptake of activator calcium from
the sarcomeres by the sarcolemma and the sarcoplasmatic reticulum produces a fast rate of
relaxation to a low minimum ventricular pressure, which facilitates high left ventricular filling
rates. The rate and extent of relaxation are influenced by changes in load and depend on the
intracellular processes controlling cross-bridge inactivation, and any regional dyssynchrony of
the contraction-relaxation sequence(69,211).
Other factors change the rate and extent of relaxation, or influence active diastolic tone: stretch
sensitive calcium channels, diastolic sarcoplasmic calcium release, the influence of neuro
hormones and endothelial modulation of active diastolic tone(108,221,287,391).
An increased number of force producing cross-bridges during diastole contributes to reduced
distensibility of the cardiomyocyte compartment  and reduced sarcomere length at a given
diastolic pressure impairing left ventricular systolic(108,183,407) and diastolic(31,397)
performance. This reduction in end-diastolic sarcomere length causes a decrease in left
ventricular equilibrium volume with a strain independent diastolic dysfunction: i.e. an upward
shift of the diastolic left ventricular pressure-volume relationship (Figure 4).
A complete evaluation of the left ventricular diastolic properties includes the determination
of left ventricular myocardial and chamber stiffness constants, end-diastolic pressure, end-
diastolic wall stress, end-diastolic stiffness, and the dynamic processes of rate and extent of left
ventricular myocardial relaxation.  The use of echocardiographic or radionuclide techniques to
quantify the rate of blood flow or volume changes in the left ventricle during diastole generates
parameters that are influenced by loading conditions in the heart and therefore cannot be viewed
as specific indexes of diastolic distensibility(53). The only way to demonstrate left ventricular
diastolic dysfunction or to calculate stiffness, is to show that the left ventricular end-diastolic
pressure-volume relation  is altered compared with normal (i.e., steeper than normal or displaced
upward in the left ventricular pressure-volume plane). By characterizing the left ventricular
end-diastolic pressure-volume relation, it is possible to show not only that left ventricular
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diastolic pressure is elevated, but also that such a pressure increase is not the result of increased
left ventricular diastolic volume as by increased preload but follows an upward shift of the left
ventricular end-diastolic pressure-volume relation(53).
Diastolic stress-strain versus pressure-volume relationships
Both structural and dynamic myocardial factors ultimately determine left ventricular chamber-
and myocardial stiffness. Chamber stiffness has to be distinguished from myocardial stiffness.
Left ventricular chamber stiffness is derived from left ventricular pressure and volume data,
whereas myocardial stiffness is derived from left ventricular wall stress and strain data. Left
ventricular chamber stiffness increases either with each increment in left ventricular filling
pressure: so called preload- or strain dependent increase in chamber stiffness, or through a
leftward and upward shift of the entire pressure-volume relation, often referred to as a decrease
in diastolic left ventricular distensibility (i.e. a strain independent increase in left ventricular
chamber stiffness). The diastolic left ventricular pressure-volume relation can be expressed as
an exponential function. A modulus of left ventricular chamber stiffness (K C) is derived from the
slope of the linear relation between left ventricular chamber stiffness (dP/dV) and diastolic left
ventricular pressures(198).
A myocardial stiffness constant (KM) is determined by the slope of the linear relation between
left ventricular myocardial stiffness (dı/d…) and left ventricular myocardial wall stress for
instance at the end of diastole(98,198). These definitions of left ventricular chamber- and
myocardial stiffness ignore the existence of stress relaxation (a time dependent decline in stress
when a material is held at a constant length after a rapid stretch), creep (a gradual increase in
length when a material is held at constant stress after a rapid stretch), viscoelasticity (causing a
higher level of stress when a material is stretched rapidly), and elastic recoil(98,198).
Elastic recoil causes diastolic suction which is created by the preceding systolic contraction.
The more forceful systolic contraction and concomitant decrease in end-systolic volume, the
greater elastic recoil and suction early in diastole(89). Diastolic suction may facilitate left
ventricular filling during exercise in the presence of an intact force-frequency response with a
decrease in the end-systolic volume below the left ventricular equilibrium volume(144,199). If
these experimental findings play a significant role clinically, is doubtful (271). Both stress
relaxation and creep probably have clinically little significance in the intact heart as well.
In summary,  the diastolic left ventricular pressure-volume relationship is determined both by
the material properties of the left ventricular wall, and by left ventricular geometry (i.e. left
ventricular shape, left ventricular volume and left ventricular wall thickness). The material
properties of the myocardium dictate the strain that follows a given stress, and determine position
and shape of the myocardial stress-strain relationship. These material properties, together with
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the left ventricular geometry also determine position and shape of the diastolic left ventricular
pressure-volume relationship. The link between the one dimensional myocardial stress-strain
relationship and the left ventricular pressure-volume relationship is LaPlace’s Law, which takes
into account left ventricular geometry. At low filling pressures the structural determinants of the
diastolic left ventricular pressure-volume relationship are the cytoskeleton titin(115,162), together
with the (residual) diastolic cross-bridges interactions  of contractile elements after a previous
contraction. At very high filling pressures the structural determinants of the diastolic left
ventricular pressure-volume relationship are determined by collagen fibers of the extracellular
matrix, superimposed on cytoskeletal properties and on the (residual) diastolic cross-bridges
interactions  of contractile elements after a previous contraction. The importance of diastolic left
ventricular distensibility will become even more obvious when the sequellae of systolic
dysfunction on heart failure symptoms will be discussed below.
1.4 Stroke volume reserve and heart failure symptoms
Frank, Starling, Bowditch, Von Anrep and Gregg
'Heterometric autoregulation'
Although the contractile performance of the heart is under continuous nervous, hormonal, and
electrophysiological influence, the heart has intrinsic mechanisms by which it can adapt its output
to changing systemic demands. An increase in left ventricular end-diastolic volume following an
increase in venous  return or an increase in aortic input impedance, instantly leads to a more
powerful contraction. This is called the Frank-Starling mechanism which allows the heart to cope
with an increase in venous return by an increased stroke volume or maintaining stroke volume
despite an increase in aortic input impedance. This is labeled ‘heterometric autoregulation’ and
corresponds to an increase in contractile performance following an increase in  left ventricular
end-diastolic volume.
Frank and Starling carried out fundamentally different experiments. Frank measured the
isovolumic pressure developed by frog heart at different volumes(93). He therefore discovered
the pressure-volume-volume relationship which depends directly on the force-length relationship
of the sarcomeres. Starling studied cardiac shortening as manifest by cardiac output and its
relationship to end-diastolic conditions as manifest by right atrial pressure(266).
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Figure 1. Diagram illustrating cardiac reserve mechanisms during exercise in the presence of intact cardiac
function. Exercise initially increases venous return(VR) and left ventricular(LV) end-diastolic volume (EDV),
causing an increase in LV stroke volume[A] (‘Fast force response’ or Frank-Starling mechanism).To date,
no data are available on the role of the ‘slow force response’(Von Anrep effect)[B] during exercise, in the
presence of an intact force-frequency response (FFR). Subsequently a heart rate increase per se[C]
increases cardiac output(CO). A  high heart rate increases myocardial contractility (positive (FFR)[D],
causing a reduction in end-systolic volume (ESV)  and EDV. This increase in contractility compensates for
a loss of the Frank-Starling mechanism. The increase in CO matches the increased VR, resulting in normal
exercise tolerance. B-type natriuretic peptide(BNP) < 100 pg / ml is in the normal range, indicating  normal
LV filling pressures and LV wall strain(228). LVEDP: left ventricular end-diastolic pressure; LVEDV: left
ventricular end-diastolic volume.
Thus he was studying the ability of cardiac muscle to shorten more at a given load from a greater
initial length. Starling in the promulgations of his law implied a common mechanism for these
two phenomena and spoke of the “energy liberated” being a function of initial muscle fiber
length(157,357). The existence of the Frank-Starling mechanism, disputed by some(174,324),
is reported to be operational in the dilated and failing left ventricle
(117,133,134,155,156,334,360,366,367,369,385,399). 
At low levels of exercise, when heart rate is only slightly increased, minute volume is mainly
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increased by an increase in venous return which forces end-diastolic volume  and stroke volume
to increase (Frank-Starling mechanism)(Figure 1). Whereas, at higher levels of exercise different
cardiac reserve mechanisms will be operable, as will be discussed below. 
(Patho)Physiology of Exercise
The inability to perform exercise without discomfort may be one of the first symptoms
experienced by patients with heart failure and is often the principal reason for seeking medical
care. Therefore, exercise intolerance is inextricably linked to the diagnosis of heart failure(282).
Increased venous return stretches the left ventricle with a concomitant length-dependent
activation and increase in ejection pressure or stroke volume or both. There is abundant
experimental evidence for a biphasic increase in contractile force production after myocardial
stretch:  an instantaneous increase in contractile force (without changing contractility(368)) due
to an increased Ca2+ sensitivity of contractile elements (Frank-Starling mechanism)
(96,145,355)  and a slow increase in contractility mediated by a stretch induced increase in the
intracellular Ca2+ transient (Von Anrep effect) (4,62-64,185,274,355,378). The peak of the Ca2+
transient after a length change does not change immediately(264,368). A rise in sarcomere length,
causes an initial increase in contractile force, followed by a slow force increase(264,296). The
slow force increase corresponds to a higher peak of the Ca2+ transient(73). This rise in the peak
of the Ca2+ transient means an increase in contractility. Contractility or inotropic state is a more
stable descriptor characterizing the cardiac muscle behavior as long as chemical environment and
temperature do not change (138,278,368). The amplitude of the Ca2+ transient is determined by
the rate at which the sarcoplasmic reticulum releases Ca2+ and the rate at which troponin C binds
free Ca2+. Interventions or states that increase the affinity of troponin C to Ca2+ decrease the
amplitude of the intracellular Ca2+ signal(30). Furthermore, the Ca2+, released from the
sarcoplasmic reticulum, does not activate the contractile proteins maximally, allowing the
myocardium to have a large contractile reserve(30). On the cellular level cardiac contractility
depends mainly on the amount of activator Ca2+ that reaches the myofilaments, the amount of
contractile protein, its Ca2+ affinity, adenosine triphosphatase (ATPase) activity, and the rate of
actin-myosin cross-bridge cycling(30,102). Thus at a constant temperature and unchanged Ca2+
sensitivity, it is the peak of the Ca2+ transient that determines myocardial contractility. Since
instantaneous sarcomere length changes do not influence the peak of the Ca2+ transient,
contractility is thus separated from the consequences of an instantaneous change of sarcomere
length, i.e. an increased Ca2+ affinity of  troponin C(73,74). Thus the slow effect of a change in
length on force development is concurrent with a change in the peak of the Ca2+ transient and may
consequently be considered as an inotropic intervention(4,368). Notably, in case a change in
cardiac muscle length is applied in order to measure contractile state, a change in contractile state
is caused eventually by that change in muscle length itself, and measurements therefore should
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be made promptly after the length change is applied(4,368).
To date, no data are available on the role of the ‘slow force response’(Von Anrep effect)
during exercise, in the presence of an intact force-frequency response(61) (see below). An
exercise induced increase in heart rate, eliciting the force frequency response, possibly causes a
decrease in end-diastolic volume before the slow force response gets operational, which takes a
couple of minutes(63). 
Exercise increases contractility further by a combination of  ȕ-adrenergic stimulation and a
positive force-frequency relation or 'Bowditch frequency treppe' (2,39,44,236,295,304,319).
Increased stroke volume and heart rate on exercise enable the heart to  increase the resting cardiac
output three to four times(2). A positive force-frequency response may be seen as a systolic stroke
volume reserve, responsible for an additional 30% increase in minute volume at high heart rates,
as compared to heart rate increase alone(2). ȕ -adrenergic stimulation of the myocardium
increases the Ca2+ transient and speeds up relaxation. A positive force-frequency relation
increases the sarcoplasmic reticulum (SR) Ca2+ content due to a reduced inhibition of SR
Ca2+-ATPase (SERCA2) by phospholamban(33,34,236,237). An increase in SR Ca2+ content
causes a higher Ca2+ transient(44,295,304). The force-frequency effects are amplified by
ȕ-adrenergic stimulation(303,304). Experimentally heart rate was shown to modulate the slow
force response(364).
A positive force-frequency relationship results in a decrease in end-systolic volume thereby
decreasing end-diastolic volume which initially was increased due to  an increase in venous
return(204,408). During exercise, before heart rate increases, the Frank-Starling mechanism is
the predominant compensatory mechanism to increase cardiac output(286). In case of a complete
heart block(219) or fixed heart rate(252) and during autonomic blockade(161) the Frank-Starling
mechanism and possibly the slow-force response (Von Anrep effect) are the principal
compensatory mechanisms available.
However, when endurance athletes (148,195,196,361), elite bicyclists(81), or endurance
trained older man(118) exercise, they all have signs of a lower diastolic chamber stiffness and
a smaller decrease of end-diastolic volume when heart rate increases, as compared to sedentary
men. This smaller decrease in end-diastolic volume during exercise in trained subjects may be
explained by an increased utilization of the Frank-Starling mechanism(118) during high levels
of exercise, notwithstanding  ȕ-adrenergic stimulation of  the  myocardium,  the force-frequency
relation, and  ȕ-adrenergic amplification of the force-frequency relation(304). In the failing heart
however, an increase in heart rate during exercise results in a decrease in active tension
development (negative force-frequency relationship)(2,188,242,280,337,343).
ȕ-adrenergic stimulation of the myocardium and  ȕ-adrenergic amplification of the
force-frequency relation in heart failure is not significant(32,59,304). The decrease in
end-diastolic volume at increased heart rate, therefore will be smaller than normal(203,237,242),
as is the case in athletes. However, heart failure  patients, in contrast  to  athletes, depend  chiefly
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on the Frank-Starling mechanism to increase cardiac output during exercise because of a negative
force-frequency relationship and blunted  ȕ-adrenergic effects on myocardial contractility (Figure
2)(169,242,304). In heart failure patients with left ventricular hypertrophy and normal EF, often
referred to as diastolic heart failure, also show a blunted or negative force-frequency response,
with sometimes even an increase in end-systolic volume, with increasing heart rate(21). Diastolic
dysfunction present at rest did not worsen during increased heart rates(142,153,169,281,343).
Assuming  the   importance of the Frank-Starling  mechanism  as a compensatory  mechanism
in heart failure, irrespective of resting systolic function or EF, myocardial stiffness plays a
momentous role. The amount of increase of the left ventricular stroke volume or stroke work is
related to the amount of increase in the left ventricular end-diastolic volume. The amount a given
end-diastolic  pressure increases end-diastolic volume depends mainly on myocardial stiffness.
A low stiffness results in a relatively higher increase in end-diastolic volume and thus in left
ventricular stroke work. Hence a low myocardial stiffness is expected to result in lower left
ventricular filling pressures and wall stresses when DCM patients  exercise, beneficially
affecting their exercise capacity (diastolic stroke volume reserve) (272)(Figure 2). 
However, in the failing heart, a  stiff ventricle is prone to continuous high myocardial wall
stress when during exertion end-diastolic volume tends to  increase as a result of a negative
force-frequency  relation  of  dilated cardiomyopathy. A high left ventricular stiffness promotes
the induction of high left ventricular wall stress, who's sequellae play an important role in the
clinical picture of human heart failure. First, high filling  pressure causes signs and  symptoms
of dyspnea on exertion. Second,  high diastolic wall stress exposes the myocardium to stimuli
initiating myocardial hypertrophy and remodeling with its specific deleterious effects on
myocardial structure and function(230,310,311,341). Third, high myocardial stiffness reduces the
ability of the ventricle to utilize the  predominant  compensatory  mechanism of a stretch induced
increase in contraction force to regulate  stroke work  (Frank-Starling mechanism  and Anrep
effect) (Figure 3)(4). 
Important in this respect is that myocardial stiffness determines the amount of stretch for a
given amount of force. In other words, the  easier  myocardium stretches, the better it is able to
cope with an increase in contraction load at a given end-diastolic pressure. Implicitly this
statement tells us that systolic function importantly depends on diastolic myocardial stiffness.
This holds true for intrinsic compensatory myocardial mechanism as the length dependent
activation (Frank-Starling mechanism) and 'Von Anrep effect'  and not for systemic and other
exogenous reflex mechanisms. But why possesses myocardium a high diastolic stiffness?  As was
discussed above, diastolic stiffness  depends, apart from changes in structural myocardial
properties,  on how the myocardium recovers from a systolic 'insult', which determines intensity
of residual diastolic cross-bridge interaction, as was discussed above.
Chapter 1
34
Von Anrep effect versus Gregg effect
Von Anrep showed in 1912 that a heart dilatation induced by clamping the heart outflow was
followed by a decline in heart volume toward the initial volume(380). Rosenblueth in 1959 (300)
reported that an increase in heart rate (Treppe effect or force frequency response(39)) and an
increase in  afterload both increase contractility of the isolated canine right ventricle. They used
the expression ‘the two-staircase  phenomenon’. Sarnoff in 1960(314) used the term
‘homeometric autoregulation’ to define a decrease in  left ventricular end-diastolic volume
occurring  after  an initial increase in  left ventricular end-diastolic volume secondary to an
increase in afterload. Both experiments (300,314) were performed in an isolated heart preparation
which rules out a possible influence of systemically released catecholamines. In 1973
Parmley(264) showed that if the length of an isolated strip of myocardial tissue was increased,
there was a corresponding rapid (Frank-Starling mechanism) and a slow (Von Anrep effect)
increase in developed force.
The  mechanism leading to the slow force response to stretch (Von Anrep effect) is calcium
entry through the reverse mode of sodium-calcium exchange causing a progressive increase in
the calcium transient(14,63,64,164,274,279). Others found however, nitric oxide produced by
activation of  endothelial nitric oxide synthase (NOS)  to act as a second messenger of stretch by
enhancing ryanodine receptor Ca2+-release channels  activity, contributing to myocardial
contractile  activation of  the  slow force response(277). Thus, lengthening of the muscle,
longitudinal stretch of the myocardium, causes an immediate increase in developed force (Frank-
Starling  mechanism) followed by a slow increase in developed force (Von Anrep effect).
An increase in coronary perfusion, however, causes transversal stretch of the myocardium,
which increases developed force as well (Gregg  effect(114,166))  through  activation of  stretch-
activated ion channels(1,186).  Stretch-activated ion channels blockade in isometrically
contracting  perfused  rat papillary muscle completely blunted the increase of developed force
and of peak intracellular calcium concentration induced by the Gregg effect; however, it did not
affect the Von Anrep effect. The slow force response was also augmented by an increase in
coronary perfusion. This suggests an increase of developed force via the Von Anrep effect on top
of the Gregg effect.  Therefore, increased coronary perfusion causing transversal stretch of the
myocardium, and  muscle lengthening causing longitudinal stretch of  the myocardium, increase
myocardial contraction  through different stretch-triggered mechanisms(185).
Cardiomyocytes and the vasculature are aligned in parallel. Increasing coronary perfusion
experimentally deforms the myocardium perpendicular to the alignment of the cardiomyocytes
(transversal stretch) through an increase in blood vessel diameter and papillary muscle
diameter(186). This activates stretch-activated ion channels with an initial, however transient,
increase in calcium influx, subsequently followed by an increase in calcium sensitivity, both
contributing to a more forceful cardiac contraction. Because the immediate stretch-activated ion
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channel-sensitive influx of Ca2+ at the onset of the Gregg effect is transient, the intracellular
[Ca2+] elevation of the Von Anrep effect is similar at low and high perfusion. In the steady state,
the Gregg effect results in increased sensitivity of the myofilaments for calcium. Together with
the Von Anrep-induced slow intracellular [Ca2+] elevation, this leads to an augmented Von Anrep
effect at high perfusion(186).
Myocardial stretch by lengthening , however, results mainly in fiber lengthening and
longitudinal stretch of cardiomyocytes with an instant increase in calcium sensitivity of
contractile elements and a slow increase of intracellular calcium concentration, not via stretch-
activated ion channels or L-type calcium channels, but likely via angiotensin II induced
endothelin-1 release and activation of the sodium-hydrogen exchanger(274) and/or via
endogenous nitric oxide mechanisms(277).
Frank-Starling relationship: Do we know its mechanism?
The increase in myofilament Ca2+ responsiveness on an increase in sarcomere length is, in part,
the cellular basis for Frank-Starling's law of the heart(79). It has been suggested that a decrease
in myofilament lattice spacing in response to an increase in sarcomere length  underlies this
phenomenon. This hypothesis is supported by previous studies in which reduced muscle width
induced by osmotic compression was associated with an increase in Ca2+ sensitivity, mimicking
those changes observed with an increase in sarcomere length. However alterations in myofilament
lattice spacing may not be the mechanism that underlies the sarcomere length-induced alteration
of calcium sensitivity in skinned myocardium(175-177,241).
Recent evidence suggests that titin may play a role in regulating active force. Titin-based
passive force enhances length-dependent activation of cardiomyocytes(58). Degradation of titin
was found to significantly increase lattice spacing. Interfilament lattice spacing is widely held as
a determinant of the probability of actomyosin interaction at a given calcium concentration
(96,229), and the effect of titin on lattice spacing may thus explain the effect of titin's passive
tension on the length dependence of calcium sensitivity. However, considering the recent work
that showed that lattice spacing and calcium sensitivity are not well correlated (176,177), it is also
worth considering that titin influences active force via an earlier proposed mechanism (113) in
which the likelihood of cross-bridge interaction is enhanced by passive force-induced thick
filament strain. This mechanism also provides an explanation for the reported length-dependent
effect of titin on maximal active tension in rat cardiac trabeculae(97). Thus the Frank-Starling
mechanism of the heart may in part be due to an effect of titin-based force on the length
dependence of maximal active tension and calcium sensitivity.
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Left ventricular dysfunction and cardiac reserve
In the presence of left ventricular dysfunction and blunted force-frequency response, the systolic
stroke volume reserve is not sufficient or even absent(2). Notwithstanding, many patients with
left ventricular dysfunction are mildly symptomatic or even asymptomatic on exertion, suggesting
an adequate rise in stroke volume. But how? Exercise increases venous return, which forces
ventricular filling and diastolic volumes to increase. An increase in ventricular diastolic volume
increases stroke volume (Frank-Starling mechanism and Von Anrep effect). If, in the presence
of left ventricular dysfunction with blunted systolic stroke volume reserve, there is an adequate
rise in minute volume at high levels of exercise, there must be an adequate increase in both heart
rate and stroke volume(Figure 2). If patients with left ventricular dysfunction are able to recruit
an adequate stroke work increase(169), they may exercise with reasonable few symptoms. In
these patients, stroke volume increase during both low and high levels of exercise is the result
of increased ventricular diastolic filling. A distensible left ventricular wall enables them to utilize
both the Frank-Starling mechanism and Von Anrep effect (Figure 2). As discussed above, in the
absence of left ventricular dysfunction, stroke volume will increase at low levels of exercise
because of an increased ventricular diastolic filling (Frank Starling mechanism) and at high levels
of exercise because of an increased ventricular emptying (positive force-frequency response)(132)
(Figure 1).
The absence of a positive force-frequency response in left ventricular dysfunction is thus
compensated for by a facilitation of ventricular filling to increase stroke volume at high levels
of exercise.
This aspect of left ventricular dysfunction may be easily anticipated in patients encountering low
left ventricular ejection fractions, with increased end-systolic and end-diastolic left ventricular
volumes. These patients show a blunted or even negative force-frequency response and, in case
they have an easily distensible left ventricular myocardium, they may be mildly symptomatic
even at higher levels of exercise(270,289) (Figure 2). But when failing hearts are studied with a
normal left ventricular systolic function or ejection fraction at rest, it may be of some surprise that
these hearts also lack a positive force-frequency response at high levels of exercise(343,352).
Thus failing hearts, with a so called normal systolic function at rest, prove to have an inadequate
increase in systolic performance at high heart rates as well. So, what is called a normal systolic
function at rest, does not preclude systolic dysfunction at high heart rates. These, mostly
hypertrophic, hearts are not able to intensify their systolic and diastolic calcium fluxes and are
in this respect as myopathic as dilated hearts with poor contractility.
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Figure 2. Diagram illustrating cardiac reserve mechanisms during exercise in the presence of left
ventricular (LV) dysfunction, with either a normal or reduced LV ejection fraction (EF), without congestive
heart  failure (CHF) symptoms. Compensatory mechanisms (neurohumoral stimulation, myocardial
remodeling) are able to maintain normal resting cardiac output at normal LV filling pressures (BNP< 100
pg / ml) and a normal exercise tolerance. Exercise initially causes an increases in venous return(VR) and
in left ventricular (LV) end-diastolic volume (EDV), with an increase in LV stroke volume[A] (‘Fast force
response’ or Frank-Starling mechanism).The Frank-Starling mechanism[A] as well as the ‘slow force
response’ or Von Anrep effect[B] has been demonstrated to be existent in the failing and hypertrophic
human myocardium(133,369). Dysfunctional myocardium, however, lacks a positive force-frequency
response (FFR), but the heart rate increase per se[C] increases cardiac output(CO). To compensate for a
blunted systolic stroke volume reserve[D], diastolic distensibility should be high enough to generate an
adequate increase in stroke volume on exertion. High myocardial distensibility enables an adequate preload
recruitable LV stroke work at normal LV filling pressures (B-type natriuretic peptide(BNP) < 100 pg / ml).
The increase in CO[A+B+C] matches the increased VR, resulting in near normal exercise tolerance.
LVEDP: left ventricular end-diastolic pressure; LVEDV: left ventricular end-diastolic volume. 
Recently Yu et al reported systolic abnormalities to be evident in patients previously labeled as
diastolic heart failure. Their findings underline the possible common coexistence of systolic and
diastolic dysfunction in  heart failure(276,403-405). In conclusion, the mechanism to increase
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stroke volume at high heart rates both in hearts with poor or normal resting contractility and
blunted force-frequency response (i.e. systolic stroke volume reserve) is the ability to utilize
preload recruitable stroke work (Frank-Starling mechanism and Von Anrep effect, i.e. diastolic
stroke volume reserve), in the presence of high diastolic myocardial distensibility.
Heart failure and filling pressure
Heart failure symptoms may be caused by pure diastolic dysfunction(100), but  more often result
from a combination of systolic and diastolic dysfunction. What all heart failure patients have in
common, however, is the difficulty in left ventricular diastolic filling and increased left
ventricular filling pressure because of diastolic dysfunction. Increased left ventricular filling
pressures and wall stress increase wall strain which results in increased production of B-type
natriuretic protein(213,313,358).
Circulating concentrations of adrenomedullin are elevated in cardiovascular disease in
proportion to the severity of cardiac and hemodynamic impairment(293). Adrenomedullin,
discovered nearly a decade ago, has undergone intensive investigation in the ensuing years,
especially in regard to participation in the regulation of cardiovascular and pressure/volume
homeostasis, and a potential role in the pathophysiology of heart disease. Raised plasma
adrenomedullin levels following acute cardiac injury and in heart failure provide prognostic
information on adverse outcomes.Administration of adrenomedullin in experimental and human
heart failure induces reductions in arterial pressure and cardiac filling pressures, and improves
cardiac output, in association with inhibition of plasma aldosterone (despite increased renin
release) and sustained (or augmented) renal glomerular filtration and sodium excretion(293).
The biomechanical stimulation of a novel heart failure biomarker ST2, an interleukin-1
receptor family member, in vitro is similar to the mechanical induction of B-type natriuretic
peptide, which is a useful diagnostic and prognostic marker in human heart failure. The change
in serum levels of ST2 over time possibly provides prognostic information in patients with severe
heart failure independent of plasma B-type natriuretic protein(386).The plasma B-type natriuretic
peptide is a useful alternative to left ventricular function parameters (e.g. left ventricular ejection
fraction) to confirm the diagnosis of heart failure. B-type natriuretic protein was accurate in
making the diagnosis of congestive heart failure, and levels correlated with severity of disease
(24,25,171,181,193,213-215,227,250,263,297). Increased B-type natriuretic peptide levels were,
understandably, unable to differentiate between systolic and diastolic dysfunction because B-type
natriuretic protein production depends only on raised left ventricular filling pressure with a
subsequent raise in left ventricular wall strain(40,180,213,224,238).This indicates the epicenter
of the heart failure syndrome: a decrease in left ventricular diastolic distensibility raises left
ventricular filling pressure  irrespective of a normal or low left ventricular ejection fraction(170)
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(Figure 3).
Figure 3. Diagram illustrating cardiac reserve mechanisms during exercise in the presence of symptomatic
left ventricular (LV) dysfunction (Congestive Heart Failure (CHF)), with either a normal or reduced LV
ejection fraction (EF).  Resting filling pressures often are elevated. (B-type natriuretic peptide (BNP) >>
100 pg / ml). High resting LVEDP may predict a  low preload recruitable LV stroke work, i.e., an insufficient
rise in LV stroke volume (blunted diastolic stroke volume reserve)[A+B].  Following an increase in  venous
return(VR), exercise raises LVEDP even further. A heart rate increase per se increases cardiac
output(CO)[C]. But, together with an insufficient rise in LV stroke volume (blunted systolic (Negative force
frequency response (FFR)) and blunted diastolic stroke volume reserve [A+B+D]),  the increase in CO does
not match the increased VR, resulting in reduced exercise tolerance. LVEDP: left ventricular end-diastolic
pressure; LVEDV: left ventricular end-diastolic volume.
Left ventricular diastolic distensibility determines left ventricular filling pressure when left
ventricular end-diastolic volume rises on exertion, thereby determining the functional class of the
heart failure patient. Despite the possibility of pure diastolic dysfunction as a cause of heart
failure symptoms(100), discriminating between so called systolic and diastolic heart failure is
misleading and distracts attention from the fact that heart failure symptoms follow a final
common pathway, i.e. decreased diastolic distensibility, irrespective of resting left ventricular
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ejection fraction. Changes in diastolic properties depend upon the underlying pathological
mechanisms or disease states with their subsequent changes in shape and position of the diastolic
pressure-volume relationships. The different types of left ventricular diastolic dysfunction and
concomitant shift of the diastolic left ventricular pressure-volume relationships, will be discussed
in chapter 1.5.
1.5 Diastolic pressure-volume relationship
and left ventricular diastolic dysfunction
Left ventricular volume, shape and wall thickness, together with left ventricular myocardial
material properties, dictate position and shape of the left ventricular end-diastolic pressure-
volume relationship as a representation of left ventricular diastolic properties(116). The material
properties of the left ventricular wall may change instantly or chronically. An instant increase in
myocardial stiffness may be strain dependent (Figure  4: A×B) or strain independent (Figure
4:A×C). A chronic increase in myocardial stiffness causes an increase in diastolic filling pressure
especially at a higher range of diastolic volumes (Figure 4: thick arrow and dotted line).
Myocardial ischemia instantaneously influences left ventricular diastolic distensibility with
an upward and leftward, or rightward shift of the left ventricular diastolic pressure-volume
relationship, depending on the type of ischemia(31,376,397) (Figure 5).
Recent findings in patients with hypertensive pulmonary edema, unchanged end-systolic and
end-diastolic volumes before and after treatment of their hypertensive crises,  suggest that this
pulmonary edema was due to the exacerbation of diastolic dysfunction by hypertension and not
the result of  transient systolic dysfunction with a secondary increase in left ventricular preload
(Figure 6)(100). Afterload elevations were recently reported to induce an upward shift of the
diastolic pressure-volume relation(189,192). These findings indicate diastolic dysfunction in the
presence of normal systolic function following positive inotropic stimulation by the sympathetic
nervous system (Figure 6). An unchanged end-diastolic volume indicates a strain independent
increase in myocardial stiffness by an upward shift of the left ventricular end-diastolic pressure-
volume relationship.
An increase in myocardial contractility, and not a preload recruited stroke work increase,
enables an unchanged left ventricular stroke volume, despite high afterload (Figure 6). In these
patients, an increase in afterload obviously profoundly altered the process of myocardial
relaxation, causing this upward shift of the end-diastolic pressure-volume relationship with high
left ventricular end-diastolic pressure and pulmonary edema, notwithstanding preserved left
ventricular stroke volume(189,190,207). These findings of intact systolic function in the phase
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of pulmonary edema during a hypertensive crisis,  do not rule out systolic dysfunction at
increased hearts rates, because all patients described, did not show a significant change in heart
rate before and after treatment of their hypertensive crisis(100).
Figure 4. Three LV end-diastolic pressure-volume relationships. Increased venous return or increased
afterload forces an increase in end-diastolic volume (A×B) (Frank-Starling mechanism). An acute
(A×C×A) and reversible increase in myocardial stiffness causes an increase in LV filling pressures at each
diastolic volume (e.g. demand ischemia(31,397)). A chronic increase in myocardial stiffness causes an
increase in diastolic filling pressure especially at a higher range of diastolic volumes (thick arrow and
dotted line).
 
Figure 5. The influence of demand (A) and supply (B) ischemia on the shift of the diastolic pressure-volume
relationship(269).
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Figure 6. Proposed mechanism of hypertensive pulmonary edema in the elderly. In these patients two
abnormalities may coexist: a steepening of the ESPVR, indicating  increased contractility, and an  upward
shift of the EDPVR, indicating impaired rate and extent of myocardial relaxation(100). ESV: end-systolic
volume. EDV: end-diastolic volume. ESPVR: end-systolic pressure-volume relationship. EDPVR: end-
diastolic pressure volume relationship. 
Otherwise, an increase in left ventricular afterload, may recruit preload reserve to sustain this
increase in afterload while maintaining stroke volume. As opposed to patients with preserved
stroke volume and unchanged left ventricular end-systolic volume and left ventricular end-
diastolic volume(190), other patients show left ventricular dilatation, with both an increase in left
ventricular end-systolic volume and left ventricular end-diastolic volume (Figure 7)(70,76). One
can only speculate on why two different mechanisms, secondary to an increase in afterload, exist.
Does older age with a concomitant stiffer myocardium play a role(100)? Or is myocardial
subendocardial ischemia possibly responsible for an afterload mismatch and left ventricular
dilatation(76)? 
Chronic changes in myocardial stiffness follow changes in the myocardial extracellular matrix
(Figure 4 thick arrow and dotted line). Hypertrophy often shows an increase in myocardial
collagen content, a change in collagen cross linking and/or a change in the ratio between type I
and type III collagen, which all influence myocardial stiffness(126,179,384).
In dilated cardiomyopathy the left ventricular dilates (with a secondary fall in ejection fraction
(EF)) due to impaired cardiomyocytic function and marked changes in the extracellular matrix.
These myocardial changes influence overall pump performance of the heart. Recently it was
shown, that an increase in intracardiac production of nitric oxide augments left ventricular stroke
Introduction
43
volume and left ventricular stroke work because of increased diastolic distensibility and a
concomitant increase in left ventricular preload reserve(57,119,165,270,289) (Figure 8).
Figure 7. Proposed  mechanism of hypertensive pulmonary edema in an occasional young patient. A
shallowing of the end-systolic pressure-volume relationship (ESPVR) indicating decreased contractility and
exhaustion of the rightward shift of the end-diastolic pressure-volume relationship (EDPVR), resulting in
increased end-diastolic filling pressure and lung edema(76). SV: Stroke volume 
Figure 8. Two  end-diastolic pressure-volume relations (EDPVR). A rightward shift of the EDPVR in
patients with dilated cardiomyopathy is positively correlated with a higher nitric oxide (NO) synthase 2
(NOS2) gene expression. An  increase  in NOS2 and of NO may result in an increase in preload recruitable
stroke work at normal filling pressures(270). 
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These findings indicate the potential existence of a diastolic stroke volume reserve, causing
an increase in myocardial distensibility which enables utilization of left ventricular preload
reserve (Frank-Starling mechanism, Von Anrep effect) at relatively low filling pressures. Low
filling pressures in heart failure are important to reduce the initiation of signaling cascades
leading to hypertrophy and remodeling. The fact that the failing heart, during exercise, depends
on the ability of the left ventricle to recruit preload reserve as its functional reserve mechanism
per se, induces the risk of triggering different potentially harmful signaling pathways for
hypertrophy and myocardial remodeling if filling pressures and wall stress remain
elevated(2,136).
1.6 Brief outline of this thesis
This thesis covers different clinical investigations on left ventricular dysfunction with special
attention to three types of shift of the left ventricular diastolic pressure-volume relationship.
Diastolic left ventricular dysfunction and an upward shift of the left ventricular diastolic pressure-
volume relationship is covered in chapter 2, diastolic left ventricular dysfunction and a lack of
rightward shift of the left ventricular diastolic pressure-volume relationship in chapter 3 and
diastolic left ventricular dysfunction and a steeper slope of the left ventricular diastolic pressure-
volume relationship is covered in chapter 4 of this thesis.
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Endomyocardial Nitric Oxide Synthase and Left Ventricular
Preload Reserve in Dilated Cardiomyopathy
Christophe Heymes, PhD; Marc Vanderheyden, MD; Jean G.F. Bronzwaer, MD;
Ajay M. Shah, MD, MRCP; Walter J. Paulus, MD, PhD
Background—Patients with heart failure have modified myocardial expression of nitric oxide synthase (NOS), as is evident
from induction of calcium-insensitive NOS isoforms. The functional significance of this modified NOS gene expression
for left ventricular (LV) contractile performance was investigated in patients with dilated nonischemic cardiomyopathy.
Methods and Results—In patients with dilated, nonischemic cardiomyopathy, invasive measures of LV contractile
performance were derived from LV microtip pressure recordings and angiograms and correlated with intensity of gene
expression of inducible (NOS2) and constitutive (NOS3) NOS isoforms in simultaneously procured LV endomyocardial
biopsies (n20). LV endomyocardial expression of NOS2 was linearly correlated with LV stroke volume (P0.001;
r0.66), LV ejection fraction (P0.007; r0.58), and LV stroke work (P0.003; r0.62). In patients with elevated
LV end-diastolic pressure (16 mm Hg), a closer correlation was observed between endomyocardial expression of
NOS2 and LV stroke volume (P0.001; r0.74), LV ejection fraction (P0.0007; r0.77), and LV stroke work
(r0.82; P0.0002). LV endomyocardial expression of NOS3 was linearly correlated with LV stroke volume (P0.01;
r0.53) and LV stroke work (P0.01; r0.52). To establish the role of nitric oxide (NO) as a mediator of the observed
correlations, substance P (which causes endothelial release of NO) was infused intracoronarily (n12). In patients with
elevated LV end-diastolic pressure, an intracoronary infusion of substance P increased LV stroke volume from 7213
to 9116 mL (P0.06) and LV stroke work from 6711 to 9015 g  m (P0.03) and shifted the LV end-diastolic
pressure–volume relation to the right.
Conclusions—In patients with dilated cardiomyopathy, an increase in endomyocardial NOS2 or NOS3 gene expression
augments LV stroke volume and LV stroke work because of a NO-mediated rightward shift of the diastolic LV
pressure-volume relation and a concomitant increase in LV preload reserve. (Circulation. 1999;99:3009-3016.)
Key Words: nitric oxide  cardiomyopathy  ventricles  diastole
In patients with heart failure, the functional significance forleft ventricular (LV) performance of modified myocardial
expression of nitric oxide synthase (NOS) remains unclear.1
Expression of cytokine-inducible, calcium-insensitive NOS
isoform (NOS2) was first reported in the ventricular myocar-
dium of patients with dilated cardiomyopathy after myocar-
ditis2 and, subsequently, in the myocardium of failing hearts,
regardless of the underlying cause.3 In the latter study, NOS2
gene expression was more frequent in NYHA class II patients
than in class IV patients, but in a subsequent study,4 high
NOS2 gene expression was associated not with functional
class but with low LV ejection fraction. In allograft recipi-
ents, a Doppler echocardiographic study5 showed that NOS2
gene expression correlated with LV dysfunction, but an
invasive assessment of LV performance6 failed to demon-
strate any effects of high myocardial NOS2 expression on LV
ejection fraction or on the peak rate of rise of LV pressure
(LV dP/dtmax). In the normal human heart and in allograft
recipients, intracoronary infusions of NO donors or of sub-
stance P, which releases nitric oxide (NO) from the coronary
endothelium, also failed to alter LV ejection fraction or LV
dP/dtmax; instead, they hastened LV relaxation and increased
LV diastolic distensibility.7,8 These effects of NO on diastolic
LV function were recently corroborated by experimental
observations. In isolated guinea pig hearts, administration of
a NOS inhibitor reduced LV diastolic distensibility,9 and in
the beating rabbit heart, a porphyrinic microsensor in the LV
wall revealed a prominent diastolic peak of myocardial NO
concentration.10
See p 2972
In end-stage explanted human cardiomyopathic hearts,
expression and activity of endothelial constitutive NOS iso-
form (NOS3) was reduced, but expression and activity of
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NOS2 were enhanced.11 In trabeculae isolated from these
hearts, NOS2 activity hastened isometric tension decline and
blunted the -agonist–induced increase in twitch tension. A
blunted myocardial contractile response to -agonists be-
cause of NOS activity was also observed in adult rat cardio-
myocytes,1 in dogs with pacing-induced heart failure,12 in
patients with LV dysfunction,13,14 and in the human
allograft.6,13
To investigate the in vivo functional significance of mod-
ified myocardial NOS expression for LV contractile perfor-
mance in patients with nonischemic, dilated cardiomyopathy,
invasive measures of LV function were derived from LV
angiograms and high-fidelity tip-micromanometer LV pres-
sure recordings; they were then correlated with the intensity
of myocardial NOS2 and NOS3 gene expression in simulta-
neously procured LV endomyocardial biopsies. To confirm
the role of NO as a mediator of the observed correlation
between LV stroke volume or LV stroke work and myocar-
dial NOS2 or NOS3 activity, repeat LV angiograms and LV
pressure recordings were obtained during intracoronary sub-
stance P infusion, which causes receptor-mediated release of
NO from the coronary endothelium.8,15
Methods
Patients
A total of 32 patients with nonischemic, dilated cardiomyopathy
underwent diagnostic cardiac catheterization and coronary angiog-
raphy. The group consisted of 9 women and 23 men (mean age, 51
years; range, 23 to 75 years). For ethical reasons, heart failure
therapy was maintained; it consisted of angiotensin-converting
enzyme (ACE) inhibitors (n31), diuretics (n31), digitalis
(n14), and -blockers (n2; Table; patients 11 and 31). LV
angiography revealed a LV end-diastolic volume index of 14837
mL/m2 and a LV ejection fraction of 2910%. A LV end-diastolic
volume index 102 mL/m2 (normal average value 2SD) and an
LV ejection fraction 45% were used as cutoff values for dilated
cardiomyopathy. Informed consent was obtained from all patients,
and the study was approved by the local review boards. There were
no complications.
Study Protocol
LV pressure was measured by using a high-fidelity tip-micromanom-
eter catheter, and right heart pressures were measured by using a
Swan-Ganz catheter. Left ventricular endomyocardial biopsies were
obtained in 20 patients (Table; patients 1 through 15 and 28 through
32) using a long bioptome-guiding sheath and a disposable trans-
femoral bioptome (Cordis Corp). Baseline LV function (Table) of
the 20 patients in whom LV endomyocardial biopsies were obtained
was comparable to the baseline LV function of the entire patient
cohort.
After diagnostic cardiac catheterization, an intracoronary infusion
of substance P (20 pmol/min for a 5-minute period)8,13 was per-
formed in 12 patients (Table; patients 16 through 27). At the end of
the infusion period, hemodynamic measures were repeated. In 11
patients (Table; patients 1, 2, 4 through 9, 12, 13, and 15), an
intravenous infusion of dobutamine6,13 was administered; it was
progressively titrated upward to a dose of 112 g  kg1  min1 to
increase resting heart rate by 20 bpm. The infusion protocols for
substance P and for dobutamine were extensively described in a
previous study.13 Data from 3 patients who were part of this previous
study were included in the present study.
Reverse Transcription–Polymerase Chain Reaction
for NOS2 and NOS3 mRNA
Biopsy Procurement
Biopsy samples used for the subsequent quantification of NOS2 and
NOS3 mRNA by reverse transcription–polymerase chain reaction
(RT-PCR) were immediately frozen in liquid nitrogen and stored at
80°C. In 15 patients (Table; patients 1 through 15), 1 biopsy
sample was used, and in 5 patients (Table; patients 28 through 32),
2 biopsy samples from different sites of the LV cavity were used. In
these 5 patients, the variability of the NOS2 and NOS3 mRNA
concentrations was 72% and 153%, respectively.
RNA Extraction
Total RNA from 25 LV endomyocardial biopsies was extracted
according to Trizol reagent protocol (Life Technologies). Purified
RNA was dissolved in water, and the concentration was measured by
absorbance at 260 nm. Quantitative RT-PCR for NOS2 and NOS3
was then performed in the presence of a defined amount of specific
RNA mutant as an internal standard.
Internal Standard Preparation
The NOS2 and NOS3 internal standards were subcloned into a
pSP(64)poly(A) vector (Promega). cRNA was then synthesized in
vitro as a sense probe from 10 g of the PvuI-linearized plasmid
using SP6 RNA polymerase in the presence of 10 Ci of -32P-UTP.
The concentration of the transcript was determined after measuring
the radioactivity incorporated into the RNA product.
Oligonucleotides Used for RT-PCR
For NOS2, the primers chosen were 5-AAGACCCAGTGCCC-
TGCTTT-3 for sense and 5-CGCAAACATAGAGGTGGCC-3
for antisense; they allowed the distinct amplification of NOS2
mRNA (388 bp) and of the internal standard (452 bp). For NOS3, the
primers chosen were 5-TGCCTGCCCCACTGCTCCTC-3 for
sense and 5-TGCACGGTCTGCAGGACGTTGGT-3 for anti-
sense, thus amplifying a DNA fragment of 616 bp for NOS3 and of
680 bp for the internal standard. These primers were chosen to
encompass several introns to avoid amplification of contaminating
genomic DNA.
Quantitative RT-PCR Protocol
Total RNA was reverse-transcribed with a fixed amount of the
specific synthetic RNA and 200 U of Moloney murine leukemia
virus reverse transcriptase (Life Technologies). Single-strand cDNA
synthesis was performed in 20 L of reaction buffer (in mmol/L):
Tris-HCl 20 (pH 8.3), KCl 50, MgCl2 4, dNTP 1, and DTT 10 and
0.2 mol/L oligo-p(dT). The reaction mixture was incubated for 10
minutes at 25°C and then for 60 minutes at 37°C. The resultant
cDNA was amplified using 2.5 U of Taq DNA polymerase (Boeh-
ringer) and 0.5 mol/L sense and antisense primers in 50 L of
(in mmol/L) KCl 50, Tris-HCl 10 (pH 8.3), MgCl2 4, and dNTP 1
and 0.01% gelatin. A total of 28 amplification cycles were under-
taken as follows: denaturation at 94°C for 1 minute, annealing at
62°C for NOS2 and at 63°C for NOS3 for 1 minute, and extension
at 72°C for 1 minute. The final extension was performed for 10
minutes. To quantify NOS isoform mRNA levels, a trace amount of
[32P]-dCTP was included in the PCR reaction. After PCR amplifica-
tion, the PCR products were separated on a 5% polyacrylamide gel,
and radioactive signals were analyzed using a computer-based
imaging system (Fuji Bas 1000, Fuji Medical Systems).
Data Analysis
LV volumes were derived from single-plane LV angiograms by
using the area-length method and a regression equation. The duration
of LV electromechanical systole (LVEST), which indicates the time
to onset of LV relaxation, was measured as the interval from the Q
wave on the ECG to the moment of the peak rate of fall of LV
pressure (LV dP/dtmin). LV stroke work was derived from the area
within the LV pressure-volume diagram. Single comparison data
were analyzed with a Student t test for paired data.
Results
NOS Gene Expression and LV Function at Rest
The Table summarizes indices of baseline LV function in the
dilated, nonischemic cardiomyopathy study population. Fig-
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ure 1 shows representative RT-PCR amplification products of
NOS2 and NOS3 mRNA derived from LV endomyocardial
biopsies obtained from 4 patients (Table; patients 1, 2, 6, 8).
In the subgroup of patients (n20) in whom LV endomyo-
cardial biopsies were obtained, a significant linear correlation
was observed between intensity of NOS2 mRNA expression
and LV stroke volume (P0.001; r0.66), LV ejection
fraction (P0.007; r0.58), or LV stroke work (P0.003;
r0.62) (Figure 2). In the same group of patients, a signifi-
cant linear correlation was also observed between intensity of
NOS3 mRNA expression and LV stroke volume (P0.01;
r0.53) or LV stroke work (P0.01; r0.52) (Figure 3).
There were no significant correlations between intensity of
NOS2 or NOS3 mRNA expression and other hemodynamic
indices, such as LV end-diastolic volume index, LV end-sys-
tolic volume index, or LV dP/dtmax.
A closer correlation was observed between intensity of
NOS2 mRNA expression and LV stroke volume (P0.001;
r0.74), LV ejection fraction (P0.0007; r0.77), or LV
stroke work (P0.0002; r0.82) when the analysis was
limited to those patients who, at the time of the study, were
using LV preload reserve, as evident from elevated LV
end-diastolic pressure (LVEDP16 mm Hg) (Figure 4). Lim-
iting the analysis to patients who were using LV preload
reserve did not improve the correlation between intensity of
NOS3 mRNA expression and LV stroke volume or LV stroke
work.
LV Preload Reserve and Coronary
Endothelial NO
To investigate the myocardial effects of NO on LV preload
reserve, an intracoronary infusion of substance P was performed
Baseline LV Function of the Dilated Cardiomyopathy Study Group
Patient HR, bpm LVPSP, mm Hg LVEDP, mm Hg
LV dP/dtmax,
mm Hg/s
LVEDVI,
mL/m2 LVEF, %
1 78 108 14 1120 108 32
2 79 103 30 550 216 14
3 92 79 35 450 181 8
4 88 157 31 1450 142 20
5 78 100 36 560 178 44
6 88 91 24 510 162 33
7 77 137 21 1240 106 39
8 82 80 24 550 240 30
9 85 150 29 1010 207 39
10 92 107 7 1050 105 39
11 55 126 12 1250 143 39
12 82 127 27 1230 146 35
13 85 112 20 630 142 27
14 89 110 38 700 214 8
15 78 95 20 720 160 17
16 88 108 22 750 162 28
17 95 100 29 750 168 22
18 82 144 36 920 170 32
19 94 84 27 640 133 21
20 91 165 17 1300 117 32
21 62 96 14 900 113 42
22 90 140 34 800 114 29
23 107 137 30 1400 120 45
24 104 121 25 1150 178 25
25 81 107 14 1250 108 45
26 88 150 7 650 174 21
27 115 95 31 840 134 23
28 70 195 28 1150 129 31
29 90 139 18 1200 107 25
30 67 115 9 950 105 45
31 88 108 40 700 106 38
32 72 144 14 1000 142 27
MeanSD 8512 12027 249 917288 14837 3010
HR indicates heart rate; LVPSP, left ventricular peak systolic pressure; LVEDVI, left ventricular end-diastolic volume
index; and LVEF, left ventricular ejection fraction. Other abbreviations are as in text.
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in 12 patients. This resulted in a significant fall in LV peak
systolic pressure from 1218 to 1117 mm Hg (P0.0009), in
LV end-systolic pressure from 646 to 586 mm Hg (P0.01)
and in LVEDP from 253 to 182 mm Hg (P0.0001) and in
LVEST from 41017 to 39317 ms (P0.04). There were no
significant changes in LV dP/dtmax, heart rate, LV end-diastolic
volume, LV ejection fraction, LV stroke volume, or LV stroke
work, except in those patients who, at the time of the study, had
elevated LV filling pressures (LVEDP 16 mm Hg). In these
patients, intracoronary substance P significantly increased LV
end-diastolic volume from 22026 to 24029 mL (P0.04),
LV stroke volume from 7213 to 9116 mL (P0.06), and LV
stroke work from 6711 to 9015 g  m (P0.03) (Figure 5).
NOS Gene Expression and LV Response to
-Adrenoreceptor Stimulation
Intravenous infusion of dobutamine caused a significant
increase in heart rate from 821 to 1003 bpm (P0.0001)
and in LV dP/dtmax from 924120 to 1356175 mm Hg/s
(P0.0001), a significant decrease in LVEST from 43019
to 32816 ms (P0.0002), and no change in LV peak or
end-systolic pressures. LV endomyocardial NOS2 mRNA
expression was inversely correlated with the dobutamine-
induced decrease in LVEST (P0.04; r0.63) and the ratio
of the dobutamine-induced decrease in LVEST divided by the
dobutamine-induced increase in LV dP/dtmax (expressed as a
fraction of baseline LV dP/dtmax value) (P0.004; r0.78)
(Figure 6). The dobutamine-induced changes in heart rate and
in LV dP/dtmax were unrelated to LV endomyocardial NOS2
mRNA. The dobutamine-induced changes in heart rate, LV
dP/dtmax, LVEST, and the ratio of LVEST/LV dP/dtmax
were also unrelated to LV endomyocardial NOS3 mRNA
expression.
Discussion
The present study provides the first evidence that LV endo-
myocardial NOS2 and NOS3 gene expression varies with the
severity of LV dysfunction in patients with dilated, nonische-
mic cardiomyopathy. In these patients, higher LV endomyo-
cardial NOS2 and NOS3 gene expression was accompanied
by higher LV stroke volume and higher LV stroke work.
Myocardial NOS Gene Expression in
Heart Failure
Experimental evidence on endomyocardial NOS3 expression
and activity in heart failure provides support for the idea that
Figure 1. Representative RT-PCR amplification products of
NOS2 mRNA (A) and NOS3 mRNA (B) derived from LV endo-
myocardial biopsies obtained in 4 patients (Table; patients 1, 2,
6, and 8). For each patient, 25 and 50 ng of total RNA were
reverse-transcribed in presence of fixed amount of internal stan-
dard (Std.; 2000 molecules for patients 1 and 6, 10 000 mole-
cules for patients 2 and 8).
Figure 2. Linear correlations between LV stroke volume (LVSV)
(A), LV ejection fraction (EF) (B), and LV stroke work (LVSW) (C)
and intensity of NOS2 mRNA expression.
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intensity of NOS3 gene expression varies with the severity of
LV dysfunction. In a pacing-induced heart failure dog model,
NOS3 activity increased after 2 weeks of pacing, as evident
from enhanced endothelium-dependent relaxation of isolated
coronary artery rings.16 This increase in NOS3 activity could
have resulted from higher coronary blood flow because of
increased myocardial metabolic demand17 or from higher
mechanical stress because of LV cavity dilatation.10 In the
same pacing-induced heart failure dog model, cardiac NO
production was reduced after 4 weeks of pacing, and this
reduction was accompanied by a switch in myocardial sub-
strate use, a rise in LV end-diastolic pressure, and a fall in LV
stroke work.18
Clinical studies reporting on myocardial NOS3 gene ex-
pression and activity in patients with dilated cardiomyopathy
used right ventricular tissue obtained by transvascular biop-
sy,2–4 right ventricular tissue excised during cardiopulmonary
bypass,3 or LV tissue from explanted hearts at the time of
cardiac transplantation.11,19,20 Detection of upregulation of
myocardial NOS3 as a result of mechanical stress applied to
the left ventricle requires LV and not right ventricular tissue,
as illustrated in spontaneously hypertensive rats in which
NOS3 activity was upregulated in LV but not right ventric-
ular tissue.21 Both low11 and high19,20 intensities of NOS3
gene expression have been observed in the LV tissue of
end-stage explanted cardiomyopathic human hearts. These
conflicting results are explained by the present study, which
observed that the intensity of NOS3 gene expression varied
with the severity of LV dysfunction. The present study
determined NOS2 and NOS3 gene expression in LV tissue
samples procured by LV transvascular biopsy. The use of LV
transvascular biopsies allowed LV endomyocardial NOS
gene expression to be assessed not only in patients with
end-stage heart failure but also in patients with compensated
heart failure. In the present study, most patients were on ACE
inhibitor therapy. ACE inhibitor therapy could have aug-
mented NOS3 expression, as evident from the Trial on
Reversing Endothelial Dysfunction (TREND), which showed
improved coronary endothelial-dependent vasodilator re-
sponses during chronic quinapril therapy.22 The 2 patients in
the present study who were on -blocker therapy had high-
Figure 3. Linear correlations between LV stroke volume (LVSV)
(A), LV ejection fraction (EF) (B), and LV stroke work (LVSW) (C)
and intensity of NOS3 mRNA expression.
Figure 4. Linear correlations between LV stroke volume (LVSV)
(A), LV ejection fraction (EF) (B), and LV stroke work (LVSW) (C)
and intensity of NOS2 mRNA expression in patients with ele-
vated LV filling pressures (LVEDP16 mm Hg).
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intensity NOS3 gene expression. In failing human myocardi-
um, NOS3 expression is more abundant in patients on
-blocker therapy,19 probably because of increased transcrip-
tion and subcellular targeting to plasmalemmal caveolae of
NOS3 as a result of reduced myocardial cAMP content.23,24
In patients with dilated cardiomyopathy, upregulated myo-
cardial NOS2 activity or gene expression was reported by
most2–4,11,19 but not all20 investigators. In a previous study,3
upregulated myocardial NOS2 gene expression was more
frequently observed in patients in NYHA class II than in
NYHA class IV. This finding corresponds with the present
observation of higher NOS2 gene expression in patients with
moderate LV dysfunction. The concordance between both
studies, despite the use of LV tissue in the present study and
right ventricular tissue in the previous one, supports regula-
tion of myocardial NOS2 expression not by local mechanical
stresses but by humoral factors, such as cytokines and
neurohormones. No differences in the intensity of NOS2 gene
expression were observed in patients receiving digitalis.
Low Myocardial NOS Gene Expression in Severe
LV Dysfunction
In the present study, both NOS2 and NOS3 gene expression
were lower in patients with low LV stroke volume and low
LV stroke work. The parallel reduction of NOS2 and NOS3
mRNA in patients with severe LV dysfunction could have
resulted from faster degradation of mRNA in biopsies from
this patient group. The procedure of biopsy procurement was,
however, identical for all patients and, therefore, not respon-
sible for the observed difference. In cardiac myocytes, regu-
lators of gene expression of NOS isoenzymes usually produce
opposite effects on NOS2 and NOS3 mRNA. Cytokines
increase NOS2 mRNA, and interferon- and interleukin-1
decrease NOS3 mRNA.1 cAMP stimulates NOS2 mRNA
stability25 and downregulates transcription of NOS3
mRNA.23 These regulators are, therefore, probably not in-
volved in the observed parallel reduction of gene expression
of NOS isoenzymes in patients with low LV stroke work. A
possible explanation for the parallel reduction of gene expres-
sion of NOS isoenzymes in severe LV dysfunction could be
depletion of the myocyte population because of apoptotic cell
death triggered by high myocardial concentrations of NO or
catecholamines.26 Such a depletion of the viable myocyte
population could explain both the parallel reduction of gene
expression of NOS isoenzymes and the impairment of LV
contractile performance.
Myocardial NOS Gene Expression and LV
Preload Reserve
In the present study, linear correlations were observed be-
tween LV stroke volume or LV stroke work and intensity of
myocardial NOS2 or NOS3 gene expression. Patients with
dilated cardiomyopathy are highly dependent on preload
recrutable LV stroke work to compensate for reduced inotro-
pic reserve.27 This enhancement of preload recrutable LV
stroke work results from a rightward displacement of the
diastolic LV pressure-volume relation. In the present study,
an intracoronary infusion of substance P, which releases NO
from the coronary endothelium,15 induced an acute rightward
displacement of the LV end-diastolic pressure-volume rela-
tion and an increase in LV stroke volume and LV stroke work
when LV filling pressures were elevated. This short-term,
NO-induced increase in LV diastolic distensibility, LV stroke
volume, and LV stroke work supports a myocardial action of
NO to mediate the observed correlations between myocardial
NOS gene expression and LV stroke volume or LV stroke
work. A similar myocardial action of NO on LV preload
Figure 5. Effects of intracoronary infusion of substance P (SP)
on LV end-diastolic volume (LVEDV) (A), LV stroke volume
(LVSV) (B), and LV stroke work (LVSW) (C) in patients with ele-
vated LV filling pressures (LVEDP16 mm Hg). *P0.05;
†P0.06.
Figure 6. Inverse correlation between intensity of NOS2 mRNA
expression and dobutamine-induced abbreviation of LV electro-
mechanical systole time (LVEST) divided by dobutamine-
induced increase in LV dP/dtmax. When endomyocardial NOS2
mRNA was higher, the dobutamine-induced abbreviation of LV
contraction was larger for similar dobutamine-induced rise in LV
dP/dtmax.
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reserve was recently observed in isolated guinea pig hearts.9
In this preparation, adding NG-monomethyl-L-arginine, a
specific inhibitor of NOS, to the coronary perfusate resulted
in a leftward displacement of the diastolic LV pressure-
volume relation and a reduction of LV stroke volume. Similar
actions of NO or its second messenger, cGMP, on diastolic
myocardial properties have been observed in isolated rat
cardiomyocytes28,29 and in isolated rabbit cardiomyocytes.30
In isolated rat cardiomyocytes, an increase in diastolic cell
length was observed after exposure to a cGMP analogue28 or
a NO donor.29 In isolated rabbit cardiomyocytes, exposure to
lipopolysaccharides30 altered cell volume through an NO- and
cGMP-mediated mechanism. Beneficial effects of NO on
diastolic LV properties could result not only from short-term
cGMP-mediated myocardial actions but also from long-term
effects on the LV interstitium because of altered extracellular
matrix metalloproteinase activity and collagen turnover.31
Myocardial NOS Gene Expression and
-Adrenoceptor Stimulation
The present study also demonstrated a significant correla-
tion between the dobutamine-induced abbreviation of LV
contraction and NOS2 mRNA expression. In a previous
study using isolated muscle strips from explanted human
cardiomyopathic hearts, a similar correlation was observed
between NOS2 activity measured by citrulline formation
and -agonist–induced changes in the timing of isometric
force decline.11 In the present study population, no relation
was found at baseline between the duration of LV contrac-
tion and myocardial NOS mRNA expression, despite the
elevated adrenergic drive and the presence of such a
relation during intravenous infusion of dobutamine. This
suggests that the myocardial effects of elevated plasma
catecholamines in heart failure may be offset by a simul-
taneous reduction in myocardial 1-receptors and/or a
simultaneous increase in myocardial Gi-proteins.
Study Limitations
The myocardial presence of NOS was established in the
present study by demonstrating NOS mRNA by quantitative
RT-PCR and not by directly demonstrating NO or cGMP in
the myocardium. This would provide more definite proof
of NOS presence and activity because of earlier reports of
posttranscriptional and posttranslational modification of
NOS.24 In the present study, the effects of NO on LV stroke
volume or on LV stroke work were reproduced during
intracoronary infusion of substance P, which releases NO
from the coronary endothelium. Intracoronary infusion of
specific NOS antagonists, which was not performed in the
present study, could provide further evidence for NO contrib-
uting to LV preload reserve in these cardiomyopathic hearts.
To address the issue of homogeneous endomyocardial ex-
pression of NOS isoenzymes, multiple biopsies were obtained
from different LV sites in 5 patients. In these patients, the
variability of NOS2 and NOS3 mRNA concentrations in the
different biopsy samples was, respectively, 72% and
153%.
Conclusions
In the present study, which was the first to analyze gene
expression of NOS isoenzymes in LV transvascular biopsies
from dilated cardiomyopathy patients, the intensity of NOS2
and NOS3 gene expression was linearly correlated with LV
stroke volume and LV stroke work. Intracoronary infusions
of substance P, which releases NO from the coronary endo-
thelium, revealed that these correlations could have resulted
from a NO-mediated rightward shift of the LV end-diastolic
pressure-volume relation and a concomitant increase in LV
preload reserve. Future studies should be directed at identi-
fying the mechanisms responsible for the fall in gene expres-
sion of NOS isoenzymes in patients with severe cardiomyo-
pathic LV dysfunction, because the present study suggests
NO exerts a beneficial hemodynamic effect in the failing
human heart through maintenance of the Frank-Starling
response.
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Abstract
Objective: In dilated cardiomyopathy and in athlete’s heart, progressive LV dilatation is accompanied by rightward displacement of the
diastolic LV pressure–volume relation. In dilated cardiomyopathy, an increase in diastolic LV stiffness can limit this rightward
displacement thereby decreasing LV systolic performance. Because nitric oxide (NO) reduces diastolic LV stiffness, the present study
relates diastolic LV stiffness and LV systolic performance to intensity of endomyocardial NO synthase (NOS) gene expression in dilated
cardiomyopathy and in athlete’s heart. Methods: Microtip LV pressures, conductance-catheter or angiographic LV volumes, ech-
ocardiographic LV wall thicknesses and snap-frozen LV endomyocardial biopsies were obtained in 33 patients with dilated car-
diomyopathy and in three professional cyclists referred for sustained ventricular tachycardia. Intensity of LV endomyocardial inducible
NOS (NOS2) and constitutive NOS (NOS3) gene expression was determined using quantitative reverse transcription–polymerase chain
reaction (RT–PCR). Results: Dilated cardiomyopathy patients with higher diastolic LV stiffness-modulus and lower LV stroke work had
lower NOS2 and NOS3 gene expression at any given level of LV end-diastolic wall stress. The intensity of NOS2 and NOS3 gene
expression observed in athlete’s heart was similar to dilated cardiomyopathy with low LV diastolic stiffness-modulus and preserved LV
stroke work. Conclusions: High LV endomyocardial NOS gene expression is observed in athlete’s heart and in dilated cardiomyopathy
with low diastolic LV stiffness and preserved LV stroke work. Favourable effects on the hemodynamic phenotype of high LV
endomyocardial NOS gene expression could result from a NO-mediated decrease in diastolic LV stiffness and a concomitant rise in LV
preload reserve.
 2002 Elsevier Science B.V. All rights reserved.
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Abbreviations: ACE, angiotensin converting enzyme; CVF, collagen This article is referred to in the Editorial by J.T. Stark
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dP/dt , peak rate of left ventricular pressure rise; LVEDP, left ventricu-max
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LVEDVI, left ventricular end-diastolic volume index; LVEDWS, left 1 . Introduction
ventricular end-diastolic wall stress; LVEF, left ventricular ejection
fraction; LVPSP, left ventricular peak systolic pressure; LVSW, left
Rightward displacement of the diastolic LV pressure–ventricular stroke work; NO, nitric oxide; NOS, nitric oxide synthase;
volume relation underlies progressive LV dilatation andNOS2, inducible nitric oxide synthase; NOS3, constitutive nitric oxide
synthase; RT–PCR, reverse transcription–polymerase chain reaction; remodeling in congestive cardiomyopathy [1]. Limitation
Stiffness-Mod, radial myocardial left ventricular stiffness modulus; of this rightward displacement leads to a hemodynamic
TNFa, tumor necrosis factor a phenotype with elevated LV diastolic stiffness, poor LV
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systolic performance and poor prognosis [2,3]. Because of expression to prevailing LV diastolic wall stress. At the
nitric oxide (NO)’s ability to shift the diastolic LV time of cardiac catheterization, measurements of LV
pressure–volume relationship rightward in patients with diastolic stiffness, LV systolic performance and LV wall
dilated cardiomyopathy [4,5], a low intensity of LV stress were derived from microtip LV pressures, conduc-
endomyocardial NOS gene expression could underlie the tance-catheter or angiographic LV volumes and echocar-
development of this hemodynamic phenotype. The objec- diographic LV wall thickness. Intensity of endomyocardial
tive of the present study therefore was to relate intensity of inducible NOS (NOS2) and constitutive NOS (NOS3)
LV endomyocardial NOS gene expression to LV diastolic gene expression was determined on simultaneously pro-
stiffness and to LV systolic performance in patients with cured snap-frozen LV endomyocardial biopsies using quan-
congestive cardiomyopathy. A rightward displacement of titative reverse transcription–polymerase chain reaction
the diastolic LV pressure–volume relation is also observed (RT–PCR).
in athlete’s heart [6]. We therefore investigated the same
relationships in professional cyclists referred for malignant
ventricular arrhythmias. 2 . Methods
Elevated LV diastolic wall stress has previously been
shown to be associated with myocardial gene expression 2 .1. Patients
and production of neurohormones [7], natriuretic peptides
[8], cytokines [9], stress proteins [10] and growth factors 2 .1.1. Dilated cardiomyopathy
[11]. To detect effects of LV diastolic wall stress on A total of 33 patients with nonischemic dilated car-
endomyocardial NOS gene expression, the present study diomyopathy underwent diagnostic cardiac catheterization,
also related intensity of LV endomyocardial NOS gene coronary angiography and LV biopsy procurement. The
Table 1
Baseline LV function and NOS2–NOS3 gene expression expressed as molecules-mRNA/mg-total RNA
Patient HR LVPSP LVEDP LV dP/dt LVEDV LVEF Stiffness-Mod NOS2 NOS3max
(beats /min) (mmHg) (mmHg) (mmHg/s) (ml) (%) (mmHg)
1 78 108 14 1350 206 32 93 10787 46453
2 79 103 25 525 411 14 500 6829 179459
3 92 79 33 425 325 8 660 10093 75252
4 88 157 35 1403 283 20 500 15635 79571
5 78 100 35 650 302 44 184 21344 181374
6 88 91 24 500 341 33 160 22670 175135
7 77 137 18 1525 181 39 95 25094 49143
8 82 80 22 450 408 30 183 29260 110451
9 85 150 21 1000 372 39 124 44471 254794
10 92 107 5 840 209 39 33 9476 167944
11 55 126 9 1275 301 32 69 15335 201364
12 82 127 26 1225 293 35 163 33666 379246
13 85 112 20 575 256 27 181 10256 285683
14 63 90 15 450 567 8 500 7664 139508
15 78 95 20 850 304 17 333 8855 91863
16 70 195 29 1125 207 31 242 20452 104400
17 90 139 19 1225 204 25 190 22336 81751
18 67 115 8 900 214 45 36 24657 183253
19 88 108 42 725 201 38 263 32989 199892
20 72 144 14 1000 244 34 127 9809 110481
21 95 97 33 672 141 24 367 8388 223331
22 105 102 28 1021 230 10 700 4898 174558
23 75 108 14 785 686 10 350 24701 200915
24 96 137 25 1230 273 19 416 20386 364629
25 74 115 27 900 292 20 338 19330 257533
26 78 89 4 743 262 40 43 37365 295265
27 87 121 14 1150 189 45 67 8708 142205
28 71 128 21 600 194 35 140 26559 316238
29 57 151 15 850 236 33 107 34280 179913
30 105 129 25 1500 269 16 500 6280 116058
31 56 92 9 950 270 36 64 63763 305238
32 73 90 29 525 211 15 483 16831 197612
33 69 97 28 550 499 7 933 7812 203562
Mean 80 116 21 894 290 26 277 20030 184100
6S.D. 13 26 9 326 116 12 221 13000 87280
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group consisted of 10 women and 23 men (mean age: 50
years; range 23–76). Individual and mean baseline hemo-
dynamic data are listed in Table 1. At the time of study,
heart failure therapy was maintained for ethical reasons
and consisted of angiotensin-converting-enzyme (ACE)
inhibitors (n533), diuretics (n531), digitalis (n515) and
b-blockers (n53; Table 1: patients 10, 19, 24). No patient
was using NO-donors. Patients 1–13, 15 (Table 1) were
also part of a previous study [4]. A LV end-diastolic
2
volume index (LVEDVI).102 ml /m and a LV ejection
fraction (LVEF)#45% were used as cutoff values for
dilated cardiomyopathy (normal values: LVEDVI572615
2
ml /m ; LVEF57268%). LV endomyocardial biopsies
were obtained using a long bioptome-guiding sheath and a
disposable transfemoral bioptome (Cordis Corp). His- Fig. 1. Diastolic portions of LV pressure–volume loops recorded by a LV
micromanometer conductance catheter during transient pullback of antological examination of the endomyocardial biopsies
inflated balloon into the inferior vena cava in a patient with low NOS2revealed no evidence of myocarditis.
gene expression (panel A) and in a patient with high NOS2 gene
expression (panel B).
2 .1.2. Athlete’s heart
Three professional cyclists (mean age: 31 years) under-
study protocol and there were no complications related to
went diagnostic cardiac catheterization, coronary angiog- procedure or study protocol.
raphy and LV biopsy procurement. They were referred for
sustained exercise-induced ventricular tachycardia. Their
2 .3. Reverse transcription–polymerase chain reactionhemodynamic and echocardiographic studies were con-
sistent with the diagnosis of athlete’s heart as evident from
2 Biopsy procurement, RNA extraction, internal standard
a large LVEDVI (129611 ml /m ), a normal LVEF
preparation, oligonucleotides used for RT–PCR and quan-(6769%), a low resting heart rate (5563 beats /min) and a
titative RT–PCR protocol were extensively described
slightly elevated echocardiographic posterior LV wall
previously [4]. NOS2 and NOS3 mRNA’s were deter-thickness (10.360.3 mm) (normal value: 9.160.5 mm).
mined in all patients. Tumor necrosis factor a (TNF a),They took no medications at the time of study. LV
Interleukin-1b (IL-1b) and Interleukin 6 (IL-6) were
endomyocardial biopsies were obtained using a long
determined in a subgroup of 10 patients.bioptome-guiding sheath and a disposable transfemoral
bioptome (Cordis Corp). Histological examination of the
2 .4. Quantitative morphometryendomyocardial biopsies revealed no evidence of myocar-
ditis.
In a subgroup of patients (n520), collagen volume
fraction (CVF) was determined on EVG (elastica von
2 .2. Study protocol Gieson) stained sections of biopsies placed in 5% formalin
using an automated image analyzer (Prodit).
Right heart pressures and cardiac outputs were measured
using a Swan-Ganz thermodilution catheter. LV pressure 2 .5. Data analysis
and LV dP/dt were derived from a high-fidelity tip-mi-
cromanometer catheter (n533). In eight patients, a con- LV volumes were derived from single-plane LV angiog-
ductance pressure–volume catheter (Leycom Sigma, rams by use of the area–length method and a regression
Zoetermeer, The Netherlands) was inserted into the left equation. LV stroke work was derived from the area within
ventricle for continuous and on-line LV volume and the LV pressure–volume diagram. Echocardiographic LV
pressure measurement. In these eight patients, a 8F balloon posterior wall thickness (h) measurements were derived
catheter was introduced from the right femoral vein into from a sector scanner (HP Sonos 5500) using a 3 Mhz
the right atrium. Transient pullback of the inflated balloon transducer. Circumferential LV end-diastolic wall stress
into the inferior vena cava, allowed for assessment of (EDWS) was calculated from microtip LV pressure (P),
diastolic LV function using end-diastolic pressure–volume angiographic LV end-diastolic major (a) and minor (b)
points of multiple, variably preloaded beats [12] (Fig. 1). semi-axes and h using the formula [13]
The study protocol was approved by the local review board
2 2LVEDWS 5 (Pb /h)(1 2 h /2b 2 b /2a )(VU University Medical Center, Amsterdam) and con-
formed with the principles outlined in the declaration of
Helsinki. Written informed consent was obtained for the To assess diastolic LV myocardial material properties, a
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radial myocardial LV stiffness modulus (Stiffness-Mod)
was calculated from the microtip LV pressure and h using
the formula [14,15]
Stiffness-Mod 5 Ds /D´ 5 2 DP/(Dh /h) 5 2 DP/D ln hR R
and assuming the increment in radial stress (Ds ) to beR
equal but opposite in sign to the increment in LV pressure
(P) at the endocardium and the increment in radial strain
(D´ ) to be equal to the increment in wall thickness (Dh)R
relative to the instantaneous wall thickness. Because Dh /
h 5 D ln h, Stiffness-Mod was equal to the slope of a P vs.
ln h plot.
In eight patients, in whom a conductance catheter was
inserted into the LV and in whom a transient caval balloon
occlusion was performed, a LV chamber stiffness constant
(k) was calculated from an exponential curve fit to the
multiple LV end-diastolic pressure–volume points of the
variably preloaded beats during caval balloon occlusion
using the formula [16]
kVP 5 b e
where P is the LV end-diastolic pressure, V the LV end-
diastolic volume and b the curve-fitting parameter. For
these eight patients, ranking of k and Stiffness-Mod
yielded an identical order, thereby validating the use of
Stiffness-Mod as a measure of LV stiffness.
All results are given as mean6standard deviation and
the level of statistical significance was set at P,0.05.
3 . Results
3 .1. Endomyocardial NOS 2 gene expression and the
hemodynamic phenotype of dilated cardiomyopathy
Table 1 summarizes indices of LV systolic and diastolic
function observed in the dilated cardiomyopathy study
population. Fig. 1 shows representative examples of dias-
tolic portions of LV pressure–volume loops recorded by a
LV micromanometer conductance catheter during transient
pullback of an inflated balloon into the inferior vena cava. Fig. 2. Linear correlations between intensity of endomyocardial NOS2
For the dilated cardiomyopathy study population, a signifi- gene expression and LV diastolic stiffness modulus (Mod), LV stroke
cant linear correlation was observed between intensity of work (SW) and LV ejection fraction (EF).
NOS2 gene expression and LV diastolic stiffness modulus
(Stiffness-Mod) (P50.003; r50.50), LV stroke work
of the data scatter arose from patients wih low NOS2 gene(SW) (P50.0008; r50.56) and LV ejection fraction (EF)
expression. In patients with low NOS2 gene expression,(P50.004; r50.49) (Fig. 2). In the group of patients in
the broad range of LV diastolic stiffness-Mod, LVSW andwhom a balloon caval occlusion was performed, a signifi-
LVEF corresponded with a broad range of LV end-diastoliccant correlation was also observed between intensity of
wall stress (LVEDWS) as shown in Figs. 3 and 4, whichNOS2 gene expression and LV chamber stiffness constant
plot NOS2 gene expression in function of LVEDWS for(k) (P50.01; r50.52). In these groups of patients, in
different levels of LV diastolic stiffness-Mod or LVEF.whom myocardial collagen volume fraction (CVF) or
In both Figs. 3 and 4, patients with high LV diastolicintensity of myocardial proinflammatory cytokine (TNFa;
2
stiffness-Mod (.300 kdyne/cm ) or low LVEF (,20%)IL-1b; IL-6) gene expression was determined, no correla-
clustered in the upper left hand corner of the graph,tion was observed between intensity of NOS2 gene expres-
patients with intermediate values occupied the middlesion and CVF or cytokine gene expression. In Fig. 2, most
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stiffness-Mod (P,0.0001; r50.80) or LVEF (P,0.0001;
r50.69) to be superior to the correlations shown in Fig. 2.
The NOS2/LVEDWS ratio was also more closely corre-
lated with LVSW (P50.0002 and r50.61).
3 .2. Endomyocardial NOS3 gene expression and the
hemodynamic phenotype of dilated cardiomyopathy
For the dilated cardiomyopathy study population, no
significant correlations were observed between intensity of
NOS3 gene expression and LV diastolic stiffness-Mod,
LVSW, LVEF, CVF or intensity of cytokine gene expres-
sion. Fig. 5 plots intensity of NOS3 gene expression in
function of LVEDWS for different levels of LV diastolic
2
stiffness-Mod. Patients with high (.300 kdyne/cm ) and
Fig. 3. Intensity of endomyocardial NOS2 gene expression plotted intermediate LV diastolic stiffness-Mod clustered in the
against LV end-diastolic wall stress (EDWS) for dilated cardiomyopathy
middle portion of the graph and patients with low LVpatients with different levels of LV diastolic stiffness modulus (Mod) and 2diastolic stiffness-Mod (,150 kdyne/cm ) in the lowerfor the professional cyclists. The professional cyclists coincided with
portion of the graph. As evident from the insert of Fig. 5,dilated cardiomyopathy patients with low LV diastolic stiffness-Mod. For
the individual data points of the cardiomyopathy patients, the slope of the the NOS3/LVEDWS ratio was significantly correlated
LVEDWS-NOS2 gene expression relation varies with the different levels with the LV diastolic stiffness-Mod (P50.0001; r50.58).
of LV diastolic stiffness-Mod. This is also evident from the insert which The slope of this linear relation was less steep than theplots the NOS2/LVEDWS ratio as a function of LV diastolic stiffness-
slope of the linear relation between NOS2/LVEDWSMod. In the insert, the professional cyclists coincide with the bottom part
versus LV diastolic stiffness-Mod (Fig. 3), consistent withof the relation between NOS2/LVEDWS ratio and LV diastolic stiffness-
Mod observed in cardiomyopathy patients. less depression of NOS3 gene expression than of NOS2
gene expression in advanced LV dysfunction. The NOS3/
portion of the graph and patients with low diastolic LVEDWS ratio was also significantly correlated with
2
stiffness-Mod (,150 kdyne/cm ) or high LVEF (.30%) LVEF (P50.003; r50.51) and with LVSW (P50.02;
clustered in the lower right hand corner of the graph. For r50.39).
the individual data points of Figs. 3 and 4, the slope of a
line connecting the data point to the origin of the graph, 3 .3. Endomyocardial NOS gene expression and the
appeared to correlate closely with the different levels of hemodynamic phenotype of athlete’s heart
LV diastolic stiffness-Mod or LVEF. The inserts of Figs. 3
and 4 confirmed this impression and showed the correla- All three athletes had slightly elevated LVEDWS be-
tions between NOS2/LVEDWS ratio and LV diastolic cause of high LV end-diastolic volume and had low LV
Fig. 5. Intensity of endomyocardial NOS3 gene expression plotted
Fig. 4. Intensity of endomyocardial NOS2 gene expression plotted against LV end-diastolic wall stress (EDWS) for different levels of LV
against LV end-diastolic wall stress (EDWS) for different levels of LV diastolic stiffness modulus (Mod). For the individual data points, the
ejection fraction (EF). For the individual data points, the slope of the slope of the LVEDWS–NOS3 gene expression relation is higher for high
LVEDWS–NOS2 gene expression relation varies with the different levels and intermediate levels of LV diastolic stiffness-Mod. This is also evident
of LVEF. This is also evident from the insert which plots the NOS2/ from the insert which plots the NOS3/LVEDWS ratio as a function of LV
LVEDWS ratio as a function of LVEF. diastolic stiffness-Mod.
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diastolic stiffness-Mod. Fig. 3 also shows the data points correlation between cytokines and NOS2 also argues
of the cyclists: the relation between NOS2 gene expression against apoptotic cell death as the cause of the downregu-
and LVEDWS observed in the athletes coincided with the lated NOS2 in patients with the worst hemodynamic
relation observed in dilated cardiomyopathy patients with phenotype. An increase in apoptotic cell death should
low LV diastolic stiffness-Mod and in the insert the however be ruled out by looking at specific markers of
athletes fell on the bottom portion of the relation between apoptosis in the biopsy samples, which was not performed
NOS2/LVEDWS ratio and LV diastolic stiffness-Mod in the present study.
observed in the cardiomyopathy population. The relation The remodeling process of progressive LV car-
between NOS3 gene expression and LVEDWS observed in diomyopathic dysfunction involves increased extracellular
the athletes also coincided with the relation observed in matrix degradation and turnover because of upregulation of
dilated cardiomyopathy patients with low LV diastolic certain matrix metalloproteinases and downregulation of
stiffness-Mod. tissue inhibitors of metalloproteinases [21,22]. This leads
to disruption of the collagen weave around individual
myocytes and to malalignment or slippage of myocytes
[23]. Disruption of the collagen weave could alter trans-
4 . Discussion mission of LV wall stress to the cardiomyocytes and
disturb wall stress-induced gene expression because of an
4 .1. Endomyocardial NOS and the hemodynamic altered cascade of signals originating from the collagen
phenotype of dilated cardiomyopathy fibers and descending to sarcolemmal integrins, to cyto-
skeletal proteins and to nuclear membranes [1]. The lack of
The present study demonstrates lower LV endomyocar- correlation in the present study between CVF and intensity
dial NOS gene expression at a given level of LVEDWS to of NOS2 gene expression, argues against myocardial
correspond with a worse hemodynamic phenotype of fibrosis as the cause of the observed downregulation of
dilated cardiomyopathy characterized by higher LV stiff- NOS2 in patients with the worst hemodynamic phenotype.
ness, lower LVSW and lower LVEF. A similar finding was Previous studies demonstrated abundant myocardial
reported by Haywood et al., who found lower endomyocar- expression of TGFb in patients with dilated car-
dial NOS2 gene expression in NYHA class IV heart failure diomyopathy [24]. TGFb is known to reduce mRNA
than in NYHA class II [17]. Selective downregulation of stability of NOS2 [25] and a high myocardial level of
myocardial gene expression in more advanced stages of LV TGFb is therefore a potential mechanism for the fall in
dysfunction has also been reported for other genes. Lower NOS2 mRNA observed in patients with the worst hemo-
¨levels of protooncogenes were observed in peroperative dynamic phenotype. Variability in the relative increase of
biopsy samples of patients with aortic regurgitation and myocardial NOS and TGFb expression after an elevation
major LV dysfunction [18] and a fall in expression of of LVEDWS could contribute to the variability of the
gp130 and of interleukin-6 related cardiotrophin-1 was hemodynamic phenotype of patients with dilated car-
proposed to trigger transition to a maladaptive LV response diomyopathy in analogy to the variable response of TGFb
to hemodynamic overload [19]. to experimental LV pressure or volume overload [26].
Downregulation of endomyocardial NOS gene expres- In the present study, the intensity of endomyocardial
sion in patients with the worst hemodynamic phenotype NOS gene expression was higher in cardiomyopathy
could have resulted from altered myocardial expression of patients with preserved LVSW and low diastolic LV
proinflammatory cytokines, from reduction of the car- Stiffness-Mod. Patients with this hemodynamic phenotype
diomyocyte population because of apoptotic cell death, had an intensity of endomyocardial NOS gene expression
from altered transmission of wall stress to the car- comparable to professional athletes. This finding confirmed
diomyocytes or from altered presence of certain growth recent observations in dilated cardiomyopathy patients
factors. which failed to demonstrate cardiodepressant effects re-
In experimental preparations, proinflammatory cytokines lated to myocardial NO production or to the presence of
are potent stimulators of myocardial NOS2 gene expres- NOS2 gene expression [27]. Absence of a NO- or NOS2-
sion and in patients with dilated nonischemic car- induced cardiodepressant effect [28,29] was also observed
diomyopathy, increased myocardial expression of proin- in isolated muscle strips of explanted cardiomyopathic
flammatory cytokines has been observed [20]. In a subset human hearts. In these muscle strips, a NOS inhibitor left
of patients, intensity of myocardial gene expression of baseline isometric tension development unaltered [30].
proinflammatory cytokines was therefore determined. The High myocardial concentrations of NO could also favor-
lack of correlation in these patients between proinflammat- ably affect the hemodynamic phenotype by blunting
ory cytokines and NOS2, supports additional control of growth promoting effects of neurohormones on car-
myocardial NOS2 expression by other mechanisms such as diomyocytes [31] and by preventing expression of a
11
elevation of LV wall stress. Because of important proapop- phenotype with depressed Ca ATPase activity and LV
totic effects of proinflammatory cytokines [20], the lack of diastolic dysfunction [32].
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4 .2. Endomyocardial NOS and the hemodynamic allow for simultaneous NOS2 immunostaining and de-
phenotype of athlete’s heart termination of myocardial cGMP concentration. The use of
transvascular biopsies however provided the advantage of
The present study observed similar levels of endo- obtaining endomyocardial tissue also from patients with
myocardial NOS expression in patients with mild LV mild LV dysfunction and not only from patients with the
dysfunction and in athletes. In dogs, exercise is known to worst hemodynamic phenotype referred for cardiac trans-
augment activity of coronary endothelial NOS3 both plantation. It was precisely in the group of patients with
acutely [33] and chronically as a result of increased NOS3 mild LV dysfunction that the level of endomyocardial NOS
gene expression [34]. Endomyocardial expression of NOS2 gene expression corresponded to the level observed in
has not been reported previously in athletes or in exercis- athletes.
ing animals but endomyocardial expression of heat shock LV endomyocardial NOS gene expression was derived
proteins and of atrial natriuretic peptide was observed in from a single biopsy sample, which therefore did not take
rats subjected to repetitive daily episodes of treadmill into account spatial heterogeneity of gene expression [41].
running [35,36]. The observed upregulation of endo- In a previous study however, multiple biopsies from
myocardial NOS2 gene expression in athletes could there- different LV sites were obtained in the same patient and in
fore have resulted from a myocardial stress response to this study [4] the variability of endomyocardial NOS2 and
repetitive exercise-related mechanical stretching. In arterial NOS3 gene expression was low (7 and 15%). Spatial
smooth muscle, cyclic stretch was recently reported to nonuniformity of LV wall thickness changes could have
enhance expression of NOS2 and of insuline-like growth influenced Stiffness-Mod calculations but in the subgroup
factor I (IGF-I) [37]. Transcardiac IGF-I production is also of patients, in whom balloon caval occlusions were
increased in physiological hypertrophy of athlete’s heart obtained, Stiffness-Mod correlated closely with k, an index
[38] and the observed upregulation of NOS2 could coun- of global diastolic LV function. The concurrent use of
teract mitogenic effects of this enhanced IGF-I production. certain medications could also have influenced intensity of
The upregulation of endomyocardial NOS2 gene expres- endomyocardial NOS gene expression. All car-
sion in athletes challenges exclusive control of NOS2 gene diomyopathy patients were on ACE inhibitor therapy,
expression by immune mediators [39,40] and supports a which is known to upregulate coronary endothelial NOS3
‘constitutive’ expression of NOS2 [41] susceptible to expression [48] and some patients were on b-blocker
upregulation by mechanical stress. The abundant myocar- therapy, which also upregulates endomyocardial NOS3
dial expression of NOS2 in the fetus [42], in hypertrophied [49]. ACE inhibitor therapy could explain the better
[43] and in senescent [44] myocardium also supports the maintenance of NOS3 than of NOS2 gene expression in
notion of a ‘constitutive’ myocardial expression of NOS2, the patients with the worst hemodynamic phenotype.
which gets upregulated during adult life as part of a The number of athletes investigated in the present study
stress-induced reexpression of the fetal gene programme. was limited (n53). They came to medical attention
An identical myocardial response to exercise- and over- because of a history of sustained ventricular arrhythmias.
load-related stretch was recently also demonstrated by the Myocarditis or another cardiomyopathic process could
different ACE genotypes, which induced a similar dis- have caused these arrhythmias and could also have in-
tribution of LV hypertrophy in response to training and to fluenced their pattern of NOS gene expression. At the time
arterial hypertension [45]. of study however, their hemodynamic phenotype was
consistent with athlete’s heart [6] as evident from an
enlarged LV end-diastolic volume, a normal LV ejection
5 . Study limitations fraction, a low heart rate and a slight increase in LV wall
thickness. Histological examination of their biopsies also
The present study correlated the hemodynamic pheno- failed to reveal any evidence of myocarditis. A major
type with endomyocardial NOS mRNA and not with inflammatory or cardiomyopathic contribution to their
endomyocardial NOS protein, myocardial cGMP concen- pattern of NOS gene expression therefore seems unlikely.
tration or transcardiac nitrite /nitrate production, which
would have provided more definite proof of endomyocar-
dial NO activity because of posttranscriptional and post- 6 . Conclusions
translational modification of NOS [39]. A previous study
in transplant recipients however showed elevated myocar- Dilated cardiomyopathy patients with preserved LVSW
dial cGMP and NOS2 protein immunostaining to correlate and low LV diastolic stiffness have LV endomyocardial
with NOS2 mRNA expression [46] and in the same patient NOS2 and NOS3 gene expression equal to professional
population higher transcardiac nitrite /nitrate production cyclists and higher than patients with low LVSW and high
was recently demonstrated in the presence of upregulated LV diastolic stiffness. A NO-mediated decrease in LV
NOS2 gene expression [47]. The limited procurement of diastolic stiffness and a concomitant rise in LV preload
endomyocardial tissue by transvascular biopsy did not reserve explains the beneficial effect of higher endo-
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Abstract. Recent experimental and clinical research solved
some of the controversies surrounding the myocardial con-
tractile effects of NO. These controversies were: (1) does
NO exert a contractile effect at baseline? (2) is NO a posi-
tive or a negative inotrope? (3) Are the contractile effects
of NO similar when NO is derived from NO-donors or from
the different isoforms of NO synthases (NOS)? (4) Does NO
exert the same effects in hypertrophied, failing or ischemic
myocardium?
Transgenic mice with cardioselective overexpression of
NOS revealed NO to produce a small reduction in basal
developed LV pressure and a LV relaxation-hastening ef-
fect mainly through myoﬁlamentary desensitization. Sim-
ilar ﬁndings had previously been reported during in-
tracoronary infusions of NO-donors in isolated rodent
hearts and in humans. The LV relaxation hastening ef-
fect was accompanied by increased diastolic LV disten-
sibility, which augmented LV preload reserve especially
in heart failure patients. This beneﬁcial effect on dias-
tolic LV function always overrode the small NO-induced
attenuation in LV developed pressure in terms of overall
LV performance. In most experimental and clinical con-
ditions, contractile effects of NO were similar when NO
was derived from NO-donors or produced by the differ-
ent isoforms of NOS. Because expression of inducible NOS
(NOS2) is frequently accompanied by elevated oxidative
stress, NO produced by NOS2 can lead to peroxynitrite-
induced contractile impairment as observed in ischemic
or septic myocardium. Finally, shifts in isoforms or in
concentrations of myoﬁlaments can affect NO-mediated
myoﬁlamentary desensitization and alter the myocardial
contractile effects of NO in hypertrophied or failing
myocardium.
Key Words. nitric oxide, myocardium, contractility,
diastole, heart failure, nitric oxide synthase
Introduction
In vascular tissue, the contractile effects of ni-
tric oxide (NO) are easily appreciated consisting
of relaxation of isolated vascular strips or va-
sodilation of perfused organs. In cardiac tissue,
the contractile effects of NO are far less obvious
and have been the subject of considerable con-
fusion and debate. Some of the most important
controversies surrounding the myocardial con-
tractile effects of NO were: (1) Does NO exert a
myocardial contractile effect under baseline con-
ditions or only following adrenergic or cholinergic
stimulation? (2) Can the contractile effects of NO
be labelled as positively or negatively inotropic?
(3) Are the contractile effects of NO similar for NO
derived from NO-donor substances, for NO pro-
duced by NOS3 (eNOS, “endothelial-constitutive”
NOS) or for NO produced by NOS2 (iNOS,
“cytokine-inducible” NOS)? (4) Does hypertrophy,
aging, transplantation, heart failure, ischemia
or sepsis alter the observed contractile effects
of NO?
Some of the controversies arose from compar-
ison of data derived from different experimen-
tal set-ups ranging from isolated cardiomyocytes,
papillary muscle strips, perfused rodent hearts,
anaesthetized open-chest dogs to humans at the
time of cardiac catheterization. In all these set-
ups, myocardial contractility was assessed in an
unequal and often incomplete way. Isolated car-
diomyocytes are contracting at low load (i.e. fric-
tion on a glass surface). Extent of muscle shorten-
ing (l) or velocity of shortening (l/dt) recorded
in isolated cardiomyocytes is therefore hard to
compare with peak force (F) or speed of force
development (dF/dt) in isometrically contract-
ing papillary muscles. Effects on diastolic LV
function can easily be appreciated in perfused
hearts, open-chest dogs or humans but are difﬁ-
cult to detect in isolated cardiomyocytes or mus-
cle strips because of the controlled preloading
conditions. Interference by NO in parasympa-
thetic or sympathetic outﬂow to the heart is ab-
sent in isolated preparations but unavoidable in
humans.
The present review summarizes the current ev-
idence for myocardial contractile effects of NO
thereby highlighting the aforementioned con-
troversies and shortcomings of the different
experimental settings.
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Contractile Effects of NO
in Normal Myocardium
Systolic Function
In isolated cardiomyocytes, administration of ex-
ogenous NO was ﬁrst reported to be associated at
baseline with a small negative inotropic effect, ev-
ident from a reduction in extent and velocity of
shortening [1]. In the same preparation, inhibi-
tion of endogenous NOS3 had no baseline effect
but reduced extent and velocity of shortening fol-
lowing adrenergic stimulation [2]. In isolated iso-
metrically contracting cardiac muscls strips, NO
produced by NOS3 of adjacent endocardial cells
or derived from high, but not low, doses of NO-
donors exerted a similar small negative inotropic
effect evident from a reduction in peak isometric
force development [3–5] without change in rate of
rise of force development (dF/dtmax) (Fig. 1). This
reduction in peak isometric force development re-
sulted from an earlier onset of isometric relax-
ation, which abbreviated duration of contraction
or time left for isometric tension build-up. This
unique pattern of effect of NO on isometric force
Fig. 1. Top: Contractile effects of NO on isometric tension
development in an isolated cat papillary muscle. NO slightly
reduces peak tension because of earlier onset of isometric
relaxation and fails to alter the rate of rise of tension. The
contractile effects of NO are abolished by a simultaneous rise
in muscle preload (NO+ stretch). Bottom: The contractile
effects of NO derived from an intracoronary NO-donor
infusion (sodium nitroprusside; SNP-IC) in a normal human
subject. In analogy to the contractile effects in a cat papillary
muscle, there is a reduction in peak LV pressure (LVP), an
earlier onset of isovolumic relaxation and no effect on the rate
of rise of LV pressure. There is also a drop in diastolic LV
pressures during SNP-IC.
development revealed the underlying mechanism:
a NO-induced reduction in myoﬁlamentary cal-
cium sensitivity because of phosphorylation of tro-
ponin I by cGMP dependent protein kinase.
A similar relaxation hastening effect was
also observed in experimental preparations using
whole heart models. In isolated ejecting guinea-
pig hearts perfused with buffer solution and con-
tracting with constant preload, afterload and
heart rate, both NO derived from an NO-donor
[6] and NO released from the coronary endothe-
lium following stimulation with bradykinin or
substance P [7] induced an earlier onset and faster
rate of LV relaxation and a small reduction in
peak LV pressure without change in LV dP/dtmax.
These changes could not be reproduced with the
cGMP-independent vasodilator nicardipine and
were therefore unrelated to coronary vasodilation
or to coronary perfusion. These effects were also
observed after addition to the perfusate of an-
giotensin converting enzyme inhibitors probably
because of slower bradykinin breakdown andwere
abolished by addition of haemoglobin, which inac-
tivates NO [8].
Experiments [9] in transgenic mice with car-
dioselective overexpression of NOS3 and a 60-fold
increase in NOS activity (3H-L-Citrulline produc-
tion) conﬁrmed NO to produce a 30% reduction
in basal LV developed pressure mainly through
myoﬁlamentary desensitization and to a lesser ex-
tent through alterations in sarcolemmal calcium
ﬂuxes [10,11] or sarcoplasmic calcium handling
[12–15]. A similar 10% reduction in basal LV de-
veloped pressure was also observed in transgenic
mice with cardioselective overexpression of NOS2
and a 20-fold increase in 3H-L-Citrulline produc-
tion [16]. In these mice, addition of L-arginine to
the perfusion corrected the substrate deﬁcit for
NOS2 and induced a further 10% drop in LV de-
veloped pressure. A similar drop in LV developed
pressure during addition of L-arginine to an in-
tracoronary substance P infusion had previously
been reported in the human allograft [17] (Fig. 2).
A NO-induced and myoﬁlamentary
desensitization-mediated LV relaxation has-
tening effect was also observed in the human
heart during intracoronary infusions of NO-donor
substances or of substance P, which releases
NO from the coronary endothelium [18–20].
In analogy to the experimental preparations,
this relaxation-hastening effect abbreviated LV
contraction, reduced the magnitude of the late-
systolic reﬂected LV pressure wave and caused
a ±10 mmHg drop in LV end-systolic pressure
at unaltered LV end-systolic volume (Fig. 1).
There were no changes in the rate of rise of LV
pressure (LV dP/dtmax). The small drop in LV
end-systolic pressure at unaltered LV end-systolic
volume implied a rightward and downward shift
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Fig. 2. Three lead electrocardiogram, LV dP/dt, LV pressure (LVP) and right atrial pressure (RAP) recorded in a human allograft
in control conditions, after 2 and 5 min of intracoronary (IC) substance P (SP) infusion, after 2 and 8 min of intracoronary (IC)
substance P + L-arginine infusion (SP + L-arg) and 5 min after cessation of IC infusion. SP releases NO from the coronary
endothelium, which reduces peak LV pressure without changing LV dP/dtmax or RAP. Addition of L-arg to the SP infusion
potentiates these effects. Reproduced with permission from [17].
of the LV end-systolic pressure-volume relation
and was therefore theoretically consistent with
a small negative inotropic effect. The unaltered
LV dP/dtmax and the simultaneous fall in LV
end-diastolic pressure however argue against sig-
niﬁcant hemodynamic deterioration as a result of
these NO-induced negative inotropic effects on LV
end-systolic performance. In fact, the NO-induced
effects on LV end-systolic performance could well
be beneﬁcial for the ejecting left ventricle as they
reduced mechanical work wasted in contracting
against late-systolic reﬂected arterial pressure
waves.
When isolated cardiomyocytes [21] or isometri-
cally contracting papillary muscle strips [5] were
exposed to low doses of NO-donors, a positive
inotropic effect was observed probably result-
ing from cGMP-induced inhibition of phosphodi-
esterase 3 and a concomitant rise in cAMP or
from direct nitrosylation of sarcolemmal or sar-
coplasmic proteins. Similar positive inotropic ef-
fects of NO have been reported in anaesthetized
dogs [22] and in the normal human heart, in
which an intracoronary infusion of L-NMMA in-
duced a modest (14%) drop in LV dP/dtmax [23].
The dose-dependent transition from a positive
to a negative inotropic effect occurred at lower
doses of the NO-donor in the presence of an intact
endocardium and in the presence of cholinergic or
ß-adrenergic stimulation [5] (Fig. 3). Larger nega-
tive inotropic effects in the presence of a function-
ing endocardium implies additive effects of NO
derived from NO-donors and of NO produced by
NOS3 of adjacent endothelial cells. Larger nega-
tive inotropic effects following cholinergic stimu-
lation implies additive effects at the level of the
second messenger cGMP, whose intracellular con-
centration rises both following NO-donor admin-
istration and cholinergic stimulation. The larger
negative inotropic effect following ß-adrenergic
stimulation suggests additive effects also at the
level of the myoﬁlaments because of simultaneous
phosphorylation of troponin I by cGMP dependent
protein kinase and by cAMP dependent protein
kinase. The latter observation has far reaching
consequences and explains why many experimen-
tal and clinical studies detected no or only small
effects of NO under baseline conditions but re-
ported large changes following ß-adrenergic stim-
ulation. In the human heart, an intracoronary in-
fusion of substance P following pretreatment with
dobutamine resulted in a fall in LV end-systolic
pressure, which was twice as large as the fall ob-
served in control conditions and accompanied by
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Fig. 3. Dose response curve of peak isometric tension of an
isolated cat papillary muscle versus concentration of an
analogue of cGMP (8-bromo-cGMP), the second messsenger of
NO. At low doses of cGMP or of NO there is a positive
inotropic effect, at high doses of cGMP of of NO there is a
negative inotropic effect. Removal of the endocardial
endothelium (−EE) shifts the descending limb of the dose
response curve to the right, addition of acetylcholine (+Ach)
shifts it to the left. This implies additive effects of exogenously
administered cGMP to the endogenously produced cGMP by
the endothelium or following Ach administration.
a 6% fall in LV dP/dtmax [24] (Fig. 4). A simi-
lar augmentation by dobutamine of NO-related
myocardial contractile effects was also observed
during intracoronary infusion of L-NMMA, which
potentiated the dobutamine-induced rise in LV
dP/dtmax by 51% [25] but failed to have any ef-
fect in the same patient population in control
conditions [23]. Larger NO-related negative in-
otropic effects following ß-adrenergic stimulation
also highlight the importance of the contraction
mode of the experimental preparation. Differences
in pre- or afterload can indeed affect calcium sen-
sitivity of crossbridges and can counteract both
cGMP- or cAMP-induced myoﬁlamentary desensi-
tization and concomitant changes in timing of my-
ocardial contraction-relaxation sequence [26,27]
(Fig. 1).
Diastolic Function
NO related phosphorylation of troponin I also in-
creasesmyocardial diastolic distensibility through
prevention of calcium-independent diastolic cross-
bridge cycling. Such an increase in diastolic dis-
tensibility, evident from a longer diastolic cell
length at constant preload, has been observed
in isolated cardiomyocytes following exposure to
cGMP, the second messenger of NO or following
exposure to sodium nitroprusside [28,29]. The in-
crease in diastolic cell length and the concomitant
reduction in cell shortening following exposure
to sodium nitroprusside have been attributed not
only to cGMP-mediatedmyoﬁlamentary desensiti-
zation but also to myoﬁlamentary desensitization
related to a fall in intracellular pH. This fall in in-
tracellular pH suggested NO, via cGMP, to disable
forward sodium-proton exchange [29]. The reverse
mechanism, intracellular alkalization, has been
observed following administration of angiotensin
II or endothelin [30] and following cardiac mus-
cle stretch, which leads to autocrine production of
angiotensin II and endothelin [31]. As discussed
earlier, cardiac muscle stretch can indeed effec-
tively counteract the NO-induced effects on tim-
ing of myocardial contraction-relaxation sequence
[27] (Fig. 1). Moreover, in a beating rabbit heart,
a sudden increase in LV diastolic stretch because
of release of a caval occluder, leads to an instan-
taneous increase in diastolic intramyocardial NO
concentrations measured by a porphyrinic sen-
sor inserted in the LV wall of the beating rab-
bit heart [32]. Hence, a rise in LV preload trig-
gers not only myocardial autocrine production
of angiotensin II but also of NO, which can re-
verse the angiotensin II-induced changes in in-
tracellular pH and in myoﬁlamentary calcium
sensitivity.
In isolated ejecting guinea-pig hearts, a per-
fusate containing the speciﬁc NOS inhibitor NG-
monomethyl-L-arginine, raised LV end-diastolic
pressure and reduced preload recruitable LV
stroke volume probably because of an acute left
and upward shift of the diastolic LV pressure-
volume relation [33]. In the same preparation, an
increase in LV preload, caused a rise in the NO
concentration of the coronary efﬂuent [34] con-
ﬁrming the preload triggered enhancement of my-
ocardial NO production recorded from porphyrinic
sensors inserted in the wall of the beating rab-
bit heart [32]. NO-related changes in diastolic LV
distensibility have been observed not only follow-
ing acute administration of a NOS inhibitor but
also following chronic NOS blockade. In rats re-
ceiving eight weeks of treatment with the NOS in-
hibitor L-NAME, the diastolic LVpressure-volume
relation shifted upward with a signiﬁcant reduc-
tion in LV unstressed volume and no increase
in LV mass despite the elevated blood pressure
[35].
In the human heart, the relaxation-hastening
effect of NO was also accompanied by an in-
crease in LV diastolic distensibility. During
intracoronary infusions of NO-donors or of sub-
stance P, the LV diastolic pressure-volume rela-
tion shifted right- and downward consistent with
increased LV diastolic distensibility [18–20]. Sim-
ilar downward shifts of the diastolic LV pressure-
volume relation had previously been observed
during intravenous administration of NO-donors
and had always been attributed to a sequence
of events consisting of venodilation, right ven-
tricular unloading and biventricular interaction
[36,37]. The downward shifts of the diastolic LV
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Fig. 4. Single lead electrocardiogram, LV dP/dt and LV pressure (LVP) recorded in a human allograft at baseline, after 2 and 5
minutes of intracoronary (IC) substance P (SP) infusion and 3 and 5 minutes following infusion in the absence (top panel) and in
the presence of an intravenous infusion of dobutamine (DOB-IV) (bottom panel). During intravenous infusion of dobutamine, an
IC-SP infusion results in a larger drop in LV pressure than before (50 mmHg vs. 15 mmHg). Reproduced with permission from [98].
pressure-volume relation observed during intra-
coronary infusion of NO-donors did however not
result from such a sequence of events but from
a direct myocardial effect of NO (probably phos-
phorylation of troponin I and reduced calcium-
independent diastolic crossbridge cycling) for the
following reasons: (1) the doses of NO-donors in-
fused intracoronarily were too low to elicit sig-
niﬁcant systemic vasodilator effects; (2) a right
atrial infusion of the same dose of NO-donor failed
to reproduce the observed shift in the diastolic
LV pressure-volume relation; (3) the shift in the
Myocardial Contractile Effects of Nitric Oxide
155
diastolic LV pressure-volume relation persisted
even after transforming the measured LV dias-
tolic pressure to transmural LV diastolic pressure
and (4) the fall in LV end-diastolic pressure was
accompanied by an increase in LV end-diastolic
volume and a fall in heart rate, both of which
were incompatible with peripheral vasodilator
effects.
Contractile Effects of NO in Hypertrophied
and Senescent Myocardium
In hypertrophied cardiomyocytes isolated from
aortic-banded rats, exposure to the NO-donor
sodium nitroprusside failed to alter diastolic cell
length, to reduce the amplitude of cell shorten-
ing or to lower intracellular pH, all of which were
observed in cardiomyocytes from normal rats fol-
lowing exposure to sodium nitroprusside [29]. In
a guinea-pig model of compensated LV hypertro-
phy induced by aortic banding, the LV relaxant
effects of endothelially released NO were signif-
icantly blunted despite a preserved response to
exogenous NO [38]. This defective contractile re-
sponse was unrelated to alterations in coronary
ﬂow but reﬂected the impact on LV performance of
an hypertrophy-induced endothelial dysfunction
and concomitant reduction of NO bioactivity. Re-
duced NO bioactivity in the hypertrophied heart
could have resulted from a decrease of NOS3 ex-
pression or from inactivation of NO by reactive
oxygen species (ROS) such as superoxide anion. In
the guinea-pig model of aortic banding [38] and in
the spontaneously hypertensive rat [39], NOS3 ex-
pression was unaltered or even upregulated. This
made increased ROS production the most likely
cause for the reduction of NO bioactivity and for
the defective LV relaxant response to coronary en-
dothelial stimulation. Increased ROS production
could have resulted from dysfunctional NOS be-
cause of deﬁciencies in cofactor or substrate (i.e.
tetrahydrobiopterin or L-arginine) or from upreg-
ulation of other enzymes such as NADH/NADPH
oxidases [40]. In the same guinea pigmodel of com-
pensatedLVhypertrophy produced by aortic band-
ing, neither tetrahydrobiopterin nor L-arginine
corrected the defective LV relaxant response to
coronary endothelial stimulation. The latter was
however restored by vitamin C, deferroxamine or
superoxide dismutase and in line with these ob-
servations, protein expression of the NADPH oxi-
dase subunits (gp91-phox and p67-phox) and my-
ocardial NADPH oxidase activity were shown to
be signiﬁcantly increased in the banded animals
[41].
In patients with LV hypertrophy of aortic steno-
sis, intracoronary administration of a NO-donor
caused a marked fall in LV end-diastolic pres-
sure and in LV end-diastolic chamber stiffness
[19]. The fall in LV end-diastolic pressure ob-
served in the aortic stenosis patients was larger
than the fall observed in normal controls (−39
vs. −21%) but the fall in peak and end-systolic
LV pressures was smaller than in control sub-
jects. The larger fall in LV end-diastolic pres-
sure observed in the aortic stenosis patients could
have resulted from their higher baseline LV end-
diastolic pressure and not from a higher myocar-
dial sensitivity to the distensibility-increasing ef-
fect of NO. When the left ventricle is operating
on the steeper portion of its diastolic pressure-
volume relation, a NO-induced rightward shift of
the diastolic pressure-volume relation will result
in a larger reduction in LV end-diastolic pressure
than when the left ventricle is operating on the
ﬂat portion of its diastolic pressure-volume rela-
tion. The smaller fall in peak and end-systolic LV
pressures was consistent with a lower sensitiv-
ity of hypertrophied human myocardium to the
relaxation-hastening effect of NO and conﬁrmed
the aforementioned reduction in contractile re-
sponse to NO observed in cardiomyocytes of aortic
banded rats [29]. Lower sensitivity of hypertro-
phied myocardium to the relaxation-hastening ef-
fect of NO could possibly be explained by lower
concentrations in hypertrophied myocardium of
troponin I, whose breakdown is accelerated when-
ever the left ventricle is chronically subjected to
elevated LV ﬁlling pressures [42]. Other mecha-
nisms for a lower sensitivity of hypertrophied my-
ocardium to the contractile effects of NO include
a lower baseline cGMP concentration in hypertro-
phied myocardium, which would make it operate
on the ﬂat portion of its biphasic dose-reponse to
NO [5,43] (Fig. 3), or blunted downstream signal-
ing in hypertrophied myocardium from cGMP to
sodium-proton exchange [29]. Both the lower my-
ocardial sensitivity to NO and the lower myocar-
dial bioactivity of NO could be important mecha-
nisms for the diastolic dysfunction of the hyper-
trophied LV.
The effects of aging on myocardial NOS activity
are controversial. In one study, myocardial NOS3
activity was increased in the aging rat heart [44].
Despite increased myocardial NOS3 activity, left
ventricular diastolic distensibility was reduced as
evident from an elevation of left ventricular ﬁlling
pressures. Similar to the human allograft [17], the
reduction in diastolic left ventricular distensibility
of the senescent rat heart reacted favourably to ad-
ministration of L-arginine. Both observationswar-
rant further investigations on the clinical use of
L-arginine for the treatment of aging-induced di-
astolic left ventricular dysfunction. Other studies
documented an aging-induced reduction of NOS3
activity [45] and upregulation of NOS2 activity
[46].
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Contractile Effects of NO in Transplanted
Myocardium
In transplanted myocardium, myocardial con-
tractile effects of NO were the subject of in-
tense research because of the early demonstration
of NOS2 gene expression in transplanted my-
ocardium [47] and because of the numerous ex-
perimental studies, which linked NOS2 gene
expression to contractile dysfunction in experi-
mental preparations [48–52]. In transplant re-
cipients free of rejection or graft vasculopathy,
a Doppler echocardiographic index of LV perfor-
mance revealed a signiﬁcant association between
systolic, diastolic or combined LV dysfunction and
intensity of NOS2 gene expression in simulta-
neously procured LV biopsies [47]. An invasive
study in transplant recipients obtained microtip
LV pressure recordings and simultaneous LV an-
giograms at the time of annual coronary angiog-
raphy but found similar indices of baseline LV
function in transplant recipients with low or high
myocardial NOS2mRNA [53]. This study however
observed a larger relaxation-hastening effect and
a larger reduction in peak and end-systolic LV
pressure in transplant recipients with high my-
ocardial NOS2 mRNA following intravenous infu-
sion of the ß-agonist dobutamine. These ﬁndings
resembled the contractile effects of NOS3-derived
NO. The latter were also studied in transplant
recipients using intracoronary infusions of sub-
stance P, which releases NO from the coronary
endothelium. The relaxation hastening effect and
the concomitant fall in peak and end-systolic LV
pressure of NOS3-derived NO were small under
baseline conditions but rose drastically following
pretreatment with dobutamine (Fig. 4) [24]. The
similar contractile effects during dobutamine in-
fusion of NOS2- or NOS3-derived NO also sup-
ports substantial bioavailability of NOS2-derived
NO. Bioavailability of NOS2-derived NO has been
questioned because of the simultaneous presence
in transplanted myocardium of rejection-related
oxidants, which could combine with NO to gen-
erate peroxynitrite [54] and which could thereby
prevent NO from exerting its direct effects on the
cardiomyocytes. The myocardial bioavailability of
NOS2-derived NO was also indirectly demon-
strated in transplant recipients by higher myocar-
dial cGMP concentrations [47] and more recently
by higher transcardiac nitrite/nitrate production
[55] in the presence of upregulated NOS2 gene ex-
pression.
Rejection related oxidants or lower baseline
myocardial concentrations of cGMP or of cAMP
could explain the smaller LV relaxation-hastening
effect of intracoronary NO-donor infusions in
transplant recipients compared to a normal con-
trol population subjected to a similar infusion
protocol [56]. In the cardiac allograft, baseline
diastolic LV dysfunction predicted a poor NO-
induced LV relaxation-hastening effect. The in-
verse correlation between the NO-induced LV
relaxation-hastening effect and baseline diastolic
LV dysfunction could be related to varying de-
grees of oxidative stress, which could induce dias-
tolic LV dysfunction because of sarcoplasmicmem-
brane damage and a reduction of the LV-relaxation
hastening effect because of lower NO bioavailabil-
ity. Low baseline cGMP concentration could result
from reduced coronary NOS3 release because of
graft vascular disease and could explain the char-
acteristically shrunken appearance of the trans-
planted LV [57] in analogy to the small LV cavity
size of rat hearts following chronic treatment with
NOS inhibitors [35]. Low baseline cAMP concen-
tration in the cardiac allograft could result from
cardiac denervation and could act in concert with
the presence of oxidants and low baseline cGMP
concentration to blunt the NO-donor induced LV
contractile effects in the cardiac allograft.
Contractile Effects of NO in Failing
Myocardium
In analogy to transplanted myocardium, the early
reports of increasedmyocardial NOS2 [58–64] and
NOS3 [65] expression in failing human hearts
stimulated research on the myocardial contrac-
tile effects of NO in failing myocardium because of
the widely proposed but unfortunately unproven
paradigm of excess NO production contributing to
contractile depression.
In dogs with pacing-induced heart failure, my-
ocardial NOS activity was signiﬁcantly increased
compared to control dogs. Administration of aNOS
inhibitor to cardiomyocytes isolated from these
hearts had no effect on baseline myocardial per-
formance but augmented the inotropic response
to ß-adrenergic stimulation [66]. Similar results
were obtained in muscle strips of explanted hu-
man cardiomyopathic hearts: L-NMMA adminis-
tration had no effect on baseline isometric force de-
velopment but increased the dobutamine-induced
rise in contractile performance [62]. Other investi-
gators however failed to conﬁrm these results and
observed no changes in the contractile response
to ß-adrenoreceptor stimulation following admin-
istration of a NOS inhibitor to cardiomyocytes iso-
lated from cardiomyopathic human hearts [67].
Moreover, in the pacing-induced heart failure dog
model, the fall in LV stroke work and the rise in
LV end-diastolic pressure observed after 4 weeks
of pacing was accompanied by a fall in cardiac
NO production as evident from a smaller tran-
scardiac nitrite/nitrate gradient [68]. In this same
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model, dampening of the myocardial ß-adrenergic
response has recently been attributed to increased
cGMP levels resulting not fromexcessNO-induced
guanylyl cyclase activity but from reduced phos-
phodiesterase 5-mediated cGMP breakdown [69].
In patients with dilated cardiomyopathy and
biopsy proven endomyocardial NOS2 gene expres-
sion, intracoronary infusion of L-NMMA had no
effect on LV contractile performance [23]. In the
same patient population, an intracoronary in-
fusion of L-NMMA had previously been shown
to potentiate the dobutamine-induced rise in LV
dP/dtmax [25]. In the pacing-induced heart failure
dog model, the latter ﬁnding was conﬁrmed and
related to abundance of caveolin protein in fail-
ing myocardium [70]. Caveolin protein abundance
in failing myocardium reduces NOS3 activity and
interferes with translocation of receptor-agonist
complexes from the sarcolemma. The beneﬁcial
outcome of statins in heart failure could, apart
from their effects on rho proteins, also relate to
reduction of caveolin and concomitant enhance-
ment of NOS3 activity [71]. In dilated cardiomy-
opathy patients with elevated LV ﬁlling pressures,
intracoronary infusion of substance P enhanced
myocardial NOS2 activity, slightly reduced LV
end-systolic pressure but improved overall hemo-
dynamic status as evident from higher LV stroke
volume and LV stroke work [64]. These beneﬁ-
cial NO-related contractile effects resulted from
a simultaneous NO-induced increase in diastolic
LV distensibility. Low intensity of LV endomy-
ocardial NOS2 and NOS3 gene expression was
recently demonstrated to coincide with a hemo-
dynamic phenotype of dilated cardiomyopathy
patients characterized by elevated LV diastolic
stiffness and reduced LV stroke work [72]. In
contrast to this hemodynamic phenotype with
poor prognosis, dilated cardiomyopathy patients
with low LV diastolic stiffness and preserved LV
stroke work had higher intensity of NOS2 and
NOS3 gene expression, which attained the level
observed in athlete’s heart [72] (Fig. 5). Low LV
diastolic stiffness, reversible right- and downward
displacement of the diastolic LV pressure-volume
relation and high LV preload reserve are typi-
cal features of athlete’s heart and could be NO-
mediated because of the documented upregulation
of NOS activity and expression following regular
physical exercise [73,74]. Simultaneous improve-
ment in diastolic LV distensibility also overrode
the NO-induced attenuation of the LV contrac-
tile response to dobutamine in terms of overall
hemodynamic status of dilated cardiomyopathy
patients. In two studies [24,75], agonist-induced
coronary endothelial release of NO during intra-
venous administration of dobutamine resulted in
a small reduction of LV contractility indices such
as LV dP/dtmax and LV elastance but without
Fig. 5. In patients with non-ischaemic dilated
cardiomyopathy, an inverse relation was observed between LV
diastolic stiffness (stiffness-Mod) and intensity of
endomyocardial NOS2 gene expression normalised for LV
end-diastolic wall stress (LVEDWS) (Top). A similar relation
was also observed for LV ejection fraction (EF) [72]. Both
relations imply better hemodynamic status in patients with
dilated cardiomyopathy when myocardial NOS2 gene
expression is elevated.
hemodynamic deterioration as evident from un-
altered LV stroke volume and reduced LV end-
diastolic pressure. The fall in LV end-diastolic
pressure was accompanied by an unchanged LV
end-diastolic volume and was therefore consistent
with an improvement in LV diastolic distensibil-
ity. NO-related modulation of diastolic LV disten-
sibility was also observed in the pacing-induced
heart failure dog model [68]. In this model, a
fall in myocardial NO production occurred after
4 weeks of pacing. This fall was accompanied by
a steep rise in LV end-diastolic presssure because
of reduced diastolic LV distensibility and a drop
in LV stroke volume. From these observations
in patients with dilated cardiomyopathy and in
dogs with pacing-induced heart failure, it seems
justiﬁed to conclude that there is no objective
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evidence for NO, whether derived from NOS2 or
NOS3, to account for hemodynamic deterioration
of failingmyocardium, either at baseline or during
ß-adrenoreceptor stimulation [43,76].
Contractile Effects of NO in Ischemic
and Septic Myocardium
NO exerts marked protective effects on isolated
reoxygenated cardiomyocytes mostly through
prevention of reoxygenation-induced hypercon-
tracture [77]. These effects are cGMP dependent
because addition of methylene blue, an in-
hibitor of soluble guanylyl cyclase, reduces NO-
induced protection. Although a speciﬁc negative
contractile effect of NO can not be excluded,
cGMP-induced phosphorylation of troponin I
could certainly contribute through prevention
of calcium-independent diastolic crossbridge cy-
cling [78]. Other mechanisms include reduction
of osmotic fragility of the sarcolemma damaged
by increased oxidative stress because of radical
scavenging properties of NO [79].
In opposition to the uniform ﬁndings in iso-
lated cardiomyocytes, reports on the outcome of
inhibition of NO synthase in ischaemic-reperfused
hearts are controversial. Especially under acidotic
conditions, as present during low-ﬂow ischemia,
peroxynitrite anions, which result from reaction
of NO with superoxide anion, get protonated and
subsequently decay rapidly to generate hydoxyl
radicals [80], which are highly toxic for sarcolem-
mal or sarcoplasmic membranes. Consistent with
this sequence of events, inhibition of NO synthe-
sis has been reported to reduce reoxygenation in-
jury in anaesthetized piglets [81] and to reduce
infarct size in rabbits [82]. In contrast to these ini-
tial results, subsequent studies reported endoge-
nous release of NO to protect against ischemia-
reperfusion. Both in the ischemic-reperfused rat
[83] and rabbit [84] heart, inhibition of endoge-
nous NO synthesis by L-nitro arginine increased
the ischemia related contractile deﬁcit possibly be-
cause of a NO-mediated scavanging effect of free
radicals with a concomitant reduction in ischemic
injury.
In the search for the contractile effects of en-
dogenous NO during ischemia-reperfusion, phar-
macological inhibition of NO was replaced by
the use of transgenic NOS2 or NOS3 knock-out
mice. Here again, the results were nonuniform:
some investigators found exacerbated ischemia-
reperfusion injury in NOS knock-out animals
while other investigators observed a protective ef-
fect of endogenous NO production [85,86]. Using
an isolated mouse heart preparation, an interest-
ing crosstalk between NOS2 and NOS3 during
ischemia-reperfusion was recently reported [87]:
in NOS3 knock-out mice subjected to 30 minutes
of global ischemia followed by reperfusion, a para-
doxical increase of NO production was observed
because of superinduction ofNOS2. This increased
NO production, blunted the hyperdynamic re-
sponse during early reperfusion and protected the
heart against myocardial injury as evident from
a reduction in infarct size. Similar ﬁndings were
observed in wild-type mice treated with the NO-
donor S-nitroso-N-acetylpenicillamine (SNAP). In
these experiments, NO-induced myoﬁlamentary
desensitization because of cGMP-induced phos-
phorylation of troponin I served as a brake for
the myocardial hypercontractile response to early
reperfusion thereby reducing energy demand and
ATP deﬁcit.
Apart from affecting the initial contractile re-
sponse to ischemia-reperfusion injury, NO could
also inﬂuence long-term left ventricular remodel-
ing after myocardial infarction [88]. In the early-
postinfarction period, left ventricular contractile
performance in wild-type and NOS2 knock-out
mice was similar, but 4 months after infarction,
NOS2 knock-out mice had superior hemodynam-
ics and better survival because of reduced apop-
totic cell death and myocyte loss in the nonin-
farcted zone [89]. Similar ﬁndings were reported
by other investigators, who noticed an earlier in-
crease in left ventricular end-diastolic diameter
and an earlier decrease in fractional shortening
at 1 month post-infarction in wild type mice com-
pared to NOS2 knock-outs [90]. In these end-
stagemice-infarctmodels, circulating levels of free
radicals become very elevated [91] and the ob-
served late deterioration of left ventricular per-
formance could therefore result not from NO it-
self but from elevated oxidative stress, which
triggers peroxynitrite production and hydroxyl-
related membrane damage in the presence of NO
[92,93]. The superior long-term outcome following
myocardial infarction in wild-type mice compared
to NOS3 knock-outmice also argues against direct
NO-related deleterious effects on long-term post-
infarct LV remodeling [94]. Moreover, in endothe-
lial cells, NO confers protection against apop-
totic cell death via s-nitrosylation of caspases. In
these cells, aging-induced loss of NOS3 activity in-
creases sensitivity to oxidizedLDLor tumornecro-
sis factor α induced apoptosis [95].
A detrimental role of peroxynitrite rather than
NO was also demonstrated in septic or endotox-
emic hearts. Once established, the depressed car-
diac function after endotoxin administration was
not reversed by NOS inhibition [96] and myocar-
dial function of the endotoxemic heart remained
depressed even after return of NOS2 protein
levels to control value [97]. The large quanti-
ties of NO produced by NOS2 during the ini-
tial episode of endotoxemia could however have
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promoted the formation of peroxynitrite, which
could have irreversibly impaired contractile per-
formance through long-lasting modiﬁcations of
proteins such as actin, sarcoplasmic Ca-ATPase
or sarcoplasmic Ca-release channel (ryanodine
receptor).
Conclusions
Recent experimental and clinical research clar-
iﬁed some of the controversies surrounding the
myocardial contractile effects of NO. In trans-
genic mice with cardioselective overexpression of
NOS3 [9] or of NOS2 [16] and with a 60- to
20-fold increase in myocardial NOS activity, NO
produced a small reduction in basal LV devel-
oped pressure and a LV relaxation-hastening ef-
fect mainly through myoﬁlamentary desensitiza-
tion and to a lesser extent through alterations in
calcium handling. Similar ﬁndings had previously
been reported during intracoronary infusions of
NO-donors and of substance P, which releases NO
from the coronary endothelium, in isolated rodent
hearts [6,7], in normal control subjects [18,20]
and in patients with aortic stenosis [19]. The LV
relaxation hastening effect was always accompa-
nied by increased diastolic LV distensibility, which
augmented LV preload reserve especially in di-
lated cardiomyopathy patients [64]. In this pa-
tient population, low endomyocardialNOS expres-
sion was accompanied by an unfavourable hemo-
dynamic phenotype characterized by elevated LV
diastolic stiffness and reduced LV stroke work
[72]. The beneﬁcial effect of NO on diastolic LV
function always overrode the small NO-induced
attenuation in LV developed pressure in terms
of overall LV performance [43]. In most experi-
mental and clinical conditions, contractile effects
of NO were similar when NO was derived from
NO-donors or produced by the different isoforms
of NOS [24,53]. Because expression of inducible
NOS (NOS2) is frequently accompanied by ele-
vated oxidative stress, NO produced by NOS2 can
lead to peroxynitrite formation and irreversible
contractile impairment as observed in post-infarct
LV remodeling [89,90] or sepsis [97]. Finally, pres-
ence of ROS and shifts of myoﬁlaments to isoforms
with reduced susceptibility to cGMP-mediated de-
sensitization can alter the myocardial contrac-
tile effects of NO in hypertrophied or failing my-
ocardium [29,38].
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Bronzwaer, Jean G. F., Christophe Heymes, Cees A.
Visser, and Walter J. Paulus. Myocardial ﬁbrosis blunts
nitric oxide synthase-related preload reserve in human di-
lated cardiomyopathy. Am J Physiol Heart Circ Physiol 284:
H10–H16, 2003; 10.1152/ajpheart.00401.2002.—The pur-
pose of the study was to investigate interactions between
myocardial nitric oxide synthase (NOS) and myocardial ﬁ-
brosis, both of which determine left ventricular (LV) preload
reserve in patients with nonischemic dilated cardiomyopathy
(DCM). In previous animal experiments, chronic inhibition of
NOS induced myocardial ﬁbrosis and limited LV preload
reserve. Twenty-eight DCM patients underwent LV catheter-
ization, balloon caval occlusions (BCO; n  8), intracoronary
substance P infusion (n  8), and procurement of LV endo-
myocardial biopsies for determinations of collagen volume
fraction (CVF), of gene expression of NOS2, NOS3, heme
oxygenase (HO)-1, and TNF-	, and of NOS2 protein. CVF
was unrelated to the intensity of NOS2, NOS3, HO-1, or
TNF-	 gene expression or of NOS2 protein expression. Pre-
load recruitable LV stroke work (PR-LVSW) correlated di-
rectly with NOS2 gene expression (P  0.001) and inversely
with CVF (P  0.04). High CVF (10%) reduced baseline
LVSW and PR-LVSW at each level of NOS2 gene expression.
In DCM, myocardial ﬁbrosis is unrelated to the intensity of
myocardial gene expression of NOS, antioxidative enzymes
(HO-1), or cytokines (TNF-	) and blunts NOS2-related re-
cruitment of LV preload reserve.
collagen; diastole; myocardial contraction
HIGHER LEFT VENTRICULAR (LV) endomyocardial nitric ox-
ide (NO) synthase (NOS) gene expression enables pa-
tients with dilated cardiomyopathy (DCM) to recruit
LV preload reserve as evident from their higher LV
stroke work (LVSW) at elevated LV ﬁlling pressures
(13). This ability to recruit LV preload reserve could
result from an acute direct myocardial action of NO,
because intracoronary infusion of substance P, which
releases NO from the coronary endothelium, induces
an instantaneous increase in LVSW in DCM patients
with elevated LV ﬁlling pressures (13). This increase in
LVSW is accompanied by a rightward shift of the
diastolic LV pressure-volume relation. A similar NO-
related rightward shift of the diastolic LV pressure-
volume relation was previously observed in control and
aortic stenosis patients after intracoronary infusion of
a NO donor (20, 24) and in DCM patients after intra-
coronary infusion of enalaprilat (37). Acute effects of
NO on myocardial diastolic distensibility have also
been reported in experimental preparations. In iso-
lated rat cardiomyocytes, exposure to cGMP, the sec-
ond messenger of NO, increases diastolic cell length
(32), and, in isolated guinea pig hearts, a coronary
perfusate containing a speciﬁc NOS inhibitor results in
an acute reduction of LV stroke volume because of a
leftward shift of the diastolic LV pressure-volume re-
lation (27).
The ability of NO to preserve LV diastolic distensi-
bility could result not only from its acute direct myo-
cardial actions but also from chronic effects on LV
hypertrophy and on collagen turnover within the car-
diac interstitium. In rats receiving chronic treatment
with a NOS inhibitor, the diastolic LV pressure-volume
relation shifts upward with a decrease in LV volume
relative to wall thickness and no increase in LV mass
despite the elevated blood pressure (1, 19). Chronic
inhibition of NO synthesis also induces progressive
myocardial interstitial and perivascular ﬁbrosis
through a signaling cascade involving endothelin, an-
giotensin II, aldosterone, and transforming growth fac-
tor-
 (3, 34).
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The present study investigates interactions between
the intensity of myocardial NOS gene expression and
myocardial ﬁbrosis in patients with nonischemic DCM
in relation to their ability to recruit LV preload re-
serve. Baseline hemodynamic measures and the
change in LVSW during balloon caval occlusion were
correlated with the intensity of NOS2 and NOS3 gene
expression, intensity of NOS2 protein expression, and
collagen volume fraction (CVF) in simultaneously pro-
cured LV endomyocardial biopsies. To reproduce inter-
actions between myocardial NO content and CVF, the
hemodynamic response to an intracoronary infusion of
substance P (13), which releases NO from the coronary
endothelium, was also analyzed in relation to CVF of
the LV endomyocardial biopsy.
METHODS
Patients and study protocol. Twenty-eight patients with
nonischemic DCM were included. The group consisted of 8
women and 20 men (Table 1). At the time of study, heart
failure therapy was maintained and consisted of ACE inhib-
itors (ACEI; n  28), diuretics (n  25), and 
-blockers (n 
2). Cutoff values for DCM were a LV end-diastolic volume
(LVEDV) index  102 ml/m2 (normal average value  2SD)
and a LV ejection fraction (LVEF) 45%. All patients had
higher than normal baseline LV end-diastolic wall stress
(LVEDWS) [85 kdyn/cm2  LVEDWS in a LV with a
LVEDV at the upper limit of normal and a LV end-diastolic
pressure (LVEDP) at the upper limit of normal (16 mmHg)
(38)]. A control group of three patients was also studied. Two
male patients (age 44 and 24 yr, LVEF: 54% and 63%) were
referred for myocarditis, and one female patient (age 72 yr,
LVEF 57%) was referred for amyloidosis. Histological exam-
ination of the LV endomyocardial biopsies revealed no evi-
dence of myocarditis or amyloidosis nor were there other
abnormalities.
LV pressure and the ﬁrst derivative of LV pressure (LV
dP/dt) were derived from a high-ﬁdelity micromanometer-
tipped catheter. In eight patients (Table 1, patients 21–28), a
5-min intracoronary infusion of substance P (20 pmol/min)
was performed (13). Substance P causes receptor-mediated
coronary endothelial release of NO. At the end of the infusion
period, LV hemodynamic and angiographic measures were
repeated and compared with baseline values. In eight pa-
tients (Table 1, patients 1–8), a conductance catheter (Ley-
com Sigma) was used for continuous LV volume and pressure
measurement. In these patients, a 8-Fr balloon catheter was
introduced into the right atrium. Transient pullback of the
inﬂated balloon into the inferior vena cava created multiple,
variably preloaded beats. LV endomyocardial biopsies were
obtained using a disposable transfemoral bioptome (Cordis).
The study protocol was approved by the local review board
(VU-University Medical Center, Amsterdam, The Nether-
lands), and informed consent for the study protocol was
obtained from all patients.
RT-PCR for NOS2, NOS3, heme oxygenase-1, and TNF-
mRNA. Snap-frozen biopsies were obtained in 20 patients
(Table 1, patients 1–20) for determination of NOS2 (n  20),
NOS3 (n  20), heme oxygenase (HO)-1 (n  14), and TNF-	
mRNA (n  10). RNA extraction, internal standard prepara-
tion, and oligonucleotides used for RT-PCR and quantitative
RT-PCR protocol, using a deﬁned amount of speciﬁc RNA
mutant as an internal standard, have been extensively de-
scribed previously (13). For HO-1, the primers chosen were
Table 1. Patient characteristics
Patient Age, yr Dig
HR,
beats/min
LVPSP,
mmHg
LVEDP,
mmHg
LV dP/dtmax,
mmHg/s
LVEDVI,
ml/m2
LVEF,
%
1 67  75 108 14 785 392 10
2 37  105 102 28 1,021 167 10
3 47  71 128 21 560 124 35
4 65  69 97 28 550 289 7
5 45  73 90 29 525 123 15
6 56  105 129 25 1,455 189 16
7 39  74 115 27 859 177 20
8 56  96 137 25 1,230 183 19
9 72  55 126 12 1,280 143 32
10 70  77 137 21 1,240 106 39
11 55  95 97 33 672 105 24
12 70  78 95 20 850 160 17
13 45  88 108 42 725 106 38
14 66  90 139 19 1,225 107 25
15 26  92 79 33 425 180 8
16 72  82 127 26 1,225 146 35
17 61  82 80 22 450 239 30
18 65  88 91 24 456 162 33
19 32  78 100 35 645 178 44
20 34  78 108 14 1,350 115 32
21 54  88 108 22 745 162 28
22 47  95 100 29 740 168 22
23 72  82 144 36 920 170 32
24 40  94 84 27 640 133 21
25 38  90 140 34 795 114 29
26 52  107 137 30 1,350 120 45
27 63  104 121 25 1,150 178 25
28 69  115 95 31 840 134 23
Dig, use of digitalis; HR, heart rate; LVPSP, left ventricular (LV) peak systolic pressure; LVEDP, LV end-diastolic pressure; LV dP/dtmax,
maximal ﬁrst derivative of LV pressure; LVEDVI, LV end-diastolic volume index; LVEF, LV ejection fraction.
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5-CAGGCAGAGAATGCTGAGTTC-3 (sense) and 5-GCT-
TCACATAGCGCTGCA-3 (antisense), amplifying the 79- to
429-bp region of HO-1. The expression of TNF-	 was quan-
tiﬁed as the ratio of the target band intensity to the 
-actin
band intensity.
Quantitative morphometry and immunohistochemistry.
The extent of interstitial ﬁbrosis was determined on elastica
von Gieson-stained sections of at least three LV endomyocar-
dial biopsies placed in 5% formalin with the use of an auto-
mated image analyzer (Prodit). Patients were divided into
low and high extents of myocardial ﬁbrosis in accordance to
the CVF. A CVF  10% corresponded to the median value of
the CVF data and was used as the cutoff value to separate
the low from the high extent of myocardial ﬁbrosis. NOS2
protein expression was analyzed by immunohistochemistry
using a commercially available antibody (NOS2, BioMol).
Antibodies were detected by an indirect peroxidase antibody
conjugate technique, and NOS2 staining was graded semi-
quantitatively on a scale of 0 to 4.
Data analysis. LVSW was derived from the area within the
LV pressure-volume diagram (13). Preload recruitable LVSW
(PR-LVSW) equaled the slope of a linear curve ﬁt to the
LVSW-versus-LVEDP data of the variably preloaded beats
induced by transient pullback of the inﬂated balloon into the
inferior vena cava. Baseline LVSW correlated closely (P 
0.001, r  0.90) with PR-LVSW. This correlation justiﬁes the
use of baseline LVSW as a measure of LV preload reserve in
the entire patient population.
Circumferential LV end-diastolic wall stress (LVEDWS)
was computed using a thick wall ellipsoid model of the LV
(23) as follows
LVEDWS PD/2h  1  h/D D2/2L2 1.332 dyn cm2]
where P is LVEDP, h is LV echocardiographic end-diastolic
wall thickness, and D and L are LV end-diastolic diameter
and length at the midwall, respectively.
To assess diastolic LV myocardial material properties, a
radial myocardial LV stiffness modulus (Stiffness-Mod) (6)
was calculated from the microtip LV pressure and the echo-
cardiographic LV wall thickness using the formula
Stiffness-Mod  R/R  P/h/h	  P/ln h
and assuming the increment in radial stress (R) to be equal
but opposite in sign to the increment in LV pressure (P) at
the endocardium, and the increment in radial strain (R) to
be equal to the increment in wall thickness (h) relative to
the instantaneous wall thickness. Because h/h  ln h,
Stiffness-Mod was equal to the slope of a P-versus-ln h plot.
All results are given as means  SE. Univariate and
multivariate linear regression analysis were performed with
the use of the SPSS software package.
RESULTS
Determinants of LV preload reserve. Univariate lin-
ear regression analysis showed the intensity of NOS2
gene expression to correlate with baseline LVSW (P 
0.0002, r  0.75; Fig. 1A) and with PR-LVSW (P 
0.001, r  0.90), NOS2 immunostaining to correlate
with baseline LVSW (P  0.003, r  0.63), and CVF to
inversely correlate with baseline LVSW (P  0.02, r 
0.48) and with PR-LVSW (P  0.04, r  0.70). Patients
with CVF  10% had higher baseline LVSW (P  0.01)
and higher PR-LVSW (P  0.03) than patients with
CVF  10%.
Determinants of LV ﬁbrosis. No signiﬁcant correla-
tions were observed between CVF and the intensity of
NOS2, NOS3, HO-1, or TNF-	 gene expression or
NOS2 immunostaining.
Interaction between NOS, ﬁbrosis, and LV preload
reserve. In a multivariate linear regression analysis, in
the evaluation of the relation of baseline LVSW to the
intensity of NOS3, NOS2, HO-1, and TNF-	 gene ex-
pression and to the extent of myocardial ﬁbrosis, only
the intensity of NOS2 gene expression (P  0.0005)
and the extent of myocardial ﬁbrosis (P  0.001) sig-
niﬁcantly correlated with baseline LVSW.
When patients with CVF 10% were separated from
patients with CVF  10%, the relation between base-
line LVSW and NOS2 gene expression was signiﬁ-
cantly (P  0.05) shifted upward in patients with
CVF  10% compared with patients with CVF  10%
(Fig. 1B). This upward shift implies a higher LVSW for
a given value of NOS2 gene expression in patients with
CVF  10%. In patients with CVF  10%, a relation
was observed between PR-LVSW and NOS2 gene ex-
Fig. 1. A: linear relation between baseline left ventricular (LV)
stroke work (LVSW) and the intensity of nitric oxide synthase
(NOS)2 gene expression in the dilated cardiomyopathy (DCM) study
population and in control patients (E). B: relation between baseline
LVSW and NOS2 gene expression is shifted upward in patients with
low-level myocardial ﬁbrosis [collagen volume fraction (CVF) 
10%].
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pression (P 0.01, r 0.85). Patients with CVF 10%
fell below the 95% conﬁdence interval of this relation.
When patients with CVF 10% were separated from
patients with CVF  10%, a signiﬁcant correlation
between baseline LVSW and the intensity of NOS3
gene expression was observed only in patients with
CVF  10% (P  0.04, r  0.64) (Fig. 2A). In patients
with CVF  10%, NOS3-related augmentation of
LVSW was no longer demonstrable. Reduced NOS3-
related augmentation of LVSW in patients with a high
extent of interstitial ﬁbrosis was also evident during
intracoronary infusion of substance P, which induces
coronary endothelial release of NO. In patients with
CVF  10%, the substance P-induced increase in
LVSW was signiﬁcantly smaller than in patients with
CVF  10% [LVSW: 10  3 g m for CVF  10% vs.
35  5 g m for CVF  10% (P  0.02)].
When patients with CVF 10% were separated from
patients with CVF  10%, a signiﬁcant correlation
between the intensity of HO-1 gene expression and
baseline LVSW was observed only in patients with
CVF  10% (P  0.04, r  0.69; Fig. 2B). In patients
with CVF  10%, these relations were absent.
Interaction between NOS, ﬁbrosis, and LV myocar-
dial stiffness. Multivariate linear regression analysis
was used to evaluate the relation of LV myocardial
stiffness to the intensity of NOS3, NOS2, HO-1, and
TNF-	 gene expression and to the extent of myocardial
ﬁbrosis. Only the intensity of NOS2 gene expression
(P  0.001; Fig. 3A) and the extent of myocardial
ﬁbrosis (P  0.04) signiﬁcantly correlated with the LV
Stiffness-Mod. When patients with CVF  10% were
separated from patients with CVF  10%, the relation
between Stiffness-Mod and NOS2 gene expression was
signiﬁcantly (P  0.05) shifted downward in patients
with CVF  10% compared with patients with CVF 
10% (Fig. 3B). This downward shift implies a lower
Stiffness-Mod for a given value of NOS2 gene expres-
sion in patients with CVF  10%.
Fig. 2. A: linear relation between baseline LVSW and the intensity
of NOS3 gene expression is observed in patients with low-level
myocardial ﬁbrosis (CVF  10%) but not in patients with high-level
myocardial ﬁbrosis (CVF 10%). B: linear relation between baseline
LVSW and the intensity of heme oxygenase (HO)-1 gene expression
is observed in patients with low-level myocardial ﬁbrosis (CVF 
10%) but not in patients with high-level myocardial ﬁbrosis (CVF 
10%).
Fig. 3. A: linear relation between the LV stiffness modulus (Stiff-
ness-Mod) and intensity of NOS2 gene expression in the DCM study
population and in control patients (E). B: the relation between the
LV Stiffness-Mod and NOS2 gene expression is shifted downward in
patients with low-level myocardial ﬁbrosis (CVF  10%).
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DISCUSSION
NO, ﬁbrosis, and LV preload reserve. Patients with
DCM are highly dependent on LV preload reserve to
augment cardiac output during exercise. The present
study identiﬁed high LV endomyocardial NOS2 and
low CVF to be important for recruitment of LV preload
reserve in these patients.
During exercise, patients with DCM are highly de-
pendent on LV preload reserve because of the blunted
myocardial inotropic response to catecholamines (14).
The enhancement of PR-LVSW in DCM results from a
rightward displacement of the diastolic LV pressure-
volume relation (15). Limitation of this rightward dis-
placement is accompanied by a restrictive LV ﬁlling
pattern on the Doppler mitral inﬂow signal, by exacer-
bation of symptoms, and by poor prognosis (25). Be-
cause of the ability of NO to shift the diastolic LV
pressure-volume relation rightward (24, 37), a low in-
tensity of endomyocardial NOS gene expression could
limit rightward displacement of the diastolic LV pres-
sure-volume relation and PR-LVSW (7, 13). A high
extent of myocardial ﬁbrosis could similarly limit LV
distensibility and PR-LVSW (36).
The ﬁndings of the present study are consistent with
NO being physiologically involved in the LV hemody-
namic response to a rise in preload and with myocar-
dial ﬁbrosis effectively counteracting this physiological
response. A physiological role for NO in the LV re-
sponse to preload augmentation was recently estab-
lished in experiments that measured the intramyocar-
dial NO concentration using a microporphyrinic sensor
in the LV wall of the beating rabbit heart (26). In these
experiments, a LV volume load due to release of a caval
occluder resulted in a prompt rise in intramyocardial
NO concentration. Pretreatment with a NOS inhibitor
(27) reduced both PR- LVSW and LV diastolic disten-
sibility, and L-arginine resulted in opposite effects.
The present study investigated relations between
myocardial ﬁbrosis and the intensity of NOS gene
expression not only because NO could reduce the col-
lagen turnover of ﬁbroblasts but also because myocar-
dial ﬁbrosis could affect myocardial NOS gene expres-
sion. Fibrosis of the failing myocardium is indeed
accompanied by disruption of the collagen weave
around individual myocytes leading to malalignment
or slippage. This disruption of the collagen weave al-
ters myocardial gene expression because of an altered
cascade of stress signals descending from the collagen
ﬁbers to sarcolemmal integrins, cytoskeletal proteins,
and nuclear membranes. Both a previous study (30)
and the present study failed to observe a relation
between the extent of myocardial ﬁbrosis and NOS2
gene expression.
The present study also failed to observe a relation
between the extent of myocardial ﬁbrosis and NOS3
gene expression or HO-1 gene expression, which is
upregulated in the failing myocardium and could aug-
ment the bioavailability of NO by protection against
oxidative stress (28). The lack of relations between
myocardial ﬁbrosis and NOS3 or antioxidative en-
zymes such as HO-1 does not exclude the involvement
of NOS3 or antioxidative enzymes in the development
of myocardial ﬁbrosis but suggests excessive myocar-
dial ﬁbrosis in DCM to result more from upregulation
of stimulatory pathways such as angiotensin II, endo-
thelin, and aldosterone than from downregulation of
inhibitory pathways (36).
Upregulation of NOS2. A potential mechanism for
the observed upregulation of NOS2 could be a compen-
satory rise for reduced expression of NOS3 (9). Recent
experiments in NOS3 knockout mice indeed observed a
superinduction of NOS2 triggered by the oxidative
stress of an ischemia-reperfusion episode (16). This
superinduction of NOS2 provided an important protec-
tive effect against ischemia-reperfusion injury with
preservation of systolic and diastolic LV performance.
Superior hemodynamic status in the presence of myo-
cardial NOS2 upregulation was also observed in the
present study, and this result conﬁrmed the ﬁndings of
a recent clinical study that failed to observe a change in
LV dP/dtmax in DCM patients during intracoronary
NG-monomethyl-L-arginine infusion despite NOS2
gene expression (8, 22). In addition, recent experimen-
tal ﬁndings have demonstrated that the heart can
tolerate high levels of NOS2 activity without detrimen-
tal functional consequences (12).
The myocardial upregulation of NOS2 observed in
the present study could also be part of the reexpression
of the fetal gene program frequently observed in hy-
pertrophied or failing myocardium. NOS2 is indeed
abundantly expressed in the fetus and gets downregu-
lated before birth (2).
Myocardial cytokines could be important determi-
nants of LV preload reserve because of their ability to
induce NOS2 (30) and to increase activity of matrix
metalloproteinases with a concomitant acceleration of
collagen breakdown (33). In the present study, myocar-
dial TNF-	 gene expression appeared unrelated to
LVSW, myocardial NOS2 gene expression, or the ex-
tent of myocardial ﬁbrosis.
Therapeutic implications. The present study shows
recruitment of LV preload reserve in patients with
DCM to relate to the high intensity of myocardial NOS
gene expression and to the low extent of myocardial
ﬁbrosis. ACEI, 
-blockers, and spironolactone have all
been shown to both upregulate myocardial NOS gene
expression and to induce regression of endomyocardial
ﬁbrosis. Some of the beneﬁts of ACEI, 
-blockers, and
spironolactone in the treatment of chronic heart failure
could therefore be ascribed to their ability to maintain
LV preload reserve of the cardiomyopathic heart be-
cause of upregulation of NOS3 activity and prevention
of myocardial ﬁbrosis. ACEI augment coronary endo-
thelial NO activity acutely as evident from intracoro-
nary enalaprilat infusion during pacing tachycardia
(21) and chronically as evident from the Trial on Re-
versing Endothelial Dysfunction, which showed im-
proved endothelial-dependent vasodilator responses
during long-term quinapril therapy (18). Apart from
beneﬁcial effects on LV preload reserve, ACEI-induced
upregulation of myocardial NO content could also
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favourably modify substrate utilization and mitochon-
drial respiration of failing myocardium (17, 29, 35). In
patients with hypertensive heart disease, 6 mo of lis-
inopril therapy induced signiﬁcant regression of myo-
cardial ﬁbrosis and improvement of diastolic LV func-
tion (5). DCM patients on 
-blocker therapy had a
higher intensity of NOS3 gene expression in their en-
domyocardial biopsies (11, 13). 
-Blocker therapy could
also favourably affect myocardial ﬁbrosis through re-
duction of angiotensin II-related activation of matrix
metalloproteinases (31). In patients with heart failure,
spironolactone improved endothelial dysfunction by in-
creasing NO bioactivity (10), and, in the Randomized
Aldactone Evaluation Study, serum levels of markers
of cardiac ﬁbrosis were signiﬁcantly reduced by spi-
ronolactone therapy (39).
Study limitations. LV endomyocardial NOS gene ex-
pression was derived from a single biopsy sample,
which therefore did not take into account spatial het-
erogeneity of gene expression (4). In a previous study
(13), however, multiple biopsies from different LV sites
were obtained in the same patient and the variability
of endomyocardial NOS2 and NOS3 gene expression
was low (7% and 15%).
In the present study, LVSW and Stiffness-Mod were
correlated with endomyocardial NOS mRNA and pro-
tein and not with measures of endomyocardial NO
activity, such as myocardial cGMP concentration or
transcardiac nitrite/nitrate production. Only the latter
could have accounted for posttranscriptional and post-
translational modiﬁcation of NOS, for substrate deﬁ-
ciency, or for the reduced bioavailability of NO because
of elevated oxidative stress.
The LV endomyocardial biopsies used for determina-
tion of interstitial myocardial ﬁbrosis were considered
representative of the whole LV myocardium and there-
fore assumed homogeneity in LV myocardial structure.
In conclusion, in the cardiomyopathic heart, a high
intensity of myocardial NOS gene expression and low-
level myocardial ﬁbrosis appeared to be essential for
maintaining LV preload reserve. Part of the beneﬁt of
ACEI, 
-blockers, and spironolactone in the treatment
of chronic heart failure could be related to their ability
to upregulate NOS2 gene expression and to regress
myocardial ﬁbrosis. Upregulation of myocardial NOS2
and regression of myocardial ﬁbrosis are important
targets for prevention of progression of cardiomyo-
pathic LV dysfunction.
The authors are indebted to Dr. Marc Vanderheyden, Imelda
Ziekenhuis, Bonheiden, Belgium, for providing the NOS2 immuno-
histochemistry.
This study was presented in part at the Scientiﬁc Sessions 2001 of
the American Heart Association, November 2001, Anaheim, CA.
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Introduction
Nitric oxide(NO) is universally accepted as an important regulator of vascular tone, capillary
permeability and platelet adhesion. NO's myocardial actions are unfortunately less well
understood despite the growing clinical awareness that progressive dysfunction of the failing
heart could well result from an imbalance between  myocardial NO and oxidative stress induced
by excess neurohormonal and inflammatory mediators(32). The appreciation of a beneficial role
of NO in failing myocardium  was a recent turnaround(8,11,15,33) and resulted mainly from an
appraisal of NO's favorable effects on cardiac energetics(51) and on LV diastolic
distensibility(35) clearly outweighing the negative inotropy of NO reported in the very initial
studies looking at its contractile effects. These studies had observed  a reduction of extent and
velocity of shortening of isolated cardiomyocytes following administration of exogenous NO(3)
and an increase in extent and velocity of shortening of adrenergically-stimulated cardiomyocytes
following inhibition of endogenous NO production(1). At that time, these experiments were
thought to provide an explanation for simultaneously published clinical observations, which
reported  inducible NO synthase(NOS2) activity in patients with nonischemic dilated
cardiomyopathy(10). These initial experimental studies and the potential link to myocardial
dysfunction of nonischemic dilated cardiomyopathy were however  rapidly rebutted by several
investigators reporting positive inotropic effects of low doses of exogenous NO or of
cGMP(23,29) and by clinical studies reporting myocardial NOS2 expression in ischemic
cardiomyopathy, in valvular heart disease and even in athlete's heart(5,16).  These clinical studies
also found higher NOS2 expression in heart failure patients with lower functional class, larger
stroke work and preserved LV diastolic distensibility. Nevertheless, the idea of NO being
deleterious because of a negative inotropic effect gained widespread acceptance and subsequently
hindered a correct appreciation of NO's favorable effects on failing myocardium.
NO-induced myocardial contractile depression:
time for acquittal!
Detailed analysis of the time course of isometric contraction of isolated cat papillary muscle strips
revealed endogenous NO, released from the endothelium, to affect cardiac muscle contraction
in a unique way (29,47): NO induced an earlier onset of isometric tension decay, which reduced
peak isometric tension(T) without  effect on the rate of rise of tension (Figure 1a). This effect was
attributed  to a NO-induced reduction in myofilamentary calcium sensitivity because of
phosphorylation of troponin I by cGMP dependent protein kinase as evident from simultaneous
recordings in isolated cardiomyocytes of cell lengthening and of calcium transient(44). In these
cardiomyocytes,  diastolic cell length was not clamped and following administration of NO or
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of cGMP diastolic cell length consistently increased (20,44). This finding implied a rightward
shift of the passive length-tension relation of the cardiomyocyte. This shift was also explained
by NO-induced phosphorylation of troponin I, which prevented calcium-independent diastolic
crossbridge cycling and concomitant diastolic stiffening of the myocardium.  Both the relaxation-
hastening  and distensibility-increasing  effects of NO were confirmed in the human heart.
During intracoronary infusions of low doses of NO-donors(35) or of substance P(36), which
releases NO from the coronary endothelium,  there was  an earlier onset of isovolumic LV
pressure decay(Figure 1b), lower LV peak-systolic, end-systolic and end-diastolic pressures and
rightward displacement of the diastolic LV pressure-volume relation(Figure 1c). In patients with
a hypertrophied LV of aortic stenosis, the NO-induced rightward displacement of the diastolic
LV pressure-volume relation was larger than in controls(27). In patients with dilated
cardiomyopathy, the rightward displacement of the diastolic LV pressure-volume relation was
accompanied by a significant increase in LV stroke volume because of improved recruitment of
LV preload reserve (18). The lower LV end-systolic pressure at unaltered LV end-systolic volume
observed during intracoronary infusions of NO-donors or of substance P implied a downward
shift of the LV end-systolic pressure-volume relation and was therefore consistent with a negative
inotropic effect of NO.  The unaltered LV dP/dtmax at larger LV end-diastolic volume was also
theoretically consistent with lower myocardial inotropic state. The simultaneous fall in LV end-
diastolic pressure and the rise in LV stroke volume or stroke work however  argue against
significant cardiac contractile depression as a result of these NO-induced effects. Finally, direct
positive inotropic effects of NO were recently demonstrated in normal control patients(7), in
whom an intracoronary infusion of L-NMMA induced a modest(14%) drop in LV dP/dt max. In
the same study, intracoronary L-NMMA failed to alter  LV dP/dt max in dilated cardiomyopathy
patients despite myocardial expression of NOS2 in simultaneously procured endomyocardial
biopsies.
Following ȕ-adrenoreceptor stimulation of isolated cardiac muscle strips, the NO-induced
relaxation-hastening  effect was larger probably because of simultaneous phosphorylation of
troponin I by cAMP dependent  and cGMP dependent protein kinases(29). In dilated
cardiomyopathy patients,  similar cooperative  effects of NO and of ȕ-adrenoreceptor stimulation
were reported: during concomitant intravenous infusion of dobutamine, intracoronary infusion
of substance P caused a larger drop in LV end-systolic pressure(±30 mmHg) and a small(6%)
reduction in LV dP/dtmax (34). Both effects were again accompanied by a fall in LV end-
diastolic pressure implying absence of hemodynamic deterioration. Similar findings had been
observed during concomitant intravenous infusion of dobutamine and intracoronary infusion of
the NO synthase inhibitor NG-monomethyl-L-arginine (L-NMMA)(14,46) or of the angiotensin-
converting enzyme inhibitor enalaprilat(50). Intracoronary L-NMMA infusion raised LV
dP/dtmax and increased the slope of the LV end-systolic pressure-volume relation without change
in LV end-diastolic pressure again implying no substantial change in overall hemodynamic status.
Intracoronary enalaprilat in the presence of angiotensin II receptor blockade caused bradykinin-
Chapter 4.2
176
induced coronary endothelial release of NO and this also resulted in a small reduction of LV
dP/dtmax accompanied by a fall in LV end-diastolic pressure and no change in LV stroke
volume.
Figure 1:  Figure 1a-Top panel: Effects of NO on isolated papillary muscle isometric contraction. NO has
no effect on the rate of rise of isometric tension but causes earlier  isometric tension decay with a
concomitant small reduction in peak isometric tension.  These effects are counteracted by an increase in
muscle preload(NO+Stretch). Figure 1b-Middle panel: Effects of an intracoronary(I.C.) infusion of sodium
nitroprusside(SNP) on LV pressure in the normal human heart. There is no effect on the rate of rise of LV
pressure but an earlier onset of isovolumic LV pressure decay with concomitant reduction in peak and end-
systolic LV pressures. Figure 1c-Bottom panel: Effects of an intracoronary infusion of substance P (SP I.C.)
on the LV pressure(LVP)-volume(LVV) relation in the normal human heart. SP I.C. causes a small  right
and downward displacement of the end-systolic pressure-volume point and a  right and downward
displacement  of the diastolic pressure-volume relation consistent with an increase in diastolic LV
distensibility. Reproduced with permission from ref 32. 
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Hence, from these observations in dilated cardiomyopathy patients, it can be concluded that
in terms of overall LV performance, improvement in diastolic LV function also overrode the NO-
induced attenuation of the LV contractile response to ȕ-adrenoreceptor stimulation.
In transgenic mice with  cardioselective overexpression of endothelial NOS(NOS3)(6) and a
60-fold increase in myocardial NOS3 activity (3H-L-Citrulline production), there was only a small
reduction in peak LV developed pressure without  hemodynamic consequence mainly because
of myofilamentary desensitization. A similar small reduction in peak LV developed pressure
without signs of cardiac dysfunction was also observed in transgenic mice with cardioselective
overexpression of NOS2 and a 20-fold increase in myocardial 3H-L-Citrulline production(17).
In these mice, addition of L-arginine to the perfusion, augmented the drop in LV developed
pressure to 20% of basal value again without hemodynamic consequence. In experimental
volume-overload, basal isometric twitch characteristics were more depressed in papillary muscles
retrieved from decompensated than from compensated rats despite similar myocardial NOS2
activity(12).
Maintenance of preload reserve:
an important task for NO in the stressed heart!
In isolated ejecting guinea-pig hearts, a perfusate containing L-NMMA raised LV end-diastolic
pressure and reduced preload recrutable LV stroke work because of an acute left and upward shift
of the diastolic LV pressure-volume relation (39). In this preparation,  use of LV preload reserve
also induced a rise in the NO concentration of the coronary effluent. This preload triggered
enhancement of myocardial NO production confirmed earlier observations using porphyrinic
sensors inserted in the wall of the beating rabbit heart(38). In rats receiving eight weeks of
treatment with a NOS inhibitor, the diastolic LV pressure-volume relation shifted upward with
reduced LV unstressed volume and no increase in LV mass despite the elevated blood
pressure(26). NO-related modulation of diastolic LV distensibility was also observed in the
pacing-induced heart failure dog model (40), in which  a fall in myocardial NO production
occurred after 4 weeks of pacing. This fall was accompanied by a drop in LV stroke volume and
a steep rise in LV end-diastolic pressure probably because of reduced diastolic LV distensibility.
A NO-induced diastolic LV distensibility increasing effect was observed  not only in
experimental models but also in the normal human heart(35), in the cardiac allograft(36), in the
hypertrophied LV of aortic stenosis(27) and in the failing LV of dilated cardiomyopathy(18). In
dilated cardiomyopathy patients with elevated LV filling pressures(18), enhanced myocardial
NOS3 activity during intracoronary substance P infusion, increased LV stroke volume and LV
stroke work. This acute increase in LV stroke work  resulted from a simultaneous NO-induced
increase in diastolic LV distensibility and LV preload reserve(5). 
In patients with dilated cardiomyopathy, limited LV preload reserve (19) corresponds with a
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restrictive LV filling pattern on the Dopplerechocardiogram(37). This phenotype of dilated
cardiomyopathy is characterized by a worse symptomatic course and a worse prognosis. Low
intensity of LV endomyocardial NOS2 and NOS3 gene expression was recently demonstrated to
coincide with this hemodynamic phenotype(5). In contrast, dilated cardiomyopathy patients with
maintained LV preload reserve, normal Dopplerechocardiographic LV filling dynamics and low
LV diastolic stiffness had a high intensity of LV endomyocardial NOS2 and NOS3 gene
expression, comparable to the intensity observed in athlete's heart(5). Low LV diastolic stiffness
and high LV preload reserve are also typical features of athlete's heart and could also be NO-
mediated because of the well documented upregulation of NOS3 activity and expression by
intense physical exercise(2,42). Further evidence for a beneficial effect of high endomyocardial
NO activity  on prognosis of dilated cardiomyopathy was recently provided by studies looking
at NOS3 gene polymorphism in man. In these studies, dilated cardiomyopathy patients of a
genotype with high NOS3 activity had a more benign course of their disease than patients of a
genotype with low NOS3 activity(28). These findings also resemble the superior long-term
outcome of LV remodeling following myocardial infarction in wild-type mice compared to NOS3
knock-out mice(41). Finally, the improved prognosis of dilated cardiomyopathy patients treated
with ACE inhibitors or ȕ blockers is paralleled by an upregulation of their endomyocardial NOS3
activity(18).
Figure 2: Additive and opposite effects of intensity of NOS2 gene expression and of  myocardial fibrosis on
diastolic LV stiffness in the failing human heart. The relation between  the LV stiffness modulus (Stiffness-
Mod) and NOS2 gene expression is shifted downward in patients with low level myocardial fibrosis
[Collagen Volume Fraction(CVF) < 10%].
A beneficial effect of high endomyocardial NO activity on diastolic LV distensibility of the
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cardiomyopathic heart could result not only from NO-induced phosphorylation of troponin I and
a concomitant reduction of diastolic crossbridge cycling but also from prevention of
endomyocardial fibrosis. Chronic inhibition of NO synthesis has indeed been demonstrated to
induce progressive myocardial fibrosis through a signaling cascade involving endothelin,
angiotensin II, aldosterone and transforming growth factor ȕ. A recent study looked at the
interaction between endomyocardial NOS gene expression and fibrosis in patients with dilated
cardiomyopathy (4).
This study found no correlation between  endomyocardial  NOS mRNA and collagen volume
fraction and observed additive but opposite effects of intensity of NOS gene expression and of
fibrosis on diastolic LV stiffness(Figure 2). The lack of correlation between  NOS expression and
collagen does not exclude involvement of NOS in the development of myocardial fibrosis in
dilated cardiomyopathy but suggests excessive deposition of collagen in cardiomyopathic hearts
to result more from upregulation of stimulatory pathways such as endothelin, angiotensin II or
aldosterone than from down regulation of inhibitory pathways such as NO or natriuretic peptides.
NO's control of diastole and energetics: Two of a kind?    
The altered energetics of failing myocardium are characterized by 1) reduced creatine kinase
activity  and phosphocreatine levels, 2) loss of control of myocardial mitochondrial respiration
leading to excessive oxygen consumption and 3) a switch in preferential myocardial substrate
utilization from free fatty acids to glucose. Apart from creatine kinase activity (13), NO appears
to correct all these derangements of myocardial energetics(49). NO can bind to heme moieties
of proteins involved in mitochondrial respiration. Reduced inhibition of these enzymes explains
the higher myocardial oxygen consumption in conscious dogs during NOS inhibition(45) and in
terminal stages of experimental(51) and clinical heart failure(25), which are characterized by low
cardiac NO production(18,40). In failing human myocardium, this excessive myocardial oxygen
consumption reacted favorably to ACE inhibitor, amlodipine or neutral endopeptidase
inhibitor(25) all of which are known to raise myocardial NO content through inhibition of kinin
degradation.  In pacing-induced heart failure, at the time of transition to decompensation,  a drop
in myocardial NO production is observed, which coincides with a switch in myocardial substrate
utilization from free fatty acids to glucose(40). A similar switch was also observed in transgenic
mice with absent NOS gene expression(48). The altered energetics of failing myocardium are
paralleled by a shift of  myofilamentary gene expression towards isoforms with higher calcium
sensitivity and lower ATPase activity. This shift in gene expression enhances contractile
efficiency of failing myocardium even in the presence of a deranged oxygen consumption(21).
In the human cardiomyopathic heart, administration of L-NMMA does not affect its
efficiency(46) despite the augmented  LV contractile response to ȕ-adrenergic stimulation.     
NO's effects on LV contractile performance appear to be synergistic with its effects on
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energetics through prevention of inappropriate contractile augmentation in the setting of
reperfusion, through prevention of myocardial energy wastage induced by LV contraction against
late-systolic reflected arterial pressure waves and through prevention of diastolic LV stiffening,
which preserves adequate subendocardial coronary perfusion.
In NOS3 knock-out mice subjected to 30 minutes of global ischemia followed by reperfusion,
a paradoxical increase in NO production was observed  because of superinduction of NOS2(22).
The accompanying increase in NO's myofilamentary desensitizing action reduced the hyper
dynamic myocardial contractile response characteristic of early reperfusion. This protected the
reperfused heart because of reduced myocardial energy demand at a time of low energy
availability. Similar NO-mediated flow-metabolism-function matching was also observed in the
high oxygen demand model of pacing-induced heart failure(30). In the early pacing period, when
myocardial NO production and NOS2 gene expression were high, there were parallel reductions
in coronary blood flow, myocardial oxygen consumption and LVdP/dt max. In a later phase,
when myocardial NO production and NOS2 gene expression declined, flow-metabolism-function
matching was disrupted because of a continuing fall in LVdP/dt max despite higher coronary
blood flow and myocardial oxygen consumption. Using the same model, other investigators had
previously observed a reduction in diastolic LV distensibility as evident from a steep rise in
LVEDP, when myocardial NO production started to decline(40). Taken together, these three
studies suggest NO to be responsible for myocardial flow-metabolism-function matching through
modulation of LV preload reserve. NO-induced prevention of reperfusion-related LV dysfunction
was also evident in-vitro from the NO-conferred protection of isolated cardiomyocytes against
reoxygenation contracture (43).
In the human heart, intracoronary infusions of NO-donors or of substance P revealed a NO-
induced reduction in late-systolic LV pressure generation because of earlier onset of LV isometric
relaxation(Figure 1b)(35,36). This reduction in late-systolic LV pressure generation corresponded
with a reduced LV contractile effort against reflected arterial pressure waves. This reduced LV
contractile effort prevented myocardial energy wastage induced by late-systolic afterload
augmentation . These beneficial effects of NO on myocardial contractile performance and
energetics are in concert with NO's well established effects on the vasculature.  A high vascular
NO activity induces arteriolar vasodilation and improves arterial distensibility, both of which
reduce magnitude and traveling speed of reflected arterial pressure waves.  A high myocardial
NO activity provides appropriate timing of isometric LV relaxation, thereby preventing an
amplifying effect elicited by late-systolic LV contraction against the reflected arterial pressure
wave(31). 
Myocardial mechanical deformation during systole is an important stimulus for NO release
by cardiac endothelial cells(24). Using an intramyocardial porphyrinic NO sensor, beat-to-beat
release of NO was recorded in the rabbit heart with a brisk rise at end-systole to optimally hasten
myocardial relaxation and to lower LV filling pressures(38). The latter effects are beneficial for
diastolic coronary perfusion especially at higher heart rates when there is a disproportionally
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larger reduction in diastolic coronary perfusion period.  In the same preparation, an increase in
LV preload was accompanied by a higher beat-to-beat release of NO allowing for a larger
desensitizing effect of NO counteracting the preload-induced augmentation of myofilamentary
calcium sensitivity. When preload rises in the setting of contractile dysfunction, as occurs in
failing myocardium, systolic mechanical deformation and the NO transient will fail to increase
leaving preload-induced augmentation of myofilamentary calcium sensitivity unopposed. Because
of induction of the fetal gene program, failing myocardium already expresses myofilamentary
isoforms with increased calcium sensitivity. This isoform shift, a high LV preload and a low NO
transient will all cause additive augmentation of myofilamentary calcium sensitivity and can
therefore predispose failing myocardium to slow relaxation kinetics and diastolic crossbridge
cycling, both of which compromise diastolic coronary perfusion and myocardial oxygen supply.
In such a setting, the expression of NOS2, which produces NO independently of mechanical
deformation, could be beneficial because it would interrupt the vicious circle of reduced
mechanical deformation, reduced NOS3-dependent NO production and deranged diastolic LV
function(18) and energetics(9).
Conclusions
In heart failure patients, beneficial effects of NO on diastolic LV function always overrode a
small NO-induced attenuation of LV developed pressure in terms of overall hemodynamic status,
either at baseline or following ȕ-adrenergic stimulation. The absence of hemodynamic
deterioration in transgenic mice overexpressing either myocardial NOS2 or NOS3 confirms these
clinical observations. In failing myocardium,  NO's correction of  diastolic LV dysfunction
reinforces  NO's energy sparing effects and the concerted action of NO on both diastolic LV
dysfunction and deranged energetics could well be instrumental for preventing relentless
deterioration of failing myocardium.
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Introduction
The increasing incidence in aging Western societies of patients with documented congestive heart
failure and a normal left ventricular(LV) ejection fraction(EF) justifies the recent surge of interest
in diastolic LV dysfunction as a cause of heart failure (1,2,11,31,62,72,81-83). Mainly
noninvasive imaging techniques, especially tissue Doppler imaging(49,65,79), and the use of
plasma B-type natriuretic peptide(BNP)(40) are currently advancing our knowledge on diastolic
LV dysfunction in heart failure. From these recent observations some questions resurface, which
are similar to questions asked in the early eighties, when investigators used mainly invasive
techniques to construct diastolic LV pressure-volume relations in order to understand the
pathophysiology of diastolic LV dysfunction. It therefore seems timely to readdress some of these
questions and to confront the new, noninvasive observations with the old framework of
invasively acquired diastolic LV pressure-volume relations. Some of the  questions on diastolic
LV dysfunction, that have recently reemerged, are:
1. Is diastolic LV dysfunction secondary to systolic LV dysfunction?  
2. Can transient elevations in LV loading induce diastolic LV dysfunction?
3. Can diastolic LV dysfunction result from heightened active diastolic cardiac muscle
tone?
Is diastolic LV dysfunction secondary to systolic LV dysfunction?
In patients with a history of heart failure and a normal LVEF (EF>50%), refined
Dopplerechocardiographic studies recently revealed significant depression of long axis systolic
shortening(9,78) and of regional myocardial systolic velocity(79). Regional myocardial systolic
velocity was significantly lower in patients with diastolic heart failure (4.6±1.3 cm/s) than in
patients with diastolic LV dysfunction (5.4±1.0 cm/s) and this finding suggested worse systolic
LV dysfunction, albeit subtle and still without effect on global LVEF, to significantly contribute
to the appearance of heart failure symptoms even in patients labeled as having isolated diastolic
heart failure because of a LVEF>50%. In accordance  to the paradigm proposed by these studies,
heart failure always results from a sequence of events, which starts with an afterload or
tachycardia-induced(29) reduction in LV systolic performance. This forces the left ventricle to
operate at a larger LV end-diastolic volume(LVEDV)  to maintain LV stroke volume. In the
presence of a steep or near vertical diastolic LV pressure-volume relation, a larger LVEDV leads
to a substantial rise in LV end-diastolic pressure(LVEDP) and appearance of heart failure
symptoms. Essential for the validity of this paradigm is the presence during the heart failure
episode of a larger LVEDV and of concordant changes in LVEDV and LVEDP, with a higher
LVEDP always occurring at a larger LVEDV. Several clinical and experimental studies looking
at LV performance during acute heart failure episodes however failed to satisfy these criteria:
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1) During an episode of acute pulmonary edema associated with arterial hypertension, the
LVEDV(109±43 ml) was not different from the LVEDV(117±50 ml) observed one to
three days later at the time of recompensation(19). 
2) A clinical study(5), which looked at LV function during acute ischemia-induced heart
failure episodes observed discordant changes in LVEDV and LVEDP when comparing
in the same patient the hemodynamic effects of pacing-induced and balloon-occlusion
ischemia. In this study, 7 minutes of pacing tachycardia in the presence of single vessel
proximal left anterior descending coronary artery stenosis resulted in a significantly
smaller LVEDV (LVEDVI=88±17 ml/m2) despite higher LVEDP(24±7 mmHg) than 60
seconds of balloon coronary occlusion(LVEDVI=96±16 ml/m2; LVEDP=21±8
mmHg)(Figure 1). In a similar clinical protocol(12), 60seconds of balloon coronary
occlusion with hypoxemic perfusion distal to the occlusion also resulted in a slightly
smaller LVEDVI (78±14 ml/m2) at a higher LVEDP (34±7 mmHg) when compared to
60 seconds of regular balloon coronary occlusion (LVEDVI=79±15 ml/m2;LVEDP=23±6
mmHg). 
3) In anaesthetized dogs with coronary stenosis on both proximal left anterior descending
and left circumflex coronary arteries(56), 3 minutes of pacing tachycardia resulted in
significant increases in LV end-diastolic segment length (from 16.8±0.9 to 17.5±0.9 mm)
and in LVEDP(from 9±1 to 15±1 mmHg). The increase in LV end-diastolic segment
length was no longer present despite a tripling of LVEDP(from 9±1 to 27±2 mmHg) after
3 minutes of pacing tachycardia with an intravenous infusion of caffeine. Caffeine
induces myocardial cytosolic calcium overload and potentiates  hypoxic cardiac muscle
contracture.
The constancy during acute hypertensive pulmonary edema of LVEDV and the discordant
changes during acute ischemia-induced heart failure episodes of LVEDV and LVEDP, with the
smaller LVEDV  being observed at the higher LVEDP, argue against systolic LV dysfunction and
a concomitant outward displacement of the LVEDP-LVEDV point along a single steep diastolic
LV pressure-volume relation to be the unique mechanism underlying all heart failure episodes.
The hemodynamic changes observed during acute pulmonary edema associated with both arterial
hypertension or demand-ischemia  support the existence during some acute heart failure episodes
of primary diastolic LV dysfunction, which corresponds to an acute and reversible upward
displacement of the diastolic LV pressure-volume relationship(Figure 1).
The opposite type of discordant changes of LVEDV and LVEDP (i.e. a larger LVEDV
occurring at a lower LVEDP) was recently also reported in dilated cardiomyopathy patients
during intracoronary infusion of substance P, which acutely released NO from the coronary
endothelium(23). In this study, intracoronary substance P induced a fall in LVEDP from 25±3
to18±2 mmHg(p<0.0001) and a simultaneous discordant rise in LVEDV from 220±26 to
240±29ml(p<0.05) because of a reversible downward and rightward displacement of the LV
diastolic pressure-volume relation(7). A similar fall in LVEDP without change in LVEDV was
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also observed in dilated cardiomyopathy patients  during intracoronary infusion of enalaprilat.
These patients had been pretreated with an angiotensin-1 receptor antagonist to expose effects
of enalaprilat on bradykinin degradation and on myocardial NO availability(75). Discordant
changes of LVEDP and LVEDV (i.e. a fall in LVEDP accompanying a rise in LVEDV) have
occasionally even been observed during intravenous administration of NO-donors despite the
venous pooling induced by the systemic administration route(32).
Figure 1. Discordant changes of LVEDV and LVEDP during acute ischemic heart failure episodes. In a
patient with single vessel LAD coronary stenosis, pacing-induced angina(PI) results in a smaller LVEDV
than 1-minute of balloon coronary occlusion(CO) despite higher LVEDP during PI than CO(5). The
discordant changes of LVEDV and LVEDP during PI are inconsistent with a unique and fixed diastolic LV
pressure-volume relation and support reversible upward displacement of the diastolic LV pressure-volume
relation during an acute ischemic heart failure episode of PI. 
Can transient elevations in LV loading induce diastolic LV dysfunction?
A recent clinical report(19) of an hypertensive episode inducing acute pulmonary edema without
Doppler echocardiographic evidence of reduced LV systolic performance or of increased mitral
regurgitation, revived scientific interest for the effects of high LV afterload on diastolic LV
function(8,30). In animal experiments, a rise in LV afterload by vasopressor infusion or by
mechanical occlusion  of the aorta slowed isovolumic LV pressure decline(16,28). This slowing
was especially evident with late-systolic loading increments(24,37,80). A late systolic LV loading
increment elevates myocardial wall stress at a time when calcium reuptake into the SR is
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completed and when no recruitment of additional cross-bridges can occur. A late systolic LV
loading increment  therefore increases individual crossbridge load, which slows cross-bridge
cycling and decelerates LV pressure decay. In the aging human heart and especially in patients
with arterial hypertension, LV systolic pressure and LV systolic wall stress always peak in late
systole because of the presence of prominent arterial wave reflections(48). This loading pattern
renders the aging and hypertensive human heart especially susceptible to afterload-induced
deceleration of isovolumic LV relaxation. This was nicely demonstrated by Kawaguchi et al.(30)
in patients with arterial hypertension, normal systolic function and a history of heart failure, who
were exercised in the cardiac catheterization laboratory. Sustained isometric handgrip exercise
induced a rise of LV end-systolic pressure to an average level of 201±12 mmHg and a rise in the
time constant of isovolumic LV pressure decay (Ĳ) to an average value of 86±23 ms, which
corresponds to profound slowing of LV isovolumic relaxation kinetics [normal value of Ĳ=36±6
ms(54)].
The slowing of LV isovolumic relaxation kinetics during exercise, also implies a blunting of
the lusitropic actions of ß-adrenoreceptor stimulation in these patients. Load-induced blunting
of the lusitropic actions of ß-adrenoreceptor stimulation has previously been reported in the
human allograft(52). In transplant recipients, LVEDP rises during the initial stages of exercise
because of a mismatch between venous return and chronotropic response. At later stages of
exercise, both heart rate and LV dP/dt max catch up due to high levels of circulating
catecholamines but Ĳ fails to abbreviate.  Even pretreatment with dobutamine does not correct this
lusitropic deficiency of the transplanted heart during exercise(69). Moreover, the close correlation
during exercise(51) between LVEDP and Ĳ suggest the initial rise in LVEDP to actually
counteract subsequent ß-adrenoreceptor induced acceleration of myocardial relaxation kinetics.
A similar interaction had previously been reported in isolated papillary muscle strips, in whom
a stretch from 95% lmax to lmax effectively reduced the acceleration of isometric tension decay
during ß-adrenergic stimulation(10,43). Hence, not only excessive elevation of late-systolic load
but also preload-induced blunting of the lusitropic response to ß-adrenoreceptor stimulation,
could have contributed to the exercise-induced prolongation of Ĳ in hypertensive patients as these
patients also developed a large rise in LVEDP (to a value of 32±9 mmHg) during exercise(30).
Although an isolated rise in LV preload does not affect isovolumic LV pressure decay in an
anesthetized dog model(17) or in man(71), a higher LV preload potentiates afterload-induced
slowing of isovolumic LV pressure decay. This was recently demonstrated in an in-vivo rabbit
model using single beat aortic cross-clamps(36). In this model, a high LV afterload prolonged Ĳ
and shifted the diastolic LV pressure-volume relation slightly upward(Figure 2). These effects
were markedly potentiated by a concomitant elevation of LV preload. Furthermore, the value of
LVEDP of the diastole following the cross-clamped beat largely exceeded the value predicted by
extrapolating the exponential LV pressure decay using the prolonged Ĳ. The latter finding argued
in favor of concomitant overload-induced diastolic crossbridge cycling, which occurred
simultaneously with the slow crossbridge detachment responsible for the prolonged isovolumic
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relaxation. From these clinical and experimental observations, the  importance of preload
elevation for afterload-induced diastolic LV dysfunction becomes evident. Preload elevation
causes an additional increase in myofilamentary calcium sensitivity and this contributes to
diastolic LV dysfunction by: 1) abolishing PKA or PKG-induced acceleration of LV relaxation
kinetics; 2) by further slowing LV isovolumic relaxation under conditions of elevated
end-systolic afterload and 3) and by promoting diastolic crossbridge cycling thereby inducing
rises in LV filling pressures, which exceed residual LV relaxation pressure.
Figure 2. Schematic  diagram of effects of LV afterload and LV preload on diastolic LV function(36). A rise
in LV afterload(B), if it augments late-systolic  LV load(see shift of arrow), slows isovolumic LV pressure
decay. A concomitant  elevation in LV preload(C) further slows isovolumic LV pressure decay and raises
LVEDP beyond the originally  imposed preload elevation.
The following sequence of events could underlie hypertension-induced pulmonary edema in
patients with normal LV systolic function: 
1) The LV mass-volume ratio(2.12±0.14 g/ml) of these patients is almost double the value
observed in systolic heart failure(1.22±0.14 g/ml)(31).Because of this myocardial
hypertrophy, the diastolic LV pressure-volume relation is steeper than normal and forces
the LV to operate under basal conditions at a higher LVEDP(84). Furthermore, their basal
LVEDP has also been shown to be higher than in patients with arterial hypertension,
normal systolic function and no heart failure history(30). 
2) These patients also have a very steep arterial elastance (slope of the ESP/SV relation)(30).
A rise in arterial impedance during a bout of arterial hypertension will therefore induce
a huge rise in LV end-systolic pressure and end-systolic wall stress. 
3) A huge rise in LV end-systolic pressure in  the presence of an elevated LVEDP
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profoundly slows isovolumic relaxation kinetics and causes a further rise of LVEDP(36),
which even exceeds the value predicted from an extrapolation of the slow isovolumic LV
pressure decay. This further rise in LVEDP sets off a vicious circle of additional elevation
of LV preload eventually leading to flash pulmonary edema. 
4) Because of the steep arterial elastance relation, there will only be minimal changes in
LVSV and therefore also in LVEDV and LVESV. Constancy of LV volumes during an
episode of pulmonary edema has indeed been observed in patients with arterial
hypertension and normal LV systolic function(19)
A prolongation of isovolumic LV pressure decay was always considered not to affect the  mid-
and late-diastolic LV filling pressures because in a normal human heart [with a time constant of
isovolumic LV pressure decay(Ĳ) = 36±6 ms] LV pressure generated by decaying LV contractile
interaction would amount to less than 2 mmHg once 3.5 times Ĳ or 126 ms had elapsed after
closure of the aortic valve. This reasoning supposed LV pressure decay to proceed along the same
mono exponential curve during the LV filling phase and led to calculation of passive
early-diastolic LV pressure by subtracting extrapolated LV relaxation pressure from the measured
early-diastolic LV pressure(50). Experimental proof validating this concept is however lacking.
In isolated papillary muscles, residual isometric force decay after isotonic reextension was
determined by the load during reextension(67). For the filling ventricle, this finding implied the
persistence during the LV filling phase of a level of active myocardial force corresponding to the
wall stress observed at mitral valve opening and predicted decay of active  myocardial force
extending well into mid- and late-diastole. The same findings had also been observed in
anesthetized open-chest dogs with a mitral annulus occluder. In this preparation, LV filling
substantially slowed LV pressure decay, which reached a value less than 2 mmHg not after 3.5
times Ĳ but after 5.4 times Ĳ(47). No data exist on mid- and late diastolic LV relaxation pressure
decay in the filling human LV but in non-filling beats during inflation of the self-positioning
Inoue balloon at the time of percutaneous mitral valvuloplasty the observed LV end-diastolic
pressure (2±4 mmHg) significantly exceeded the value extrapolated from a mono exponential
curve using the time constant of LV pressure decay (-9±11 mmHg; p<0.001)(59). This
observation likewise suggested significant slowing of active myocardial force decay in the human
heart with residual persistence of active myocardial force and of active crossbridge cycling during
mid- and late-diastole. 
In the human heart, modest changes in LV afterload had no effect on isovolumic LV
relaxation(13,66) but a drastic reduction in LV afterload, as imposed in patients with aortic
stenosis by a sequence of balloon aortic valvuloplasty and sodium nitroprusside infusion
markedly slowed isovolumic LV pressure decay(55). These successive interventions  resulted in
a threefold reduction of LV end-systolic wall stress (from 90±30.103  to 26±6.103 dyne/cm2) and
a marked abbreviation of LV contraction (Figure 3). This abbreviation of LV contraction made
the onset of LV isovolumic relaxation probably coincide with the terminal phase of myocardial
cytosolic calcium reuptake, thereby allowing for some crossbridge reattachment, which could
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explain  the considerable slowing of isovolumic LV pressure decay. Apart from slowing, LV
pressure decay also became nonexponential as evident from the biphasic appearance of the
negative dP/dt signal (Figure  3). A similarly  slow, nonexponential LV pressure decay and a
biphasic negative dP/dt signal were later reported in a mouse model of hypertrophic
cardiomyopathy(ĮMHC403/+)(20). Despite profound slowing of Ĳ in both aortic stenosis patients
following drastic unloading(73±23 ms) and in hypertensives following excessive loading during
exercise(86±23 ms)(30), the aortic stenosis patients lowered their LVEDP from 23±8 to
14±8mmHg but the hypertensives raised their LVEDP from 24±5 to 32±9 mmHg. These opposite
effects on LVEDP are consistent with the different effects of both loading interventions  on
myofilamentary calcium sensitivity, which gets downregulated by unloading but upregulated by
Figure 3. LV pressure(LVP), peripheral artery pressure(PP) and LV dP/dt in a patient with aortic stenosis
in control conditions, in control conditions during nitroprusside infusion, after balloon aortic valvuloplasty
and after balloon aortic valvuloplasty during nitroprusside infusion(55). After drastic unloading of balloon
aortic valvuloplasty and nitroprusside infusion, there is marked abbreviation of LV contraction and
profound slowing of isovolumic LV pressure decay. In contrast to figure 2, the slowing of isovolumic LV
relaxation is accompanied by a fall in LVEDP.
loading. Hence, load-induced systolic upregulation of myofilamentary calcium sensitivity and not
slowing of LV isovolumic relaxation per se appears to be essential for the induction  of diastolic
LV dysfunction, which therefore probably results from persistent diastolic crossbridge cycling
because of upregulated myofilamentary calcium sensitivity and not from continuing slow LV
relaxation pressure decay.
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Can diastolic LV dysfunction result
from a heightened active diastolic cardiac muscle tone? 
The existence of active diastolic cardiac muscle tone had been the subject of intense clinical and
experimental research in the eighties and recently resurfaced as a potential mechanism of flash
pulmonary edema in the overloaded hypertensive heart(19). Active diastolic cardiac muscle tone
was especially looked for in myocardial ischemia and in myocardial hypertrophy(18,53).
In Krebs-perfused isovolumic guinea-pig hearts, a switch from aerobic to hypoxic perfusion
at constant perfusion pressure induced within a 5-minute period a fall in developed tension and
a rise in resting tension, which under isovolumic conditions corresponded to a drop in LV
distensibility(46). In blood perfused isovolumic rabbit hearts, pacing tachycardia superimposed
on global low-flow ischemia simulated human demand angina and also resulted in a rise in
resting tension and a drop in LV distensibility(26).  A drop in LV distensibility, evident from an
upward shift of the diastolic LV pressure-volume relation had previously been reported following
an atrial pacing stress test in patients with multivessel coronary disease(3) and in anaesthetized
dogs with two vessel coronary stenosis(63). In this last model, intravenous administration of
caffeine during the pacing stress test, greatly enhanced the upward shift of the diastolic LV
pressure-volume relation and suggested diastolic crossbridge cycling to be the underlying
mechanism because of caffeine's known effects on myoplasmic calcium reuptake and on
myofilamentary calcium sensitivity(56). Recent experiments  in the aforementioned isovolumic
blood-perfused rabbit heart however rebutted the idea of calcium overload as the mechanism
underlying diastolic crossbridge cycling. These experiments suggested ischemia to induce
reversible crossbridge-rigor bounds because quick stretches, which disrupt rigor bounds, and not
a calcium desensitizer (butanedionemonoxime) corrected the ischemia-induced drops in diastolic
LV distensibility(70). A large drop in diastolic LV distensibility  was also observed in the human
heart during simulated hypoxemia created by maintaining distal hypoxic coronary perfusion at
the time of balloon coronary angioplasty(12).
Clinical observations consistent with deranged LV diastolic function caused by elevated active
diastolic cardiac muscle tone were also obtained in LV hypertrophy caused by either hypertrophic
cardiomyopathy or aortic stenosis(39,58). In some patients with hypertrophic cardiomyopathy,
both high-fidelity tip-micromanometer LV and pulmonary capillary wedge  pressure recordings
revealed a unique diastolic LV pressure waveform with continuous LV pressure decline
throughout diastole and minimum diastolic LV pressure occurring just prior to the onset of the
a-wave of the subsequent beat(Figure 4). Continuous LV pressure decline at a moment when the
LV cavity actually expands is incompatible with passive LV distension and implies the presence
of active diastolic cardiac muscle tone in these patients. Further arguments for the presence of
active diastolic cardiac muscle tone were the restoration of a normal diastolic LV pressure
morphology (i.e. fast and slow rising LV pressure waves) following administration of calcium
channel blockers(39) and the induction in other patients of a continuous diastolic LV pressure
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decline following postextrasystolic potentiation(58).  Both interventions again highlight the
intimate link between active diastolic cardiac muscle tone and abnormal intracellular calcium
kinetics of hypertrophied myocardium(Figure  5).
Figure 4. LV pressure and LV dP/dt in a patient with nonobstructive hypertrophic cardiomyopathy (HCM)
during regular sinus rhythm(upper panel) and after a premature ventricular beat(lower panel)(57). During
regular sinus rhythm and especially in the diastole following the potentiated beat(second beat of the lower
panel), there is continuous LV pressure decline throughout diastole, incompatible  with passive LV
distension and suggestive of active diastolic cardiac muscle tone.
Such linkage seems to be present already at the level of isolated cardiomyocytes where low-grade
diastolic crossbridge cycling coincided with small cytosolic calcium sparks(34). An abnormal
high rate of calcium leak from the sarcoplasmic reticulum was especially evident in cardiac
muscle isolated from failing hearts(42) because of a high phosphorylation state of the calcium
release channel (ryanodine receptor).  In muscle strips of explanted human hearts, a rise in
diastolic force at higher stimulation rates was correlated with modified activity of other calcium
handling proteins such as sarcoplasmic reticular calcium-ATPase and sodium-calcium
exchanger(22). In pressure-hypertrophied cardiomyocytes of cats, diastolic constitutive properties
(=ǻstrain for a given ǻstress) were also dependent on intracellular calcium concentration(85).
In a perfused rat papillary muscle, an increase in coronary perfusion pressure augmented
transversal muscle stress(35). This opened stretch activated ion channels with a prompt rise in
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myocardial calcium influx.  This effect was different from the effect of longitudinal stress, which
caused an immediate increase in myofilamentary calcium sensitivity. The effect of transversal
cardiac stress on myocardial calcium influx is especially relevant to arterial hypertension, which
greatly elevates coronary perfusion pressure and transversal muscle stress. In the failing
hypertensive heart, abnormal myocardial calcium influx and handling gets superimposed on an
enhanced myofilamentary calcium sensitivity, resulting from reduced phosphorylation of myosin
light chain 2 and of troponin I(68). Especially  the reduced phosphorylation of troponin I could
be a main contributor to diastolic LV dysfunction(4) because of the marked diastolic LV
dysfunction in troponin I knock-out mice(25) and because of the accelerated myocardial troponin
I degradation in isolated rat hearts following elevation of LV preload from control value to 25
mmHg(14).
Figure 5. Increased myofilamentary calcium sensitivity and elevated diastolic cytosolic calcium predispose
to diastolic crossbridge cycling and diastolic LV dysfunction in hypertrophied and failing myocardium.
Myofilamentary calcium sensitivity  is increased because of deficient phosphorylation of troponin I (low
TnI-P or TnI-2P)(68), low NO bioavailability(41), high preload and late systolic afterload. Cytosolic
diastolic calcium is elevated because of opening of stretch activated ion channels (SAC) at the high coronary
perfusion pressure of arterial hypertension(35), because of diastolic calcium leakage into the cytosol from
the hyperphosphorylated ryanodine receptor(RyR-P)(42) and because of reduced diastolic calcium reuptake
from the cytosol by sarcoplasmic reticulum calcium-ATPase(SERCA2) and by sodium-calcium exchanger
(Na+-Ca2+ Ex)(22).    
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Because of its ability to induce cGMP-mediated phosphorylation of troponin I, myocardial NO
can prevent diastolic crossbridge cycling and the induction of active diastolic LV tone. In beating
rabbit hearts, release of a caval occluder raises the intramyocardial NO concentration measured
by a porphyrinic sensor in the LV wall(60). In isolated ejecting guinea pig hearts, a perfusate
containing a NOS inhibitor, results in an elevation of LVEDP and a reduction in preload
recrutable cardiac output because of a left- and upward shift of the diastolic LV pressure-volume
relation(61). Finally, in isolated cardiomyocytes, both NO and cGMP increase resting diastolic
cell length because of PKG-mediated phosphorylation of myofilaments (27,64). All these
experimental observations indicate a close link between muscle preload and myocardial NO
content and suggest a preload-induced rise of myocardial NO to maintain LV preload reserve
through PKG-mediated myofilamentary desensitization and eventual prevention of diastolic
crossbridge cycling. A similar role for myocardial NO has also been deduced from clinical
observations. In patients with dilated cardiomyopathy, an intracoronary infusion of substance P,
which acutely releases NO from the coronary endothelium, augments LV stroke work because
of improved diastolic LV distensibility evident from a rightward shift of the diastolic LV
pressure-volume relation(7,23). In patients with dilated cardiomyopathy and elevated myocardial
collagen volume fraction, the NO-induced augmentation of LV stroke work and improvement of
LV diastolic distensibility are still present(6). The latter finding is important because it implies
independent modulation of LV diastolic distensibility by intracellular elements, some of them
active, and extracellular elements. A similar conclusion of overall cardiac muscle stiffness
resulting from a summation of intracellular and extracellular elements has also been reached from
isolated cardiac  tissue preparations with intracellular elements, such as titin, responsible for
myocardial stiffness within the physiological range of stress and extracellular elements
preventing overstretch at extreme stresses(76).
Active diastolic cardiac muscle tone could also arise from mechanisms other than diastolic
crossbridge cycling. These mechanisms include interactions between cytoskeletal proteins and
myofilaments, phosphorylation of cytoskeletal proteins and induction of myofibroblasts. A
specific domain of the giant cytoskeletal protein titin, which is responsible for some of its
spring-like elastic properties, was recently shown to interact with the actin filament  in a
calcium-dependent way. This interaction  accounted  for viscous forces produced by the
myocardium at higher stretch velocities  as occur during rapid LV filling(33). Another domain
of titin with similar spring-like elastic properties gets phosphorylated after ß-receptor stimulation
or exposure to cyclic AMP-dependent protein kinase (PKA) and this phosphorylation is
accompanied by a significant reduction in passive tension(77). Myofibroblasts arise from
interstitial fibroblasts and/or pericytes at sites of myocardial fibrogenesis, express a-smooth
muscle actin and can impose a contractile "smooth muscle cell"  tone on surrounding tissue via
cell-cell connections(e.g. gap junctions) and via cell-matrix connections (e.g. fibronexus)(74).
In tissue engineered cardiac muscle constructs, ß-receptor stimulation  reduced the tone of smooth
muscle cells lining the strip and this resulted in a simultaneous fall in resting tension of the entire
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cardiac muscle construct(86).
Because of NO's ability to improve diastolic LV distensibility through prevention of diastolic
crossbridge cycling, raising myocardial NO bioavailability becomes a logical target for treatment
of diastolic LV dysfunction. So far only calcium channel blockers(39), ACE inhibitors(15) and
angiotensin II receptor blockers(73) have been demonstrated to exert beneficial effects on
diastolic LV performance in patients with LV hypertrophy related to hypertrophic
cardiomyopathy, aortic stenosis and arterial hypertension. All three classes of drugs could well
exert part of their beneficial effect on diastolic LV function  through elevation of myocardial NO
bioavailability. In failing human myocardium, both amlodipine and ramiprilat decreased
myocardial oxygen consumption through inhibition of kinin degradation and concomitant
elevation of myocardial NO content(38). In hypertrophied myocardium, NO's bioavailability is
reduced because of excess free radical production by endothelial NADH/NADPH oxidase(41).
Angiotensin II is a potent stimulus for endothelial NADH/NADPH oxidase and administration
of an angiotensin II receptor blocker could therefore augment NO's bioavailability.   NO's ability
to improve diastolic LV distensibility could eventually support the chronic use of NO-donors for
treatment of diastolic heart failure. Chronic use of NO-donors however induces a limitation of
vascular NO bioavailability and results in impairment of endothelium-dependent vasodilation and
an increased incidence of adverse cardiovascular events(45). Two important mechanisms
contribute to this limited vascular NO bioavailability  during chronic use of NO-donors: vascular
production of superoxide because of angiotensin II triggered activation of NAD(P)H oxidase(44)
and dysfunction of vascular NO synthase(NOS), which produces superoxide instead of NO,
probably because of lack of tetrahydrobiopterin(21). Similar mechanisms could be operative in
the myocardium and could therefore render chronic use of NO-donors detrimental  for diastolic
LV function. 
Conclusion
                                
The smaller LV end-diastolic volume during acute hypertensive pulmonary edema than following
recompensation  and the discordant changes during acute ischemic heart failure in LV
end-diastolic volume and pressure, with the smaller volume occurring at the higher pressure, are
inconsistent with subtle reductions in myocardial systolic performance and a fixed, steep diastolic
LV pressure-volume relation underlying all heart failure episodes, also those occurring with a
normal LVEF. Accordingly, these findings imply the existence during some acute heart failure
episodes of primary diastolic LV dysfunction, defined as transient upward displacement of the
diastolic LV pressure-volume relation. The late systolic LV loading increment of a hypertensive
episode and the elevated LV preload of a hypertrophied heart both predispose to diastolic LV
dysfunction through slowing of isovolumic LV pressure decay and possibly also through
induction of active diastolic  cardiac muscle tone. The latter could result from diastolic
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crossbridge cycling, from lack of phosphorylation of cytoskeletal proteins or from induction of
myofibroblasts. In the hypertrophied and failing heart, raised myofilamentary calcium sensitivity,
because of low troponin I phosphorylation or low NO bioavailability, and  elevated diastolic
cytosolic calcium, because of leakage from or slow reuptake into the sarcoplasmic  reticulum,
could favor such diastolic crossbridge cycling.
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Summary
Diastolic left ventricular (LV) distensibility is determined by the material properties of the LV
wall and by LV geometry (i.e., LV shape, LV volume and LV wall thickness). These material
properties are influenced both by the physical structure of the LV myocardium and by the
dynamic process of myocardial relaxation. The material properties of the myocardium dictate the
strain that follows a given stress, and determine position and shape of the myocardial stress-strain
relationship. The material properties, together with the LV geometry, also determine position and
shape of the diastolic LV pressure-volume relationship. Diastolic LV distensibility is best
characterized by this diastolic LV pressure-volume relationship. The crucial role of diastolic LV
distensibility in relation to the heart failure syndrome are discussed in chapter 2, 3 and 4 of this
thesis.
Chapter 2 of this thesis discusses diastolic left ventricular dysfunction, characterized by an
upward shift of the left ventricular diastolic pressure-volume relationship.
Chapter 2.1 describes the effects of myocardial ischemia, either  pacing-induced or by
coronary occlusion, on the diastolic properties of the same LV anterior wall segment in 12
patients with single-vessel proximal left anterior descending coronary artery stenosis at rest,
immediately after 7 ± 1.2 minutes of pacing, and at the end of a 1- minute balloon occlusion of
coronary angioplasty (CO).
Shifts of the diastolic LV pressure-length relation, derived from simultaneous
tip-micromanometer LV pressure recordings and digital subtraction LV angiograms, were used
as an index of regional diastolic LV distensibility of the anterior wall segment. The diastolic LV
Pressure(P)-Radial Length(RL) plot of the ischemic segment was shifted upward for portions of
the plot that overlapped with the diastolic LV P-RL plot at rest. This upward shift at the end of
CO was significantly smaller than that immediately after pacing. At the end of CO, a correlation
was observed for the ischemic segment between percentage systolic shortening and upward shift
of the diastolic LV  pressure-radial length plot.
The upward shift of the diastolic LV  pressure-radial length plot, which was used as an index
of decreased regional diastolic LV distensibility, was larger immediately after pacing than at the
end of CO. Persistent systolic shortening of ischemic myocardium seems to be a prerequisite for
a decrease in diastolic distensibility of the ischemic segment because of the higher percentage
systolic shortening of the ischemic segment immediately after pacing, and because of the
correlation at the end of CO between the upward shift of the diastolic LV pressure-radial length
plot and percentage systolic shortening of the ischemic segment. 
Chapter 2.2 describes the different effects of low- flow ischemia, pacing-induced ischemia,
and hypoxemic perfusion on LV performance in humans. During the initial phase of an ischemic
insult, left ventricular (LV) performance depends on the complex interaction between oxygen
deprivation, vascular turgor, and accumulation of metabolites.
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In experimental preparations, low-flow ischemia decreases systolic shortening and increases
diastolic LV distensibility, whereas pacing- induced ischemia or hypoxic perfusion produces
smaller decreases in systolic shortening but decreases LV diastolic distensibility. Therefore, the
different effects of low-flow ischemia, pacing-induced ischemia, and hypoxemic perfusion on LV
performance was studied in 20 patients with a significant stenosis in the left anterior descending
coronary artery.
Micromanometer-tip LV pressure recordings, LV angiography, and coronary sinus blood
sampling were obtained at rest and during pacing-induced ischemia, low-flow ischemia due to
balloon coronary occlusion, and hypoxemia induced by balloon coronary occlusion with
hypoxemic perfusion distal to the occlusion. LV stroke work index was lower at the end of
balloon coronary occlusion than during pacing-induced ischemia and was lower at the end of
balloon coronary occlusion than at the end of hypoxemia induced by balloon coronary occlusion
with hypoxemic perfusion distal to the occlusion.
LV end-diastolic pressure rose from 16±5 mm Hg at rest to 23±6 mm Hg at the end of balloon
coronary occlusion. However, LV end-diastolic pressure was lower at the end of balloon coronary
occlusion than during pacing-induced ischemia and was lower at the end of balloon coronary
occlusion than at the end of hypoxemia induced by balloon coronary occlusion with hypoxemic
perfusion distal to the occlusion. LV end-diastolic volume index increased at the end of balloon
coronary occlusion. Left ventricular end-diastolic volume index increased to values similar to
those for balloon coronary occlusion during pacing-induced ischemia and at the end of
hypoxemia induced by balloon coronary occlusion with hypoxemic perfusion distal to the
occlusion. Higher values of LV end-diastolic pressure and unchanged values of LV end-diastolic
volume index for pacing-induced ischemia and hypoxemia induced by balloon coronary occlusion
with hypoxemic perfusion distal to the occlusion, compared with balloon coronary occlusion,
suggested a lower end- diastolic LV distensibility during pacing-induced ischemia and during
hypoxemia, as compared with low-flow ischemia. Upward shifts of individual diastolic LV
pressure-volume curves during pacing-induced ischemia (9 of 11 patients) and at the end of
hypoxemia induced by balloon coronary occlusion with hypoxemic perfusion distal to the
occlusion (7 of 9 patients), compared with balloon coronary occlusion, were also consistent with
lower LV diastolic distensibility during pacing-induced ischemia and during hypoxemia,
compared with low-flow ischemia.
Coronary sinus lactate, H+, and K+ levels increased after balloon deflation (balloon coronary
occlusion and hypoxemia induced by balloon coronary occlusion with hypoxemic perfusion distal
to the occlusion) and during pacing-induced ischemia. Thus, during low-flow ischemia, LV
systolic performance was lower and LV diastolic distensibility larger than during pacing-induced
ischemia or hypoxemia. The variable response of the human myocardium to different types of
ischemia was probably related to the degree of vascular turgor and accumulation of tissue
metabolites. 
Chapter 2.3 covers a pathophysiologic perspective of the comparative effects of ischemia and
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hypoxemia on left ventricular diastolic function in humans.
In Chapter 2.4 the presence of a deficient acceleration of left ventricular relaxation is reported
during exercise after heart transplantation. The exercise-induced rise in left ventricular filling
pressures after cardiac transplantation is considered to be the result of a blunted heart rate
response, of elevated venous return, and of unfavorable passive late-diastolic properties of the
cardiac allograft. In contrast to passive late-diastolic left ventricular properties, the effect of left
ventricular relaxation on the exercise-induced rise in left ventricular filling pressures of the
cardiac allograft has not yet been studied.
In the present study, the response of left ventricular relaxation to exercise was investigated in
transplant recipients and compared with left ventricular relaxation observed in normal control
subjects exercised to the same heart rate. Moreover, the response of left ventricular relaxation of
the cardiac allograft to beta-adrenoreceptor stimulation, to reduced left ventricular afterload, and
to increased myocardial activator calcium was investigated by infusion of dobutamine and of
nitroprusside and by postextrasystolic potentiation. Twenty-seven transplant recipients were
studied 1 year (n = 17), 2 years (n = 7), 3 years (n = 2), and 4 years (n = 1) after transplantation.
All patients were free of rejection and of significant graft atherosclerosis at the time of study.
Tip-micromanometer left ventricular pressure recordings and cardiac hemodynamics were
obtained at rest, during supine bicycle exercise stress testing, during dobutamine infusion at a
heart rate matching the heart rate at peak exercise, during nitroprusside infusion, and after
postextrasystolic potentiation.
Tip-micromanometer left ventricular pressure recordings were also obtained in a normal
control group at rest and during supine bicycle exercise stress testing to a heart rate, which
matched the heart rate of the transplant recipient group at peak exercise. Left ventricular
relaxation rate was measured by calculation of a time constant of left ventricular pressure decay
(T) derived from an exponential curve fit to the digitized tip-micromanometer left ventricular
pressure signal. In the transplant recipients, exercise abbreviated T and caused a rise of left
ventricular minimum diastolic pressure.
 In normal control subjects, exercise induced a larger abbreviation of T and a smaller drop in
left ventricular minimum diastolic pressure than was found in the transplant recipients. In the
transplant recipients, the change in T from rest to exercise was variable, ranging from an
abbreviation, as observed in normal controls, to a prolongation and was significantly correlated
with the change in RR interval on the ECG and the change in left ventricular end-diastolic
pressure.
In a first subset of transplant recipients, dobutamine infusion resulted in a heart rate equal to
the heart rate at peak exercise, a left ventricular end-diastolic pressure (lower than at peak
exercise) and a T value, which was shorter than both the resting value and the value observed at
peak exercise. In a second subset of transplant recipients, nitroprusside infusion and
postextrasystolic potentiation resulted in a significant prolongation of T and a characteristic
negative dP/dt upstroke pattern with downward convexity as previously observed in left
ventricular hypertrophy. Exercise after cardiac transplantation resulted in a smaller acceleration
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of left ventricular relaxation than in a normal control group exercised to the same heart rate.
These transplant recipients, who made the largest use of left ventricular preload reserve during
exercise, showed least acceleration of left ventricular relaxation. This association between a rise
of left ventricular end-diastolic pressure and slower left ventricular isovolumic relaxation was
also evident in the individual transplant recipient from the slower isovolumic relaxation during
exercise than during dobutamine infusion despite equal heart rates.
After postextrasystolic potentation during nitroprusside infusion, a slow left ventricular
relaxation with downward convexity of the dP/dt signal was observed in the cardiac allograft.
This finding suggests depressed function of the sarcoplasmic reticulum in left ventricular
myocardium after transplantation, which could be related either to decreased adrenergic tone or
to preceding ischemic injury during organ retrieval or to hypertrophy caused by cyclosporine
induced arterial hypertension.
Chapter 3 of this thesis discusses diastolic left ventricular dysfunction, characterized by a lack
of rightward shift of the left ventricular diastolic pressure-volume relationship.
In  chapter 3.1 the functional significance of a modified NOS gene expression for left
ventricular (LV) contractile performance was investigated in patients with dilated nonischemic
cardiomyopathy. Patients with heart failure have modified myocardial expression of nitric oxide
synthase (NOS), as is evident from induction of calcium-insensitive NOS isoforms. In patients
with dilated, nonischemic cardiomyopathy, invasive measures of LV contractile performance
were derived from LV microtip pressure recordings and angiograms and correlated with intensity
of gene expression of inducible (NOS2) and constitutive (NOS3) NOS isoforms in
simultaneously procured LV endomyocardial biopsies. LV endomyocardial expression of NOS2
was linearly correlated with LV stroke volume, LV ejection fraction, and LV stroke work. In
patients with elevated LV end-diastolic pressure, a closer correlation was observed between
endomyocardial expression of NOS2 and LV stroke volume, LV ejection fraction, and LV stroke
work. LV endomyocardial expression of NOS3 was linearly correlated with LV stroke volume
and LV stroke work. To establish the role of nitric oxide (NO) as a mediator of the observed
correlations, substance P (which causes endothelial release of NO) was infused intracoronarily.
In patients with elevated LV end-diastolic pressure, an intracoronary infusion of substance P
increased LV stroke volume and LV stroke work and shifted the LV end-diastolic pressure-
volume relation to the right. It is concluded, that in patients with dilated cardiomyopathy, an
increase in endomyocardial NOS2 or NOS3 gene expression augments LV stroke volume and LV
stroke work because of a NO-mediated rightward shift of the diastolic LV pressure-volume
relation and a concomitant increase in LV preload reserve.
In Chapter 3.2, because nitric oxide (NO) reduces diastolic LV stiffness, diastolic LV stiffness
and LV systolic performance are related to intensity of endomyocardial NO synthase (NOS) gene
expression in dilated cardiomyopathy and in athlete's heart. In dilated cardiomyopathy and in
athlete's heart, progressive LV dilatation is accompanied by rightward displacement of the
diastolic LV pressure-volume relation. In dilated cardiomyopathy, an increase in diastolic LV
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stiffness can limit this rightward displacement, thereby decreasing LV systolic performance.
Microtip LV pressures, conductance-catheter or angiographic LV volumes, echocardiographic
LV wall thicknesses and snap-frozen LV endomyocardial biopsies were obtained in 33 patients
with dilated cardiomyopathy and in three professional cyclists referred for sustained ventricular
tachycardia. Intensity of LV endomyocardial inducible NOS (NOS2) and constitutive NOS
(NOS3) gene expression was determined using quantitative reverse transcription-polymerase
chain reaction (RT-PCR). Dilated cardiomyopathy patients with higher diastolic LV stiffness-
modulus and lower LV stroke work had lower NOS2 and NOS3 gene expression at any given
level of LV end-diastolic wall stress. The intensity of NOS2 and NOS3 gene expression observed
in athlete's heart was similar to dilated cardiomyopathy with low LV diastolic stiffness-modulus
and preserved LV stroke work. High LV endomyocardial NOS gene expression is observed in
athlete's heart and in dilated cardiomyopathy with low diastolic LV stiffness and preserved LV
stroke work. Favorable effects on the hemodynamic phenotype of high LV endomyocardial NOS
gene expression could result from a NO-mediated decrease in diastolic LV stiffness and a
concomitant rise in LV preload reserve.
In Chapter 3.3 findings from recent experimental and clinical research are covered, which
solved some of the controversies with respect to the myocardial contractile effects of NO. These
controversies were: (1) does NO exert a contractile effect at baseline? (2) Is NO a positive or a
negative inotrope? (3) Are the contractile effects of NO similar when NO is derived from NO-
donors or from the different isoforms of NO synthases (NOS)? (4) Does NO exert the same
effects in hypertrophied, failing or ischemic myocardium? Transgenic mice with cardioselective
overexpression of NOS revealed NO to produce a small reduction in basal developed LV pressure
and a LV relaxation-hastening effect mainly through myofilamentary desensitization. Similar
findings had previously been reported during intracoronary infusions of NO-donors in isolated
rodent hearts and in humans. The LV relaxation hastening effect was accompanied by increased
diastolic LV distensibility, which augmented LV preload reserve, especially in heart failure
patients. This beneficial effect on diastolic LV function always overrode the small NO-induced
attenuation in LV developed pressure in terms of overall LV performance. In most experimental
and clinical conditions, contractile effects of NO were similar when NO was derived from NO-
donors or produced by the different isoforms of NOS. Because expression of inducible NOS
(NOS2) is frequently accompanied by elevated oxidative stress, NO produced by NOS2 can lead
to peroxynitrite-induced contractile impairment as observed in ischemic or septic myocardium.
Finally, shifts in isoforms or in concentrations of myofilaments can affect NO-mediated
myofilamentary desensitization and alter the myocardial contractile effects of NO in
hypertrophied or failing myocardium.
Chapter 4 of this thesis discusses diastolic left ventricular dysfunction, characterized by a steeper
slope of the left ventricular diastolic pressure-volume relationship.
The purpose of the study reported in chapter 4.1 was to investigate interactions between
myocardial nitric oxide synthase (NOS) and myocardial fibrosis, both of which determine left
ventricular (LV) preload reserve in patients with nonischemic dilated cardiomyopathy. In
previous animal experiments, chronic inhibition of NOS induced myocardial fibrosis and limited
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LV preload reserve. Twenty-eight  dilated cardiomyopathy  patients underwent LV
catheterization, balloon caval occlusions, intracoronary substance P infusion, and procurement
of LV endomyocardial biopsies for determinations of collagen volume fraction, of gene
expression of NOS2, NOS3, heme oxygenase, and TNF-alpha, and of NOS2 protein.  Collagen
volume fraction was unrelated to the intensity of NOS2, NOS3, heme oxygenase, or TNF-alpha
gene expression or of NOS2 protein expression. Preload recruitable LV stroke work correlated
directly with NOS2 gene expression and inversely with  collagen volume fraction. High  collagen
volume fraction (>10%) reduced baseline LV stroke work and preload recruitable LV stroke work
at each level of NOS2 gene expression. In  dilated cardiomyopathy , myocardial fibrosis is
unrelated to the intensity of myocardial gene expression of NOS, antioxidative enzymes (heme
oxygenase), or cytokines (TNF-alpha) and blunts NOS2-related recruitment of LV preload
reserve.
Chapter 4.2 reports on heart failure patients, in which beneficial effects of NO on diastolic LV
function always overrides a small NO-induced attenuation of LV developed pressure in terms of
overall hemodynamic status, either at baseline or following ß-adrenergic stimulation. The absence
of hemodynamic deterioration in transgenic mice over expressing either myocardial NOS2 or
NOS3 confirms these clinical observations. In failing myocardium,  NO’s correction of  diastolic
LV dysfunction  reinforces  NO’s energy sparing effects and the concerted action of NO on both
diastolic LV dysfunction and deranged energetics could well be instrumental for preventing
relentless deterioration of failing myocardium. Another beneficial effect of high endomyocardial
NO activity on diastolic LV distensibility of the cardiomyopathic heart could result not only from
NO-induced phosphorylation of troponin I and a concomitant reduction of diastolic crossbridge
cycling but also from prevention of endomyocardial fibrosis. Chronic inhibition of NO synthesis
has indeed been demonstrated to induce progressive myocardial fibrosis through a signaling
cascade involving endothelin, angiotensin II, aldosterone and transforming growth factor ȕ.
Chapter 5 discusses left ventricular dysfunction in relation to different changes in the left
ventricular pressure-volume relationships. New, mainly noninvasive observations on diastolic
LV dysfunction are confronted in this chapter with the old framework of diastolic LV pressure-
volume relations to confirm their validity or to clarify their cause. Some questions recently
emerged:
1. Is diastolic LV dysfunction always secondary to systolic LV dysfunction ?  
2. Can transient elevations in LV loading induce diastolic LV dysfunction ?
3. Can diastolic LV dysfunction result from heightened active diastolic cardiac muscle tone?
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Samenvatting
Het lijkt voor de hand te liggen, dat de kwaliteit van de pompfunctie van het hart is af te meten
aan de kracht waarmee de hartspier samentrekt. Iemand met een ‘zwakke’ hartspier kan zich
minder goed inspannen en is eerder kortademig dan iemand met een krachtig samentrekkende
hartspier. Een ‘zwakke’ hartspier verplaatst immers minder bloed per hartslag. Studies hebben
aangetoond, dat medicamenten die de hartspier versterken een averechts effect hebben en zelfs
de mortaliteit doen toenemen. Is het wellicht beter een ‘zwakke’ hartspier te ontlasten in plaats
van ‘op te zwepen’? Het is inderdaad gebleken, dat medicamenten die bloedvaten verwijden, wel
een gunstige invloed hebben op zowel het klachtenpatroon van mensen met een ‘zwak’ hart, als
op hun overlevingskans. Door het verwijden van bloedvaten ondervindt een ‘zwak’ hart minder
weerstand bij het uitpompen van bloed en wordt dus ontlast. 
De laatste jaren is er echter ook belangstelling ontstaan voor de soepelheid van de hartspier.
Hoe soepeler de spier, des te gemakkelijker de linker ventrikel (hartkamer) zich vult met bloed,
anders gezegd: de druk tijdens de vulling van de linker ventrikel zal lager zijn bij een soepele in
vergelijking met een stugge hartspier en hoe lager de druk tijdens de vulling van de linker
ventrikel, des te minder iemand kortademig is als hij of zij zich inspant. Het onderzoek dat ten
grondslag ligt aan dit proefschrift heeft inzichten opgeleverd in de factoren die een stugge of
soepele hartspier tot gevolg hebben en waarom bepaalde hartspierafwijkingen bij de ene patiënt
wel en bij de andere geen aanleiding geven tot het ontstaan van lichamelijke klachten. Het
onderzoek heeft aangetoond dat de kracht waarmee de hartspier samentrekt, ook wel 'systolische
functie' genoemd, mogelijk zelfs van ondergeschikt belang is en dat de soepelheid of stugheid
van de hartspier, ook wel 'diastolische functie' genoemd, bij patiënten met hartfalen daarentegen
een cruciale rol lijkt te spelen bij het ontstaan van lichamelijke klachten.
De mate van diastolische distensibiliteit (soepelheid) van de hartspier wordt bepaald door de
eigenschappen van het materiaal van die spier, door de spierwanddikte, de grootte en de vorm van
de linker ventrikel. Deze eigenschappen van het spiermateriaal worden beïnvloed door de fysieke
eigenschappen (bijvoorbeeld door de verhouding van spierweefsel/bindweefsel) en door de
dynamische processen in de hartspier als deze relaxeert (zich ontspant) na een contractie
(samentrekking). Deze relaxatie kan vertraagd zijn, waardoor de spierwand van de linker
ventrikel minder soepel is als de linker ventrikel zich vult met bloed na een contractie. Een
soepele hartspier zorgt er dus voor dat de linker ventrikel een relatief groot bloedvolume kan
ontvangen bij een relatief lage vullingsdruk. Om deze diastolische distensibiliteit in maat en getal
uit te drukken wordt de linker ventrikeldruk afgezet in een grafiek tegen het linker
ventrikelvolume, de zogenaamde druk-volume relatie. De linker ventrikeldruk moet dan wel op
hetzelfde moment worden gemeten als het linker ventrikelvolume. Dit kan momenteel alleen met
een 'combinatie catheter' die geplaatst wordt in de linker ventrikel en tegelijkertijd linker
ventrikeldruk en ventrikelvolume kan registreren.
De diastolische linker ventrikeldistensibiliteit wordt grafisch weergegeven door de diastolische
linker ventrikeldruk-volume relatie en veranderingen in de positie van deze druk-volume relatie
zijn specifiek voor  onderliggende ziekteprocessen die respectievelijk in hoofdstuk 2, 3 en 4 van
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dit proefschrift aan bod komen. Een verschuiving van de diastolische linker ventrikeldruk-volume
relatie naar links en naar boven betekent een afname van de diastolische linker
ventrikeldistensibiliteit, de hartspier is stugger, de linker ventrikelvulling wordt bemoeilijkt. Een
verschuiving van de diastolische linker ventrikeldruk-volume relatie daarentegen naar rechtsonder
betekent een afname van de stugheid van de hartspier, hetgeen de diastolische vulling van de
linker ventrikel vergemakkelijkt. Een bijkomend voordeel van een soepele hartspier, is de
eigenschap van de hartspier, dat hoe meer hij uitrekt, zoals bij een groter vullingsvolume van de
linker ventrikel, des te groter de contractiekracht zal zijn. Deze eigenschap wordt ook wel de
'preload reserve' genoemd en is door Frank en Starling rond 1900 voor het eerst beschreven. Deze
preload reserve is dus groter naarmate de spierwand van de linker ventrikel soepeler is. Grafisch
weergegeven is dat een verschuiving van de diastolische linker ventrikeldruk-volume relatie naar
rechtsonder.
In hoofdstuk 2 wordt het mechanisme beschreven dat ten grondslag ligt aan het naar boven
verschuiven van de diastolische linker ventrikeldruk-volume relatie.
Hoofdstuk 2.1 beschrijft het effect van ischemie ('zuurstoftekort') van de hartspier als gevolg van
1 een te hoog zuurstofgebruik bij een opgelegde hoge hartfrequentie met behulp van een
pacemaker bij patiënten met een coronair arteriestenose (vernauwing van de kransslagader).
2 een te laag  zuurstofaanbod door occlusie (afsluiting) van deze kransslagader tijdens een
PTCA (dotterbehandeling) van diezelfde coronair arteriestenose. Gevonden werd dat de
diastolische linker ventrikeldruk-volume relatie meer naar boven verschuift na pacing
ischemie dan na occlusie ischemie. Het grotere verlies aan diastolische linker
ventrikeldistensibiliteit na pacing gaat gepaard met behoud van linker ventrikel systolische
functie. Na occlusie ischemie was de diastolische linker ventrikeldistensibiliteit minder
gestoord in combinatie met een fors gestoorde linker ventrikel systolische functie.
Hoofdstuk 2.2 beschrijft de verschillende effecten van occlusie ischemie, pacing ischemie en
hypoxemische perfusie in combinatie met occlusie ischemie. Hypoxemische perfusie wordt
verkregen door tijdens een PTCA met een balloncatheter het bloedvat af te sluiten
(ballonocclusie) en  via een kanaal in die balloncatheter een fysiologische zoutoplossing toe te
dienen. Deze zoutoplossing bevat ongeveer 38 maal minder zuurstof (sterk hypoxemisch) dan
slagaderlijk bloed. Toediening van deze zoutoplossing heeft tot gevolg dat de verschillende
stofwisselingsproducten als gevolg van het 'zuurstoftekort' van de hartspier worden uitgewassen,
in tegenstelling tot de situatie met ballonocclusie alléén, waarbij alle stofwisselingsproducten zich
achter de ballon ophopen. Hierdoor wordt het mogelijk de effecten van deze
stofwisselingsproducten op de diastolische en systolische linker ventrikelfunctie te bestuderen.
Tijdens pacing ischemie, occlusie ischemie en occlusie ischemie met hypoxemische perfusie
worden diastolische linker ventrikeldruk-volume relaties geconstrueerd met behulp van simultane
linker ventrikelcontrastinjecties voor volumemeting en linker ventrikeldrukmetingen met een
cathetertipmanometer  en wordt er bloed afgenomen uit de sinus coronarius, het bloedvat
waardoor het bloed het hart weer 'verlaat'.
Tijdens pacing ischemie en hypoxemische perfusie met occlusie ischemie is de diastolische
linker ventrikeldistensibiliteit duidelijk minder dan tijdens occlusie ischemie alleen. Net als in
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de studie die beschreven is in hoofdstuk 2.1 vinden we ook hier een combinatie van verminderde
linker ventrikel systolische functie en een betere diastolische linker ventrikeldistensibiliteit tijdens
occlusie ischemie in vergelijking met pacing ischemie en hypoxemische perfusie. De
verschillende reacties van de menselijke hartspier op verschillende soorten ischemie zijn mogelijk
het gevolg van de mate waarin de bloedvaten van het hart zijn gevuld (vasculaire turgor) of van
de ophoping van stofwisselingsproducten in de hartspier als gevolg van een gebrekkige
doorbloeding tijdens PTCA ballonocclusie.
Hoofdstuk 2.3 zet de bevindingen van hoofdstuk 2.1 en 2.2 in perspectief.
In hoofdstuk 2.4 worden de effecten bestudeerd van lichamelijke inspanning op de kwaliteit
van relaxatie van de linker ventrikelhartspier bij patiënten na harttransplantatie. De hartfrequentie
bij patiënten met een donorhart neemt tijdens lichamelijke inspanning niet veel toe. Als gevolg
hiervan zullen de linker ventrikel vullingsdrukken meer stijgen dan gewoonlijk. Ook is de
hartspier bij patiënten met een donorhart vaak wat stugger dan normaal. Hierdoor zullen de
vullingsdrukken ook wat hoger zijn. Onbekend en onderwerp van deze studie is: Waarom is de
hartspier van deze patiënten stugger? Komt dit door de gewijzigde structurele eigenschappen van
de hartspier, of door een afwijkende relaxatie van de spier? De relaxatie van de linker
ventrikelhartspier wordt gemeten tijdens inspanning en bij dobutamine (=een hartspier
'versterkend' medicijn) toediening bij patiënten met een donorhart en bij patiënten met een
normale linker ventrikelfunctie, die om een andere reden een hartcatheterisatie ondergaan. De
snelheid van relaxatie van de linker ventrikelhartspier wordt bepaald door de tijdsconstante Tau
waarmee de linker ventrikeldruk daalt en wordt uitgedrukt in milliseconden. Inspanning na
harttransplantatie resulteert in een kleine toename van de relaxatiesnelheid in vergelijking met
de normale controlepatiënten. De patiënten met een donorhart maken het meest gebruik van hun
preload reserve (= een toename van de contractiekracht van de linker ventrikelhartspier bij een
diastolische vulling tot een groter linker ventrikelvolume) tijdens inspanning en hadden de
kleinste toename van de relaxatiesnelheid. Deze bevindingen wijzen mogelijk in de richting van
een gestoorde calciumhuishouding in de hartspiercel van het donorhart als gevolg van schade
door de transplantatieprocedure, waarbij het hart noodgedwongen lange tijd zonder doorbloeding
is geweest.
In hoofdstuk 3 wordt het mechanisme beschreven dat ten grondslag ligt aan het ontbreken van een
adequate verschuiving van de diastolische linker ventrikeldruk-volume relatie naar rechts.
In hoofdstuk 3.1 wordt in een biopt (stukje hartspier) de hoeveelheid stikstofoxide synthetase
(een enzym dat de aanmaak van het stikstofoxide  stimuleert) bepaald  en in verband gebracht met
de contractiele functie van de linker ventrikel waaruit het biopt is genomen. Deze biopten worden
genomen uit de linker ventrikel van patiënten met gedilateerde cardiomyopathie (een groot en
'zwak' hart). De diastolische linker ventrikeldruk-volume relatie wordt ook hier weer  bepaald met
de 'combinatie catheter' die geplaatst wordt in de linker ventrikel en tegelijkertijd linker
ventrikeldruk en ventrikelvolume kan registreren. In deze groep patiënten met gedilateerde
cardiomyopathie vonden we een groter, door de linker ventrikel verplaatst,  volume (slagvolume)
als er een hoger gehalte werd gevonden aan stikstofoxide synthetase of als er extra stikstofoxide
werd toegediend, c.q. de aanmaak van stikstofoxide werd bevorderd. Het grotere slagvolume van
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de linker ventrikel is het gevolg van het naar rechtsonder verschuiven van de diastolische linker
ventrikeldruk-volume relatie en een daarmee gepaard gaande toename van de preload reserve.
In hoofdstuk 3.2 is onderzocht of patiënten met een gedilateerde cardiomyopathie en een
stugge hartspier en relatief laag linker ventrikelslagvolume ook een laag stikstofoxide
synthetasegehalte hadden. Dat bleek inderdaad het geval te zijn en deze bevindingen waren
ongeacht de hoogte van de wandspanning van de linker ventrikel. Bij atleten werd evenals bij
patiënten met een  gedilateerde cardiomyopathie en een soepele hartspier en een groot linker
ventrikel slagvolume, een grotere hoeveelheid stikstofoxide synthetase aangetroffen dan bij
patiënten met een stugge hartspier. Gunstige effecten op het linker ventrikelslagvolume en op de
preload reserve van grote hoeveelheden stikstofoxide synthetase in de hartspier zijn mogelijk het
gevolg van een soepele hartspier onder invloed van het stikstofoxide zelf.
Hoofdstuk 3.3 vat de effecten samen, die stikstofoxide heeft op het functioneren van de
hartspier. 
In hoofdstuk 4 wordt het mechanisme beschreven dat ten grondslag ligt aan een steilere helling
van de diastolische linker ventrikeldruk-volume relatie. 
Hoofdstuk 4.1 beschrijft de relatie tussen de hoeveelheid collageen (bindweefsel) van de
hartspier en de hoeveelheid aangetoond stikstofoxide synthetase in diezelfde hartspier van
patiënten met een gedilateerde cardiomyopathie. De gedachte heerst dat hoe hoger het
collageengehalte is, des te stugger de hartspier zal zijn. Er bleek echter geen relatie aantoonbaar
tussen de hoeveelheid stikstofoxide synthetase als indicator van de stugheid van de hartspier en
de hoeveelheid aangetroffen collageen. Wel bleek dat de toename van preload reserve in
aanwezigheid van een grotere hoeveelheid stikstofoxide synthetase verminderd was bij een grote
hoeveelheid collageen. 
Hoofdstuk 4.2 behandelt de invloed van stikstofoxide op bindweefselvorming en daarmee op
de structurele eigenschappen van de hartspier op lange termijn. Ook wordt hierin beschreven wat
de instantane effecten zijn van het stikstofoxide op de diastolische eigenschappen van de
hartspier.
In hoofdstuk 5 volgt een discussie over functiestoornissen van de linker ventrikel in relatie tot de
verschillende veranderingen in de positie van de diastolische linker ventrikeldruk-volume relatie.
Er wordt daarbij ingegaan op een drietal vragen. 
1 Is een diastolische functiestoornis van de linkerventrikel altijd het gevolg van een
systolische functiestoornis?
2 Kan een voorbijgaande overbelasting van de linker ventrikel aanleiding geven tot een
diastolische functiestoornis? 
3 Kan een diastolische disfunctie van de linker ventrikel het gevolg zijn van een gestoorde
relaxatie van de hartspierwand van de linker ventrikel?
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Nawoord
In de eerste plaats ben ik de patiënten erkentelijk, die allen onbaatzuchtig hun medewerking
hebben verleend aan de uitbreiding van invasieve procedures ten dienste van het onderzoek, dat
de basis vormt van dit proefschrift.
Sylvia, Willemijn, Ties en Kasper, ik dank jullie voor de support, in de breedste zin, en het
engelengeduld gedurende de tijd die ik aan dit proefschrift heb gewerkt.
Prof.dr. Walter Paulus en prof.dr. Cees Visser, mijn promotoren, dank ik voor de niet aflatende
steun tijdens het afleggen van wat bleek een lange weg te zijn.
Walter, het was in het najaar van 1986 toen ik je voor het eerst in Aalst opzocht. We hebben
toen de basis gelegd voor onze eerste gezamenlijke studie. Het is een lange periode waarin we
met wisselende intensiteit hebben samengewerkt in een continue sfeer van vriendschap en waarin
ik na ieder bezoek aan Aalst (en dat waren er vele) weer vol enthousiasme huiswaarts reed, omdat
jij het licht aan het eind van de tunnel weer wat dichterbij had gebracht. Je bespeelt het
onderzoeksterrein van de diastolische eigenschappen van het hart met een virtuositeit die mij doet
denken aan de wijze waarop de Canadese pianist Glenn Gould, Bach vertolkt. Ik kijk met plezier
uit naar de komende tijd, nu je in Amsterdam benoemd bent.
Cees, je voortdurende optimisme en stimulans ondanks het passeren van vele 'deadlines'
waardeer ik zeer.
Naast mijn mede stafleden van de afdeling Cardiologie van het VUmc, Aernout Beek, Otto
Kamp, Herman Mannaerts, Bert van Rossum, Gerrit Veen en Frans Visser, die ik dank voor hun
solidariteit, dank ik in het bijzonder mijn maten, interventie cardiologen, Carel de Cock, Koen
Marques, Martin Stoel en Emile Jessurun die de invasieve cardiologie rimpelloos hebben laten
doordraaien met vaak 'een mannetje minder'. 
De overige leden van de promotiecommissie prof.dr. Jan Baan, prof.dr. Albert Bruschke,
prof.dr. Cees van Echteld, prof.dr. Wiek van Gilst en prof.dr. Nico Westerhof dank ik voor hun
bereidwilligheid dit proefschrift te beoordelen.
Albert, ik ben jou nog altijd erkentelijk dat je me hebt toegelaten tot de cardiologieopleiding
(als 'juco' had ik mijn opleidingsplaats reeds op zak) en dat ik van jou en van Sjef Ernst, Thijs
Plokker, Norbert van Hemel, Carl Ascoop en Frans Slooff het vak heb mogen leren.
Prof.dr. Freek Verheugt, destijds hoofd a.i. van de afdeling Cardiologie AZVU, heeft een
belangrijke rol gespeeld bij mijn komst naar de VU. Freek hiervoor ben ik je nog altijd dankbaar.
Johan Karreman en Leo Stokkel, ik ben jullie erkentelijk, dat ik op de meest onverwachte
momenten een beroep kon doen op jullie technische expertise.
De catheterisatie laboranten (een 'dreamteam') onder aanvoering van Noortje Bijvoet, dank ik
voor hun gewaardeerde en professionele medewerking aan de invasieve procedures die
uiteindelijk hebben geleid tot dit boekje.
Els de Groot en Annelies Folkers vormen samen het secretariaat Invasieve Cardiologie (hoofd:
Ankie Müller) maar zeker zo belangrijk: ze houden ons, interventie cardiologen, op de been met
onder andere een kop overheerlijke soep  (extra zout voor Carel  wordt nooit vergeten) dagelijks,
klokslag om 11.00 uur.
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De verpleging van de afdeling cardiologie van het VUmc, onder leiding van Jeannette Kemp,
Ivette Sprenkels en Yvonne Reinhard dank ik voor hun ondersteuning.
De collegae van andere afdelingen binnen het VUmc, waar in veel gevallen uiterst plezierig
mee valt samen te werken, ben ik daarvoor erkentelijk.
De leden van het MT Cardiologie, Cees Visser, Edwin van der Meer, Jeannette Kemp en Ben
Nijman, dank ik voor hun immer gewillig oor en positieve instelling in deze tijd van krapte.
Mijn paranimfen, Paul Tolenaar en Richard Bronzwaer, hebben met succes hun uiterste best
gedaan om 'de moraal' erin te houden.
En 'last but not least' mijn vakbroeders van de afdeling hartchirurgie van het VUmc, Rien
Huybregts, Stefan Spiegelenberg, Evert Jansen, Douglas Janssen en Alexander Vonk: mannen
we zijn er trots op met jullie één Hartteam te mogen vormen.
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